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PROSTATE
CANCER
An evaluation of reported markers to identify men 
at increased risk
Prostate cancer is the most frequently diagnosed cancer among Western males. 
It is also a very heterogeneous disease: many men will die with prostate cancer 
instead of from prostate cancer. One of the most challenging issues is to 
identify those men at increased risk of aggressive prostate cancer. Many mark-
ers have been reported that claim to do this. In this thesis, a critical evaluation 
of these markers is performed, using different epidemiological designs.
Hereditary prostate cancer (HPC) is a speciﬁc sub-group 
of prostate cancer. There is no test for HPC: the diagno-
sis depends on the number of cases in a family and age 
of onset. Men in HPC families are advised to be tested 
for prostate cancer.
Intuitively, HPC comprises families in which aggressive 
prostate cancers occur. However, HPC might also 
increasingly be the result of extensive prostate cancer testing in families, 
ﬁnding mainly ‘non-aggressive’ cancers. Here, we explore whether differences 
exist between HPC and prostate cancer in the general population.
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Chapter 1
PROSTATE CANCER
The prostate is a walnut-sized glandular organ, located beneath the urinary bladder in men (figure 1). 
The prostate contributes to urinary flow control and produces several enzymes that play a role in 
the function of seminal fluid. Testosterone and its more active metabolite dihydrotestosterone 
serve as nourishment for prostate tissue and regulate mitosis of prostate cells. Malignant neoplasms 
of the prostate, further referred to as prostate cancer (ICD-10 C61), usually originate in the glandular 
tissue. These adenocarcinomas are most often located in the peripheral zone of the prostate. Occa-
sionally, other morphological types of prostate cancer are diagnosed, e.g., cribriphorm carcinomas, 
acinar-cell carcinomas or (myo)sarcomatous neoplasms. From a clinical point of view, prostate 
cancer is a very heterogeneous disease that can be treated with curative intent when detected early. 
This can be done, e.g., by complete surgical removal of the prostate or by irradiating the prostate 
with external beams or by placing the radioactive particles directly into the prostate tissue (brachy-
therapy). However, the current means to detect prostate cancer and to distinguish potentially lethal 
prostate cancers from their less damaging counterparts are far from ideal. This makes it challenging 
to confidently counsel a man who is (worried about being) diagnosed with prostate cancer. One in 
every four to five men diagnosed with prostate cancer will eventually succumb to the disease.
Figure 1 The prostate gland, anatomical reference
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General Introduction
1PROSTATE CANCER 
INCIDENCE AND 
MORTALITY
Prostate cancer is the second most common non-skin cancer neoplasm diagnosed in men worldwide, 
exceeded only by lung cancer. In Europe, due to the decreasing number of lung cancer cases following 
the decreasing trend of smoking prevalence and an increase of prostate cancer cases, it has even 
been the most frequently diagnosed cancer in men for several years. In 2008[1], 371,000 European 
men were newly diagnosed with prostate cancer (crude incidence rate 59 / 100,000 person-years[2]), 
accounting for 22 percent of all cancer diagnoses in males (excluding non-melanoma skin cancers)1. 
Large differences in incidence rates exist between continents. Compared to other parts of the world 
(global total 900,000 prostate cancer diagnoses annually or 28.0 per 100,000 person-years in 2008), 
Northern and Western Europe are amongst the regions with the highest prostate cancer incidence 
(73.1 and 93.1 per 100,000 person-years, respectively). Only the Australian region (i.e., Australia and 
New Zealand) reports a higher average incidence rate with 104.2 cases per 100,000 person-years 
(Figure 1). The lowest incidence rates are found in Asia (in Asia as a whole: 7.2 per 100,000 person-
years, with China and India reporting 4.3 and 3.7 cases per 100,000 person-years, respectively).
Generally speaking, a decreasing polar-to-equatorial and west-to-east gradient can be observed for 
prostate cancer incidence. Explanations for this phenomenon might be sought in a combination of 
genetic (ethnic) risk differences on the one hand and environmental, dietary and lifestyle factors on the 
other hand, although the specifics of these risk factors are largely unknown. For the smaller differences 
seen within continents, where genetic differences are probably less prominent, differences in health-
seeking behavior and health care systems might play an important role. Stage-specific data would 
shed more light on the reasons for these incidence differences, as an overrepresentation of localized 
prostate cancer in higher-income countries could be indicative of more aggressive opportunistic 
testing strategies. Unfortunately, the quality and methods of the cancer registries across the world 
are too heterogeneous for such an evaluation. 
Prostate cancer can be treated with curative intent if detected in a localized stage. However, some 
cancers will progress to metastatic disease in spite of proper treatment of an apparently localized 
tumor or will already be metastasized at the time of diagnosis. The progression of metastasized 
[1] Data on incidence and mortality were obtained from Globocan, a database maintained by the International Agency for Research on
   Cancer (IARC). See Ferlay et al, 2010.
[2]  All reported incidence and mortality rates in this chapter were age-standardized to the World Standard Population.
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prostate cancer can be slowed down for a few months to, in some cases, several years by hormonal 
treatment and chemotherapy, but cure is not possible if distant metastases have occurred. The varia-
tion in prostate cancer mortality is considerably smaller than the variation in incidence (figure 2). 
When looking only at Europe, the countries with the highest mortality rates are the Baltic states: 
Estonia, Latvia and Lithuania have mortality rates of 22.0, 19.9 and 19.3 per 100,000 person-years, 
respectively, followed closely by the Nordic countries such as Sweden (19.9) and Norway (18.6)1. 
The lowest mortality rates are, similar to the incidence rates, found in the states in Eastern and 
Southern Europe, particularly in Moldova (6.6), Malta (6.9), Romania (8.9) and Italy (9.0). On average, 
the age-adjusted prostate cancer mortality in Europe in 2008 was 12.0 per 100,000 person-years. 
Compared to other parts of the world (global total 258,000 prostate cancer deaths annually or 7.5 
deaths per 100,000 person-years in 2008), Europe is in the middle to upper league with regard to pros-
tate cancer mortality. Along with the very low incidence rates, the Asian countries have the lowest 
prostate cancer mortality rates: Asia as a whole: 3.1 deaths per 100,000 person-years, China 1.8 and 
India 2.5 per 100,000 person-years. The highest rates are found in Sub-Saharan Africa (average 
15.0) and particularly the Caribbean (average 26.3). 
RISK FACTORS
For a disease as prevalent and incident as prostate cancer, relatively little is known about its exact 
etiology. Convincing evidence has been reported for only a few risk factors: age, genetic predisposition 
and ethnicity. Numerous scientific papers have suggested a long list of other risk factors, of which 
those most intensely investigated, will be reported in this section.
AGE
The most well known risk factor for prostate cancer is increasing age. Prostate cancer is hardly ever 
found before the age of 45 and the mean age at diagnosis in Europe lies above 70 years of age. 
This has already come down significantly from an even higher age due to the increasing trend of 
opportunistic testing. Post-mortem investigations suggest that 35-80% of European Caucasian 
men aged 80 harbor one or more (microscopic) foci of prostate cancer2-4. This underlines one of the 
greatest dilemmas in prostate cancer diagnostics nowadays: most men who have prostate cancer 
will die with prostate cancer and not from it. So, which of these prostate cancers should be detected 
and treated? In absence of more discriminative tests that can accurately predict invalidating and lethal 
prostate cancers, this will remain the pivotal issue of investigation that has already kept prostate 
cancer scientists busy for many years. 
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Figure 2 Prostate cancer incidence and mortality rates in 2008, region-specific for worldwide reference and 
country-specific for Europe (age-standardized to the World Standard Population)
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FAMILY HISTORY AND GENETICS
Besides age, a positive family history of prostate cancer is the most well established risk factor for 
prostate cancer. First-degree relatives of affected men carry a 2 to 3-fold increased risk of being 
diagnosed with the disease themselves. It is estimated that 5 to 10% of prostate cancers have a true 
genetic (Mendelian) cause. Yet, only a few very rare high-penetrance gene mutations have been 
identified that cause prostate cancer5. The prevalence of these mutations is so low, though, that 
testing would not be useful in the general population. Testing for mutations in these genes is not 
even considered useful in families with Hereditary Prostate Cancer (HPC), i.e., families with three 
or more first-degree relatives (or two first- or second-degree relatives diagnosed before 55 years 
of age) with prostate cancer or families with prostate cancer in three consecutive generations6. 
In recent years, genome-wide association studies have added dozens of low-penetrance genetic 
polymorphisms (single nucleotide polymorphisms – SNPs) that are associated with an increased 
risk of prostate cancer7. Some of these SNPs are in or near genes, e.g., the HNF1B-gene, the KLK3-
gene (PSA) and the MSMB-gene, but also in intergenic regions with unknown functions. The 8q24 
region is a good example of the latter type, containing multiple SNPs that are significantly associated 
with prostate cancer and also with other cancer types. Because the associations of individual SNPs are 
relatively weak (typically, odds ratios of 1.1-1.3 are found), polygenic risk scores are being developed 
to aid in predicting the individual risk of prostate cancer8. Recently, a somewhat more prevalent but 
still rare mutation was identified in the HOXB13-gene in a number of HPC families9. Interestingly, further 
fine-mapping of the HOXB region showed that SNPs might actually tag rarer causal variants with a 
much higher relative risks10. These so-called ‘synthetic associations’ might bridge part of the gap 
between the assumed amount of heritable risk and the lack of reproducible findings so far.
ETHNICITY
Enormous differences in prostate cancer incidence exist between ethnic populations. The lowest 
incidence is found in men of Asian descent, whereas men who live in North America and Northern 
Europe have a very high prostate cancer risk. Particularly men of African-American heritage have a 
very high risk of prostate cancer. Ethnic differences are most probably caused by a combination of 
genetic factors, exposure to environmental risk factors and factors related to health-seeking behavior. 
This is illustrated most clearly by migration studies, which looked at prostate cancer incidence 
trends in Asian men (low incidence) who migrated to the USA (high incidence); prostate cancer 
incidence in these men increased markedly and significantly, but to a level that was intermediate 
between the incidence in the Japanese and the original American population11. A similar phenomenon 
was found for Japanese men who migrated to Brazil12.
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ANDROGENS
Androgens play an important role in prostate cancer development. Prostate cancers are usually 
androgen sensitive and respond to hormonal therapy with a temporary remission of disease. After 
some time, this remission is followed by relapse and the disease is termed to be castration-resistant. 
Multiple markers for androgen status have been described and tested for an association with prostate 
cancer, e.g. serum testosterone and dihydrotestosterone levels, male-pattern baldness and acne 
vulgaris. Nevertheless, not a single one of these markers has been consistently replicated to have 
any significant predictive value for prostate cancer or, more interestingly, aggressive prostate cancer. 
So, although hormones remain the best target of treatment in case of metastasized prostate cancer, 
the exact relationship between androgens and the development of prostate cancer remains to be 
elucidated13. Another way in which hormones have more recently been targeted, is the attempt 
to prevent prostate cancer occurrence with the use of 5-alpha reductase inhibitors (5-ARIs). Two 
large prospective randomized trials examined the effect of daily use of 5-ARIs: the Prostate Cancer 
Prevention Trial (PCPT), in which men with a PSA < 3.0 ng/ml and a normal digital rectal examination 
(DRE) were treated with finasteride 5 mg daily or placebo for seven years, and the REduction by 
DUtasteride of prostate Cancer Events (REDUCE) trial, in which men at increased risk of prostate 
cancer (PSA 2.5-10 ng/ml, one negative prostate biopsy session) were treated with dutasteride 0.5 
mg daily or placebo for four years14,15. In both studies, patients underwent scheduled biopsies at 
the end of the study and both reported a lower risk of prostate cancer occurrence of approximately 
20 to 25%. This difference in prostate cancer occurrence between the two trial arms was, however, 
wholly contributable to relatively low-grade tumors, which have a higher chance of being clinically 
irrelevant. In addition to this, due to the end of study biopsies, the overall incidence of prostate 
cancer in these trials was approximately 25%, which is much higher than what is the lifetime chance 
of contracting prostate cancer in the general population. In Europe the chance of being diagnosed with 
prostate cancer until 75 years of age is 7.4%1. A similar relative reduction of 20 to 25% would not be 
clinically meaningful, as this would not outweigh the possible negative effects of 5-ARI treatment in 
the general population, notably increasing risk of libido loss, erectile dysfunction and possibly even 
cardiac failure16.
DIET
Diet is, probably, a major factor in the development and progression of prostate cancer. Dietary fats, 
red and processed meat, vitamins D and E, selenium, lycopene, cruciferous vegetables and green 
tea have all been associated with prostate cancer risk. Pathways that have been suggested to play 
a role in this process include the androgen receptor (AR) and insulin growth-factor (IGF) signaling. 
Suggested chemopreventive agents (including lycopene and selenomethionine) cause the degradation 
of the AR via downregulation of IGF-I. Another downstream effect of downregulation of IGF-I is inhi-
bition of the IGF-Aki pathway, which affects cellular proliferation, migration and survival17. 
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However, prospective population-based studies into a possible preventive effect of these dietary 
factors have failed to yield consistent results. A clear example of this is the SELECT trial (Selenium 
and Vitamin E Cancer Prevention Trial)18. This large prospective trial, in which 31,000 men were in-
cluded, studied the effect of vitamin E, selenium, and the combination of both vs. placebo. No effect 
on prostate cancer incidence was found for administering selenium, either alone or in combination with 
vitamin E. This refuted the result found in the Nutrition Prevention of Cancer (NPS) trial that observed 
a 50% reduction in prostate cancer incidence in men randomized to selenium supplements19. All in 
all, too little evidence exists to give a definitive advice on any dietary factor beyond the common or 
garden advice: have a versatile diet containing fruits and vegetables and use everything in moderation.
EARLY DETECTION
Detection of prostate cancer in an early stage can be important, as early-stage prostate cancer can 
still be treated curatively. Serum prostate-specific antigen (PSA) is to date the only widely used and 
approved biomarker to identify men at increased risk of prostate cancer. The PSA test was first report-
ed in 1987 and still has an enormous impact on prostate cancer diagnostics20. The detection of an 
elevated PSA (serum PSA > 3.0 ng/ml) can be followed by prostate biopsies, in which, typically, between 
25-40% of the cases prostate cancer is diagnosed. In the other men, another reason has caused the 
elevated PSA (PSA is prostate-specific, not prostate-cancer specific), such as benign prostatic hyper-
plasia (BPH) or prostatitis. The prostate cancer diagnosis is completed by further reporting of the 
growth pattern (Gleason grade) and the extent of the disease: locally confined, locally advanced or 
(distantly) metastasized. Depending on these complete data as well as the patient’s fitness, activity 
pattern and life expectancy, a treatment advice is given. This can be an advice to refrain from invasive 
treatment (e.g., if a very small, relatively non-aggressive prostate cancer is diagnosed), an advice to 
surgically remove the prostate, to initiate hormonal treatment, and so on.
Although PSA can lead to early detection of prostate cancers, population-wide screening with PSA 
is not advised21,22. A large European randomized trial, including over 180,000 men, concluded that 
a reduction in prostate cancer mortality can be achieved by PSA screening. This would come at the 
cost of serious overtreatment of relatively non-aggressive prostate cancers, though. The most recent 
estimates based on 13 years of follow-up are that 781 men would have to be screened and 27 men 
treated for prostate cancer as to avert 1 prostate cancer-related death. As the mortality reduction 
cannot be denied, these results have led to a focus on methods to inform men on the risks and benefits 
of having their serum PSA tested. Multiple risk calculators have been developed that can graphically 
and numerically (ERSPC calculator – www.prostaatwijzer.nl) support the patient, general practitioner 
and urologist in this decision-making process.
Many other markers for prostate cancer have been reported. Of these, only the PCA3 urine test is 
registered for clinical use: PCA3 is used as an indicator for repeat biopsies in a patient with a persistent-
ly elevated PSA and previous negative prostate biopsies. Other markers, such as the TMPRSS2-ERG 
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gene fusion, serum testosterone or more easily obtainable markers such as male-pattern baldness 
or a history of acne have not been sufficiently consistently reported to be of use in clinical practice 
nowadays.
HIGH-RISK GROUPS
As previously described, several risk factors are known for prostate cancer. In some cases, these 
risk factors are used to pre-select men for prostate cancer screening, as their a priori risk of prostate 
cancer is sufficiently higher than the general population to justify a screening advice.
Hereditary prostate cancer (HPC) is used as a criterion to advise men with an increased hereditary 
risk for prostate cancer to undergo PSA screening. Due to its definition, hereditary prostate cancer 
is a purely frequency-dependent phenomenon. A family is diagnosed as “HPC” when three or more first-
degree relatives are diagnosed with prostate cancer, or two or more first-or second-degree relatives are 
diagnosed with prostate cancer before 55 years of age, or when prostate cancer is diagnosed in three 
consecutive generations in either the maternal or paternal lineage6. This definition was introduced 
in 1993 and has not been changed since. Given the changes in society (increasingly less siblings 
are being born in the Western world) and the medical world (increased use of opportunistic PSA 
testing, more sensitive tests, better treatment options with less side-effects), this definition might be 
subject to validity loss. On the one hand this could be happening because there is no correction for 
the number of siblings or family members at risk in the definition. As a result, the number of families 
with HPC decreases with the decrease in the number of siblings. On the other hand, as there is no 
incorporation of the severity or aggressiveness in the HPC definition, many more families might 
meet the HPC criteria because the increase in PSA testing could lead to an accumulation of many 
relatively small non-aggressive prostate cancers, because of increased prostate cancer awareness 
within that family.
Another group that might be at an increased hereditary risk for prostate cancer is that of the BRCA-
mutation carriers. Previous reports have given estimates of prostate cancer risks that could be 
increased up to 7-8 times for men with a BRCA2-mutation and up to 2-3 times for men with a BRCA1-
mutation23. In the case of BRCA2, this is accompanied by a more aggressive prostate cancer phenotype 
and a worse prognosis24. Similar types of reports, though less consistent, have been made for carriers 
of mismatch repair-gene mutations in families with Lynch syndrome. Currently, a large international 
trial, IMPACT, is investigating the effectiveness of PSA screening among BRCA-mutation carriers. 
The first results point towards a possible benefit for BRCA2-mutation carriers only25.
Underlying these large trials and difficult considerations is the fact that we are still missing the answers 
to vital questions for many pieces of the ‘prostate cancer-puzzle’. For one, the biomarkers to indicate 
prostate cancer are suboptimal. PSA, the only widely used screening tool knows a large amount of 
false-positive but also false-negative results20. Insufficiencies in the current standard of care, i.e., 
trans-rectal ultrasound (TRUS)-guided random prostate biopsies, add to the uncertainty surrounding 
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prostate cancer diagnostics. Often, prostate cancer is found during repeat TRUS-guided biopsies or 
on magnetic resonance imaging (MRI)-guided biopsies in men with a persistently increased PSA26. 
Then, if prostate cancer has been diagnosed, the tool that best predicts prostate cancer metastasis 
and death, the Gleason score, knows an unnervingly large inter-observer variability27,28. This might 
in part be aggravated by the fact that, in the absence of a radical prostatectomy, there is no way of 
knowing whether the most aggressive or representative part of the prostate cancer has been biopsied. 
Also, we don’t know whether (when and how) an aggressive form evolves from a non-aggressive 
form, which would make a plea for the treatment of all prostate cancers, or whether aggressive 
prostate cancer emerges from normal or benign hyperplastic prostate tissue.
Next, there are many possible treatment options for prostate cancer, all of which can have serious 
side-effects, such as operative risks, urinary complaints, erectile dysfunction and fatigue29. However, 
none of these options guarantees that a man will not eventually succumb to prostate cancer. 
The aim of this thesis is to report our efforts in identifying groups at high risk of prostate cancer and, 
more importantly, aggressive prostate cancer. The general discussion in chapter 9 will focus on the 
implications of our own research, but it will also go into the underlying problems.
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1OUTLINE OF THIS 
THESIS:
In chapter 2 the recent trends in prostate cancer incidence and mortality in the Netherlands are 
described. This was done using data from the Netherlands Cancer Registry from 1989-2006, allowing 
for a detailed evaluation and interpretation of the most important prostate cancer trends.
In chapter 3 the additional value of the PCA3 urine test in a possible high-risk group, i.e., BRCA- 
mutation carriers, was evaluated in a nation-wide screening trial. This trial was performed as a 
sub-study in a large international trial, IMPACT, which is investigating the potential for PSA-screen-
ing in BRCA-mutation carriers.
In chapter 4 a genetic association analysis was performed in order to evaluate differences between 
prostate cancer in the general population and in one of the possible high-risk groups: hereditary pros-
tate cancer. The 74 known risk SNPs for prostate cancer (detected in the general population) were 
genotyped in 2 large groups with sporadic and hereditary prostate cancer and in a large referent group.
In chapter 5 a further evaluation of the differences between sporadic and hereditary prostate cancer 
was performed, comparing the clinical characteristics and prognosis of hereditary prostate cancer 
patients (registered at the Netherlands Foundation for the Detection of Hereditary Tumours, diag-
nosed in the year 2000 and later; n = 324) with sporadic prostate cancer patients, who were participants 
in a population-based study into the (genetic) susceptibility of prostate cancer, diagnosed between 
2003-2006 (n = 1664). 
In chapter 6 we describe the state of knowledge about HPC of Dutch urologists, general practitioners 
and clinical geneticists. We aimed to assess whether these physicians were up-to-date with their 
knowledge on the HPC definitions, the influence of family history on prostate cancer and whether they 
used this knowledge in clinical practice. The data were collected by means of an online questionnaire.
In chapter 7 and chapter 8 two previously reported markers for prostate cancer, particularly aggressive 
prostate cancer, were evaluated in a case-referent setting. The aim of these studies was to replicate 
the previously reported associations between these very easily obtainable markers, i.e. male-pattern 
baldness and a history of acne, and aggressive prostate cancer.
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ABSTRACT
Background Prostate cancer occurrence and stage distribution changed dramatically during the 
end of the 20th century. This study aimed to quantify and explain trends in incidence, stage distribution, 
survival and mortality in the Netherlands between 1989 and 2006.
Methods Population-based data from the nationwide Netherlands Cancer Registry and Causes of 
Death Registry were used. Annual incidence and mortality rates were calculated and age-adjusted 
to the European Standard Population. Trends in rates were evaluated by age, clinical stage and 
differentiation grade.
Results 120,965 men were newly diagnosed with prostate cancer between 1989 and 2006. Age-ad-
justed incidence rates increased from 63 to 104 per 100,000 person-years in this period. Two periods 
of increasing incidence rates could be distinguished with increases predominantly in cT2-tumours 
between 1989 and 1995 and predominantly in cT1c-tumours since 2001. cT4/N+/M+-tumour incidence 
rates decreased from 23 in 1993 to 18 in 2006. The trend towards earlier detection was accompanied 
by a lower mean age at diagnosis (from 74 in 1989 to 70 in 2006), increased frequency of treatment 
with curative intent and improved 5-year relative survival. Mortality rates decreased from 34 in 1996 
to 26 in 2007.
Conclusions The increase of prostate cancer incidence in the early 1990s was probably caused by 
increased prostate cancer awareness combined with diagnostic improvements (trans-rectal ultrasound, 
(thin) needle biopsies), but not PSA testing. The subsequent peak since 2001 is probably attributable 
to PSA testing. The decline in prostate cancer mortality from 1996 onwards may be the consequence 
of increased detection of cT2-tumours between 1989 and 1995. Unfortunately, data on the use of 
PSA tests and other prostate cancer diagnostics to support these conclusions are lacking.
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INTRODUCTION
In the last decades of the 20th century, prostate cancer incidence increased in most high-income 
countries. It is generally accepted that a large part of this increase can be accounted for by earlier 
(and increased) detection due to more frequent digital rectal examination (DRE) as a consequence 
of greater prostate cancer awareness, incidental diagnosis due to the increasing use of transurethral 
resection of the prostate (TURP) and developments in diagnostic techniques such as trans-rectal 
ultrasound (TRUS) imaging and thin needle biopsies1-4.
In the late 1980s, PSA testing became available5. Particularly in the USA, but also in other high- 
income countries, a further steep increase in prostate cancer incidence was observed after the 
introduction of PSA testing6. Welch et al. calculated that from 1986 to 2005 an excess of at least one 
million men were diagnosed with and treated for prostate cancer in the USA due to PSA testing7. 
Recently, the European Randomized study of Screening for Prostate Cancer (ERSPC) showed a 20% 
decrease in prostate cancer related mortality in study participants as an effect of programmed 
population-based PSA testing8. However, PSA testing is not routine practice yet in The Netherlands9. 
Consequently, whether PSA testing is responsible for the observed decrease in the incidence of 
metastasised tumours and mortality in the Netherlands over the past 15 years is questionable.
New therapies or improvements in existing therapies can also cause trends or trend changes in 
prognosis. Radical surgery and radiotherapy (external-beam radiotherapy and brachytherapy) are 
available for the treatment of localised prostate cancer and, for advanced disease, these treatments 
are sometimes combined with hormonal therapy10. It is not known whether changes in the application 
of these therapies have had an effect on trends in the prognosis of patients with prostate cancer in 
the Netherlands.
Insight in incidence, disease stage and mortality patterns may reveal a need for policy changes. 
Prostate cancer represents a large burden for society and with the ageing population the number of 
newly diagnosed patients in the Netherlands is expected to rise from 9,500 patients in 2006 to an 
estimated 15,000 in 201511. The number of prevalent patients for whom periodical check-ups will be 
necessary is expected to increase even more dramatically. The aim of this population-based study 
was to identify and explain temporal trends in prostate cancer incidence, disease stage, survival 
and mortality in the Netherlands from 1989 to 2006.
METHODS
 
The Association of Comprehensive Cancer Centres (CCC) has registered data of all newly diagnosed 
neoplasms in the Netherlands since 1989. The resulting nationwide Netherlands Cancer Registry 
(NCR; www.ikcnet.nl) is considered to be of very high quality due to the standardised identification 
2
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of new cases of cancer through the national automated pathology archive (PALGA), the national 
registry of hospital discharges (LMR), haematology departments and radiotherapy institutions, and 
because of the thorough training and testing of the registrars. After identification of new cases, 
these registrars abstract data from the medical files in all Dutch hospitals. Computerised consistency 
checks and re-abstraction and re-entry of data further improve the quality of the data. Completeness 
is estimated to be at least 95%12. Population-based data concerning prostate cancer diagnoses 
between 1989 and 2006 were analyzed for the purpose of this study11. One of the eight CCCs (CCC 
South) began with cancer registration in the 1950s. Therefore, we were also able to make use of data 
from CCC South for the period 1970 to 1988 in order to investigate longer-term trends in overall 
incidence13. The data from the CCC South were used only for the long-term evaluation of overall 
incidence and mortality. For the calculation of survival, the NCR links its database with the popula-
tion-based demography registry that keeps data on vital status of all Dutch citizens. This nationwide 
demography database was started in 1995. Four of the 8 CCCs contributing data to the NCR have 
retrospectively collected vital status data for all patients diagnosed before 1995. Mortality data, 
obtained from Statistics Netherlands, were available from 1970 to 200714.
Histology was coded according to the International Classification of Diseases for Oncology (ICD-O)15. 
Differentiation was graded using the WHO grading system until 2003, after which it was replaced by the 
Gleason score16. Histological grading was categorised as well-differentiated (WHO grade 1 or Gleason 
score 2-6), moderately differentiated (WHO grade 2 or Gleason score 7) or poorly differentiated (WHO 
grade 3 or Gleason score 8-10). Patients with undifferentiated (grade 4) tumours (< 1%) were included 
in the category ‘poorly differentiated tumours’.
Clinical stage was recorded strictly according to the formal TNM classification in use at the time of 
diagnosis and grouped into cT1a/b, cT1c (existing since 1993), cT2, cT3, cT4/N+/M+ or ‘unknown’ 
(cTx) if insufficient information was available for accurate staging17. For patients who had undergone 
a radical prostatectomy, the clinical and post-surgical T-stage were crosstabulated to evaluate 
trends in clinical overstaging and understaging by period of diagnosis.
The first-line treatment (or treatment combination) was recorded. Patients who were incidentally 
diagnosed with prostate cancer in transurethral resection of the prostate (TURP) specimens and 
who received no further treatment, were categorised into the “no therapy”-group.
The study period was divided into three 5-year periods and one 3-year period: 1989-1993, 1994-1998, 
1999-2003, and 2004-2006. Patients were grouped into three age categories in order to identify 
age-specific trends in stage distribution and treatment (<65, 65-74 and ≥75 years) and into five age 
categories for incidence and mortality rates (45-54, 55-64, 65-74, 75-84 and ≥85 years).
STATISTICAL ANALYSIS
Annual incidence and mortality rates for the period 1989-2006 were calculated per 100,000 person-
years, using the annual mid-year population size as obtained from Statistics Netherlands. Rates 
were age-standardised to the European standard population (European Standardised Rates (ESR)). 
Changes were evaluated by calculating the estimated annual percentage change (EAPC) and the 
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corresponding 95% confidence interval. To calculate this, a regression line was fitted to the natural 
logarithm of the rates, using the calendar year as regressor variable (i.e. y=ax + b where y = ln(rate) 
and x = calendar year; then EAPC = 100 * (ea – 1))18. Incidence rates were also calculated per age group, 
differentiation grade and clinical stage. Treatment administration was described as percentage per 
age group and calendar period.
Follow-up of all patients was calculated as the time from diagnosis to death or to January 1st 2008. 
Five-year relative survival was used to estimate disease-specific survival. Relative survival was 
calculated as the absolute survival among cancer patients divided by the expected survival for the 
general male population with the same age19. For the stage-stratified survival analysis, the pTNM 
classification was used. If pTNM was not available, cTNM was used. Traditional cohort-based relative 
survival analysis was used for the period 1989-2003 which represents the survival of patients diag-
nosed during 1989-2003. Period-based relative survival analysis was used for the most recent period 
2004-2006, in order to obtain a more up-to-date estimate for this period20. Survival trends were 
quantified as the mean annual percentage change (MAPC) from 1989 to 2006 as estimated by a linear 
regression model. This calculation assumes that the rates increased or decreased at a constant rate 
over the entire period. SAS software (SAS system 9.2, SAS Institute, Cary, NC) was used to perform 
the statistical analyses.
RESULTS
AGE-SPECIFIC INCIDENCE
A total of 120,965 patients were diagnosed with prostate cancer between 1989 and 2006. The annual 
number of diagnoses more than doubled from 4,201 in 1989 to 9,516 in 2006. The mean age at diag-
nosis decreased from 74 years in 1989 to 70 in 2006.
Prostate cancer incidence rates gradually increased in the CCC South catchment area between 
1970 and 1989, with an EAPC of 1.9% (95%CI: 1.1 to 2.7%). Thereafter, the incidence in the whole 
country increased steeply from 63 per 100,000 person-years in 1989 to 90 in 1995, with an EAPC of 
7.1% (95%CI: 4.5 to 9.8%) (Figure 1). Incidence rates remained stable between 1995 and 2000 (EAPC 
-0.9%; 95%CI: -5.9 to 3.8%), but rose from 88 in 2000 to 104 in 2006 (EAPC 3.6%; 95%CI: 1.1 to 6.1%). 
The CCC South data in the period 1989-2006 showed the same pattern as the nation-wide data.
Age-stratified incidence rates increased over time for men under the age of 75 years (figure 2). 
Incidence rates for men aged 65-74 years rose from 1989 until 1995 (EAPC 8.9%; 95%CI: 5.9 to 
12.7%), were stable until 2000 (EAPC 0.7%; 95%CI -2.9 to 4.4%) and then rose again until 2006 (EAPC 
4.5%; 95%CI: 0.8 to 8.4%). For men aged 55-64 incidence rates increased throughout the study period: 
EAPC 17.7% (95%CI: 0.8 to 37.3%) from 1991 to 1994 and 5.8% (95%CI: 4.9 to 6.8%) from 1994 to 2006.
For men over 75, incidence rates increased until 1994, but then decreased until 2006 with EAPCs of 
-1.8% (95%CI: -2.7 to -0.9%) for men aged 75-84 and -7.4% (95%CI: -12.1 to -2.7%) for men over 85.
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Figure 1 Age-standardised rates (European Standard Population) for incidence and mortality of prostate cancer in the 
Netherlands 1970-2006 (incidence rates 1970-1988: data Comprehensive Cancer Centre South; incidence rates 1989-
2006: data Netherlands Cancer Registry - no differences between CCCS and NCR data in period 1989-2006; mortality 
rates 1970-2006: Statistics Netherlands) 
 
 
Figure 2 Age-standardised incidence rates per 100,000 person-years (European Standard Population) for prostate 
cancer in the Netherlands 1989-2006, stratified by age category
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STAGE-SPECIFIC INCIDENCE
Since the introduction of the cT1c-category in the TNM-classification for PSA-detected prostate 
cancer in 1993, cT1c-tumour incidence rose to 35 per 100,000 person-years in 2006 (EAPC: 18.2%; 
95%CI: 16.0 to 20.5%) (Figure 3). The largest increase was observed from 2001 onwards. The incidence 
rate for cT1a/b-tumours dropped from 1992 to 1993 and decreased further until 2001. The incidence 
rate of cT2-tumours increased from 19 in 1989 to 37 in 1995 (EAPC 16.7%; 95%CI: 13.5 to 20.0%) 
and then decreased to 30 in 2006 (EAPC -1.6%; 95%CI: -2.7 to -0.5%). After increasing from 1989 to 
1994 (EAPC 12.4%; 95%CI: 6.0 to 19.3%), the incidence rate of cT3-tumours remained stable until 
the end of the study period (EAPC 1.4%; 95%CI: -0.2 to 3.0). The incidence rate of cT4/N+/M+-tumours 
decreased from 1993 to 1999 (EAPC = -4.5%; 95%CI: -6.6 to -2.2%), after which it remained stable. In 
absolute numbers, the annual number of diagnosed cT4/N+/M+-tumours increased gradually from 
1,345 cases nationwide in 1989 to 1,614 in 2006.
Figure 3 Age-standardised incidence rates per 100,000 person-years (European Standard Population) for prostate cancer 
in the Netherlands 1989-2006, stratified by clinical stage
Age-stratified analysis of these data shows that the increase in cT1c-tumours was most markedly 
present in men under 75 years of age and that increase seemed to accelerate from 2001 onwards 
(Figure 4a-c). The incidence rate of cT2-tumours rose quickly until the mid-1990s for all age categories, 
after which it remained stable for men under 75 and decreased for men over 75. The incidence rate 
of cT3-tumours gradually increased for men under 75 and remained nearly constant for men over 
75. The decrease in cT4/N+/M+-tumour incidence from 1993 to 1999 was most clearly present for 
men over 75.
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b
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Figure 4 Age-standardised incidence rates per 100,000 person-years (European Standard Population) for prostate cancer 
in the Netherlands 1989-2006, stratified by clinical stage in three age categories; a. < 65 years of age b. 65-74 years of 
age c. > 74 years of age
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The incidence rate of well-differentiated tumours increased from 1991 to 1995 (EAPC 8.3%; 95%CI: 
5.5 to 11.2%) and then decreased until 2003 (EAPC -6.1%; 95%CI: -9.2 to -2.9%) (Figure 5). For 
moderately differentiated tumours, the EAPC was 5.5% (95%CI: 4.2 to 6.9%) from 1989 to 2003. 
Since 2003, the incidence of well-differentiated tumours increased, while moderately differentiated 
tumours decreased.
Figure 5 Age-standardised incidence rates per 100,000 person-years (European Standard Population) for prostate cancer 
in the Netherlands, stratified by grade of differentiation (until 2003 the WHO grading system was used to determine 
differentiation; from 2004 onwards the Gleason scoring system was used: Gleason score 2-6 = well-differentiated, 
Gleason score 7 = moderately differentiated, Gleason score 8-10 = poorly differentiated)
CLINICAL UNDERSTAGING
17,117 patients underwent a radical prostatectomy. For these patients, both cTNM and pTNM were 
known. Approximately one third of these patients who were considered cT2 (n = 8868) were clinically 
understaged and had pT3 (n = 2675) or pT4 (n = 246). Patients classified as cT3 were overstaged in 27% 
of the cases with a known pT-classification (n = 136/499). The amount of understaging of cT2- and 
cT3-tumours remained relatively constant during the last 3 periods of diagnosis. Clinical overstaging 
of cT3 tumours occurred more frequently over time, rising from 18% in 1989-1993 to 37% in 2004-2006.
TREATMENT
For 1333 patients (1.1%) the primary treatment was not registered. These patients were excluded from 
this analysis. Over time, patients under 75 with cT1- and cT2-tumours more frequently underwent 
radical prostatectomy. Patients aged 65-74 with localised tumours underwent surgery less fre-
quently than their younger counterparts. Still, the percentage of men undergoing radical prostatecto-
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my almost doubled to 20% between 2004 and 2006. Radiotherapy as sole therapy increased mainly 
through increased application of brachytherapy. Active surveillance was chosen less often (from 
38% of all cT1-tumours in 1989 to 9% in 2006). This latter group included patients with incidental 
prostate cancer found during TURP. Patients under 75 with cT3-tumours received concurrent radio-
therapy and hormonal therapy in more than 70% of cases since the late 1990s. Patients over 75 with 
localised disease most often received either no therapy (60%, 30% and 20% of the patients with cT1-, 
cT2 and cT3-tumour, respectively) or hormonal therapy. 
For cT4/N+/M+ prostate cancer the only available therapy is hormonal therapy. This was given to 
80% to 90% of the patients in all age categories. The combination of radiotherapy and hormonal 
therapy was chosen for approximately 10% of patients under 75 years of age (data not shown).
SURVIVAL
Five-year relative survival significantly increased in all age categories under 85 and all stages (Figure 7). 
The age-stratified analysis showed that men aged 45-54 had the highest MAPC with 1.8% annual in-
crease (95%CI: 1.2 to 2.3%). This increase declined gradually with every higher age category to 1.3% 
(95%CI: 1.0 to 1.6%) for men aged 75-84 and no change for men over 85 years of age. The stage-
specific increase in survival was strongest for men with pT3/pT4-tumours with a MAPC of 1.6% 
(95%CI: 1.2 to 2.0%). Locally extended or metastatic cancer had the lowest MAPC with 0.4% annual 
increase in survival (95%CI: 0.2 to 0.7%).
MORTALITY
Disease-specific mortality rates increased from 1970 until 1995 (from 26 to 34 per 100,000 person-
years) (EAPC = 1.2; 95%CI: 1.0 to 1.3%) and then decreased to 26 in 2007 (EAPC = -2.5%; 95%CI -3.0 
to -2.0%) (Figure 1). This pattern was observed for all men over 65 years of age (figure 6) and was most 
evident in men over 85 years of age, with an EAPC from 1996 to 2007 of -3.4% (95%CI: -4.0 to -2.8%).
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a. 45-54 years, 55-64 years
b. 65-74 years,75-84 years, 85+ years
Figure 6 Age-standardised mortality rates per 100,000 person-years (European Standard Population) for prostate cancer 
in the Netherlands 1970-2006, stratified by age category
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Figure 7 
A. Five-year relative survival from prostate cancer by period of diagnosis, stratified by age category (*calculation by period 
analysis for period of diagnosis 2004-06)
B. Five-year relative survival from prostate cancer by period of diagnosis, stratified by pathological stage (*calculation 
by period analysis for period of diagnosis 2004-06); 
† significant change (p < 0,05) in five-year relative survival
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DISCUSSION
AGE-SPECIFIC INCIDENCE
Between 1989 and 2006, two periods with significant increases in prostate cancer incidence were 
observed. The increase in the first period, from 1989 to 1995, is often explained as an effect of PSA 
testing13,21,22. However, arguments exist against this explanation. In the Netherlands, PSA testing 
was introduced relatively slowly, although valid population-based data about the use of PSA tests 
throughout the study period are not available. An interim analysis of the Rotterdam section of the 
ERSPC found 8% effective contamination in the control arm between 1997 and 200023. Also, according 
to a Statistics Netherlands survey, in 2001 only 14% of men over 45 years of age had a PSA mea-
surement in the previous five years9. Moreover, the increase in incidence from 1989 to 1995 was 
present in all age categories, while PSA testing in asymptomatic men would be expected to be used 
less frequently among the elderly (over 75 years of age) because of reservations toward treatment 
for men with a relatively short life expectancy (less than 10 years). Although the percentage of men 
over 75 years of age who had a PSA test in the previous 5 years (40%) is approximately equal to the 
percentage of men between 55 and 75 years of age, 43% of all the men over the age of 70 who reported 
having had a PSA test, was between 70-74 years of age (Dr. Bruggink, Statistics Netherlands, personal 
communication). A difficulty with the interpretation of these percentages, though, is that with these 
numbers one cannot distinguish whether these PSA tests were the first to be undergone by the inter-
viewed men. This is unfortunate as the first PSA test is the most important one when testing for 
prostate cancer. Very likely, men who have had PSA tests before, will remain to be tested at a later 
age by their GP or urologist.
STAGE-SPECIFIC INCIDENCE
Unfortunately, there is no detailed information available about PSA-detected tumours before 1993, 
as the cT1c-category was only introduced in the cTNM classification (and the NCR registry protocol) 
in 1993. Therefore, the cT1a/b-category is heterogeneous until 1992, comprising both TURP-detected 
and PSA-detected prostate cancer. The stage-specific analyses from 1993 onwards reveal that 
cT1c-tumour incidence continuously increased and was accompanied by a decrease in the incidence 
of cT1a/b-tumours until 2001. This increase, together with the increase in cT2-tumour incidence until 
1995 and the decrease in cT4/N+/M+-tumour incidence from 1993 to 1999, results in the biphasic 
increase observed in the overall incidence. 
From these data, it can be deduced that the rise of prostate cancer incidence in the early 1990s was 
mainly caused by an increase in cT2-tumours, probably due to more frequent digital rectal examinations 
(DRE) and technical improvements in diagnostics, such as trans-rectal ultrasound (TRUS) imaging 
and the use of (thin) needle biopsies. Because cT1c-tumour incidence continued to rise while the 
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incidence of all other stages stabilised since 2000, PSA testing must have caused the subsequent 
peak from 2000 to 2006. This is further supported by the fact that incidence rates increased only for 
patients under 75 years of age and by the results of the Statistics Netherlands survey, which showed 
that the percentage of men over 45 years of age who had their serum PSA measured in the previous 
five years rose from 14% in 2001 to 26% in 20089. Direct population-based data to support this are 
not available, however.
Incidence rates of locally extended and metastatic (cT4/N+/M+) disease evidently decreased from 
1993 to 1999, particularly in men over 65. As interventions directed at detection of cancer in an earlier 
stage need time to show their beneficial effect on metastasised disease or mortality, a delay between 
the rise in localised tumours and decrease in metastasised tumours is to be expected. Also, one might 
expect to see a rise of localised prostate cancer in a younger age category, followed by a decrease 
in more advanced disease in an older age category. This study found a difference in onset of the 
increase in localised prostate cancer (1989/1990) and decrease of metastasised prostate cancer 
(1993) of approximately 4 years. This corresponds reasonably well to the effect of early detection of 
prostate cancer on mortality as observed in the ERSPC, which only became apparent after 7 to 8 years8. 
Thus, some change must have occurred around 1990, most probably an increased use of DRE, TRUS-
imaging and (thin) needle biopsies, but not yet PSA testing. However, this conclusion is somewhat 
speculative. Other factors might also have contributed to a rise in localised prostate cancer and the 
subsequent decrease in metastasised disease. 
From 1995 to 2003, more moderately differentiated tumours were detected, whereas the incidence 
of well-differentiated tumours decreased. Knowing that the incidence of cT1c-tumours increased in the 
same period, this could indicate that PSA testing was effective in detecting moderately differentiated 
tumours. The trend continued until the registration protocol was changed from the WHO grading 
system to the Gleason scoring system in 2004. Unfortunately, these systems are not easily inter-
changeable, as the WHO grading system is based on cellular and nuclear characteristics and the 
Gleason scoring system on growth patterns. The sudden changes in well-differentiated and moderately 
differentiated tumours around 2004 were most probably caused by this change in protocol.
Other western countries have shown similar increases in prostate cancer incidence in the study period. 
The situation in the United Kingdom might resemble the Dutch situation. In the UK, similar trends 
were seen with regard to prostate cancer incidence and mortality24. In the UK, as in the Netherlands, 
PSA uptake was considerably lower than in the USA, as illustrated by an overall annual rate of 6.0% for 
PSA testing in men aged 45-84 with no previous diagnosis of prostate cancer between 1999-200225. 
Consequently, it is possible that the rise in prostate cancer incidence in the UK in the early 1990s 
and the decrease in mortality since the mid-1990s was also caused by an increased prostate cancer 
awareness. Without an analysis of stage-specific data from the UK, however, this will remain unclear.
The overall prostate cancer incidence in the Netherlands is still considerably lower than in, e.g., Sweden 
and North America26,27. Interestingly, prostate cancer incidence has been decreasing in the USA 
since 200128. This might indicate that the “prevalent pool” of prostate cancer cases in the USA is being 
exhausted. The following years will show whether a similar trend will occur in the Netherlands and 
other western countries. 
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TREATMENT
Over time, patients under 65 with localised (cT1- and cT2-) tumours more often underwent surgery 
(radical prostatectomy). At the same time, the proportion of patients who received no therapy/
TUR-only decreased. This might again be explained by PSA testing. Since PSA became available, 
patients who were otherwise eligible for TURP may now have had a PSA test with, if indicated, sub-
sequent random prostate biopsies prior to the resection. This would result in an increasingly smaller 
proportion of prostate cancers detected at TURP29.
Patients under 75 with cT3-tumours received radiotherapy in 50% of the cases in the early 1990s. 
Since 1999, the combination of radiotherapy and hormonal therapy was chosen for over 70% of 
cT3-patients. This reflects that this combination is considered the gold standard for cT3 prostate 
cancer, as proposed by Bolla and colleagues in 199730. In addition to this indication, our data showed 
that, with time, this combination was also given more often to patients under 75 with cT1- and cT2-
tumours.
Men over 75 years have a life expectancy shorter than 10 years31. As a result, according to the guide-
lines, the majority of patients over 75 with a cT1-tumour did not receive therapy. Those who received 
treatment were most often treated with hormonal therapy. As for the younger patients, combined 
radiotherapy and hormonal therapy for cT3-tumours was applied more frequently with time.
Treatment options for cT4/N+/M+ prostate cancer are still very limited. Hormonal treatment remained 
the cornerstone of treating extensive disease, reflected by the fact that over 90% of these patients in 
all age categories received hormonal treatment. A small minority received radiotherapy in addition 
to the hormonal treatment.
SURVIVAL
Survival from prostate cancer improved for all stages and age categories, except for patients over 85. 
Tumour stage and grade changes may have played a role in this. With the development of new imaging 
techniques, tumour staging became more precise. This could result in upstaging, for example, of what 
previously would have been recorded a large cT2-tumour to a minimal cT3-tumour, consequently 
increasing survival in both strata. Also, a grade shift could have been caused by the insight that 
Gleason scores lower than 6 should not be based on needle biopsy material, an advice stated by 
Epstein in 2000 and adopted by the ISUP in 200532-34. However, as a decrease in prostate cancer 
mortality was also observed, this suggests that a genuine improvement of prostate cancer specific 
survival is also present.
MORTALITY
Prostate cancer mortality rates in the Netherlands have decreased since the mid-1990s. In most 
western European countries, a leveling-off of prostate cancer mortality rate has also been observed 
since the mid-1990s35. Another study comparing 1985-1989 with 1995-1998 found that prostate 
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cancer mortality for males between 65 and 84 years declined by 4% in the EU and 6% in the USA36.
The decrease in prostate cancer mortality in the Netherlands might again be attributed to PSA testing. 
However, we have argued that PSA testing probably did not cause the decrease in incidence of 
metastasised cancer from 1993 to 1999. A similar argument can be put forward for the mortality 
rates although, again, we cannot support this with hard data. As the decrease in mortality started in 
1996, the change most probably took place around 1990 (assuming approximately 7 years lag-time 
before an intervention shows an effect on mortality rates) and was therefore most probably due to 
an increased use of DRE, TRUS and needle biopsy rather than to PSA testing. In addition to this, more 
precise staging and, subsequently, better treatment might also have contributed to the decrease in 
prostate cancer mortality. Unfortunately, it is not possible to disentangle the extent to which these 
factors have played a role in the observed trends.
CONCLUSION
The NCR data presented here have shown that prostate cancer incidence increased between 1989 
and 2006. This increase was most likely caused by an increased application of DRE in combination 
with technical improvements in diagnostics (TRUS, (thin) needle biopsies), whereas the subsequent 
peak in prostate cancer incidence from 2000 to 2006 can be attributed to PSA testing. The decline in 
prostate cancer mortality from 1996 onwards may be the consequence of the increased detection 
of cT2 prostate cancer from 1989 to 1995. Other unobserved factors may also have played a role in 
causing these trends.
Prostate cancer was more often detected in an early stage and treated with a curative intent, lead-
ing to a decreased incidence of metastatic prostate cancer, a lower mortality rate and increased 
survival. Thus, it can be said that significant progress has been made against prostate cancer in the 
Netherlands. However, this progress has come at the expense of considerable overdiagnosis. With 
the rising burden of prostate cancer due to the ageing population, major improvements are still 
needed in the areas of biomarkers and detection, imaging, and staging in order to avoid overdiagnosis. 
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ABSTRACT
 
Objective To evaluate the additive value of the prostate cancer gene 3 (PCA3) urine test to serum 
PSA in prostate cancer (PC) screening among BRCA-mutation carriers. This study was performed 
among the Dutch participants of IMPACT, a large international study into the effectiveness of PSA 
screening among BRCA-mutation carriers.
 
Materials and methods Urinary PCA3 was measured in 191 BRCA1-mutation carriers, 75 BRCA2-
mutation carriers and 308 non-carriers. The physicians and participants were blinded for the results. 
Serum PSA ≥3.0 ng/ml was used to indicate prostate biopsies. PCA3 was evaluated (1) as an inde-
pendent indicator for prostate biopsies and (2) as an indicator for prostate biopsies among men with 
an elevated PSA. PC detected up to the two-year screening was used as gold standard as end-of-study 
biopsies were not performed. 
 
Results Twenty-three PCs were diagnosed, twenty of which in men with an elevated PSA in the initial 
screening round. 
(1)  PCA3, successfully determined in 552 participants, was elevated in 188 (cutoff ≥25; 34%) or 134 
(cutoff ≥35; 24%) participants, including two of the three PCs missed by PSA. PCA3 would have 
added 157 (≥25; 28%) or 109 (≥35; 20%) biopsy sessions to screening with PSA only. 
(2)  Elevated PCA3 as a requirement for biopsies in addition to PSA would have saved 37 (cutoff≥25) 
or 43 (cutoff≥35) of the 68 biopsy sessions. Seven or eleven PCs would have been missed, re-
spectively, including multiple high-risk PCs. So far, PCA3 performed best among BRCA2-mutation 
carriers, but the numbers are still small. Because PCA3 was not used to indicate prostate biopsies, 
its true diagnostic value cannot be calculated.
 
Conclusions The results do not provide evidence for PCA3 as a useful additional indicator of prostate 
biopsies in BRCA-mutation carriers, as many participants had an elevated PCA3 in the absence of 
PC. This must be interpreted with caution because PCA3 was not used to indicate biopsies. Many 
participants diagnosed with PC had low PCA3, making it invalid as a restrictive marker for prostate 
biopsies in men with elevated PSA.
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INTRODUCTION
Prostate cancer (PC) is the most frequently diagnosed cancer in men in the Western world1. Serum 
prostate-specific antigen (PSA) testing is the only commonly used biomarker for PC, but its low 
specificity has led to a consensus not to implement population-wide screening2,3. Possibly, the 
advantages of screening may outweigh the disadvantages for groups with an increased risk of PC. 
It has been suggested that carriers of a pathogenic mutation in one of the ‘breast cancer, early onset’ 
genes (BRCA1 or BRCA2) have an increased risk of PC4,5. Particularly, BRCA2-mutation carriers 
might present with PC at a younger age, more aggressive disease and shorter survival6-10. To evaluate 
the effectiveness of PSA screening in BRCA-mutation carriers, an international study was initiated, 
entitled ‘IMPACT: Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted 
screening in BRCA1/2 mutation carriers and controls’ (www.impact-study.co.uk). The results of 
IMPACT’s first screening round were already published. These preliminary results support PSA-
screening among BRCA2-mutation carriers11,12.
The large number of false-positive PSA-tests, particularly in the range of 3-10 ng/ml, has prompted 
ongoing research into new (bio)markers to improve PC diagnosis. One of the promising biomarkers, 
prostate cancer gene 3 (PCA3), was discovered in 1999 as a gene that is strongly up-regulated in 
PC13. Based on the prostate-specific and cancer-associated expression of PCA3, the PROGENSA® 
urine-based test was developed. Previous multicenter studies suggested that its specificity and 
sensitivity were significantly higher than serum PSA14-16. PCA3 is currently used as a biomarker to 
determine the need for repeat biopsies when PSA remains elevated after negative prostate biopsies. 
We aimed to determine the potential role of PCA3 in addition to PSA testing in this high-risk group 
by performing a sub-study among the Dutch participants of IMPACT.
MATERIALS AND 
METHODS
Men eligible for IMPACT, i.e., BRCA-mutation carriers and their relatives who were proven non-carriers, 
were identified and contacted by the ten Dutch Clinical Genetic Centres (CGCs). All eligible men re-
ceived an invitation by mail, including a detailed patient information leaflet describing IMPACT and 
the Dutch sub-study (IMPACT-NL). The IMPACT protocol has been described in detail elsewhere17. 
Due to restrictions set by the Dutch Minister of Health (the Dutch ‘Law on Screening’ requires all 
cancer screening projects to obtain ministerial approval), the IMPACT-NL protocol (figure 1) deviated 
from the IMPACT protocol: [1]the screening interval was once every two years instead of annually; 
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[2]men were eligible if they were between 45-69 instead of 40-69 years of age;[3]only men who were 
not tested for PC before, were eligible;[4]end-of-study biopsies were not allowed. Informed consent 
was sent to the study coordinator (JRB) at the Netherlands Foundation for the Detection of Hereditary 
Tumours (NFDHT).
Figure 1. The IMPACT screening protocol in the Netherlands, adapted accordingly to the ministerial approval
Abbreviations: BRCA: breast-cancer, early-onset gene; CGC: clinical genetic centre; FU: follow-up; PCA3: prostate cancer 
gene 3; PIN: prostate-intra-epithelial neoplasia; PSA: prostate-specific antigen
Of the 2,181 men who were invited, 500 refused consent and 458 did not reply. Of the 1,223 men 
providing informed consent, 552 had undergone previous PC testing (including 42 men with PC) and 
were excluded (figure 2). Of the 671 remaining men, 634 completed a baseline questionnaire and 
were referred to a urologist. In IMPACT-NL, in addition to a serum sample for PSA analysis (analyzed 
at the screening site) all participants provided a urine sample after digital rectal examination (DRE). 
The urine samples were collected by the urologist at the screening site, immediately transferred to 
collection & transportation tubes and sent to NovioGendix Servicelab (Nijmegen, the Netherlands). 
Upon arrival, the samples were frozen and stored. Samples were analyzed according to the manu-
facturer’s protocol in regular runs together with clinical samples, using the PROGENSA® PCA3 test. 
The initial screening round was completed by 574 participants (191 BRCA1-mutation carriers, 75 
BRCA2-mutation carriers and 309 non-carriers). To avoid interference with the IMPACT protocol, PCA3-
scores were not used to indicate prostate biopsies. To ensure this, both urologists and participants 
were blinded towards the PCA3-scores. 
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Figure 2. Flowchart of the invitations and response rates for the Dutch part of the IMPACT study
Prostate biopsies were taken at the Department of Urology of the hospitals of referral, which all adhere 
to the guidelines of the Dutch Association of Urology. According to this guideline, at least 8 trans-rectal 
prostate biopsies are taken (the traditional ‘sextant biopsies’ complemented with at least one extra 
biopsy on each side – preferably from the anterolateral peripheral zone). If prostate cancer was 
diagnosed, staging and treatment decisions were based on to the national guidelines at the discretion 
of the treating urologist.
If participants had an elevated PSA and negative prostate biopsies, they were re-screened after one 
year (repeat screening round). Men with a normal PSA in the initial screening were re-screened after 
two years. The results of the repeat and two-year screening round were also presented, as to enable 
the detection of PC up to and until the second screening (a two-year period) to serve as gold standard 
for the diagnostic performance in the initial screening round.
The NFDHT collected all data regarding PSA, prostate biopsies, PC diagnoses, staging and initial 
therapy by standardized forms completed by the treating physicians. These data were used to stratify 
the PCs into low-, intermediate and high-risk PCs using the 2014 NICE-classification, which is identical 
to the d’Amico risk classification: high-risk = all PC with lymph node or distant metastasis and PC 
with the following characteristics: ≥pT2c, PSA > 20 or Gleason score ≥ 8; intermediate risk = PC without 
high-risk features and with pT2b, PSA 10-20 ng/ml or Gleason score = 7; low-risk = PC without high-risk 
or intermediate-risk features18,19. If post-surgical TNM staging and Gleason score were not available, 
clinical stage and biopsy Gleason score were used. Data regarding carrier status and the PCA3 scores 
were sent directly to the study coordinator (JRB), who coded and stored all data. The first author (RC) 
was provided with an anonymized version of the database to perform the data analyses.
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STATISTICAL ANALYSIS
PCA3 was evaluated (1)as a supplementary test, indicating prostate biopsies if either PSA or PCA3 
was increased or (2)as a restrictive test, indicating prostate biopsies only if PCA3 was elevated among 
men with an elevated PSA. Cut-off values of ≥25 and ≥35 for PCA3 were evaluated and results were 
stratified by BRCA-mutation status. We calculated detection rates as a percentage of diagnoses for 
all participants per BRCA-mutation stratum and the positive predictive value (PPV) of the PSA test 
among the biopsied men per stratum. We calculated the Spearman rho correlation between PCA3 
and PSA and made cross-tables for the concordance between PCA3 and PSA.
RESULTS
The BRCA-mutation carriers and the non-carriers were comparable with respect to age, BMI and co-
morbidity. The BRCA2-mutation carriers more often reported a medical history of neoplasms (table 
1), particularly non-melanoma skin cancer (five non-carriers, two BRCA1- and two BRCA2-mutation 
carriers), colorectal cancer (two non-carriers, four BRCA1- and two BRCA2-mutation carriers) and breast 
cancer (one non-carrier and four BRCA2-mutation carriers).
Table 1. Baseline characteristics of the participants, stratified by BRCA-mutation status
BRCA1 carriers
N = 191
BRCA2 carriers
N = 75
Non-carriers
N = 309
Total
N = 575
Age group in years, n (%)
    45-49 38 (20%) 8 (11%) 44 (14%) 90 (16%)
    50-59 73 (38%) 33 (44%) 139 (45%) 245 (43%)
    60-69 80 (42%) 34 (45%) 126 (41%) 240 (42%)
Family history of prostate cancer
    Yes 25 (13%) 13 (17%) 51 (17%) 89 (15%)
    No 99 (52%) 39 (52%) 147 (48%) 285 (50%)
    Unknown 66 (35%) 23 (31%) 111 (36%) 200 (35%)
BMI (median, P5-P95) 26.5 (22.2-34.7) 26.2 (21.2-33.2) 26.5 (22.2-32.3)
Co-morbidity
    Cardiac disease 31 (17%) 15 (20%) 42 (14%) 88 (15%)
    Renal disease 6 (3%) 3 (4%) 18 (6%) 27 (5%)
    History of cancer 18 (10%) 13 (17%) 15 (5%) 46 (8%)
    LUTS 37 (20%) 20 (27%) 69 (22%) 126 (22%)
    Prostatitis 3 (2%) 2 (3%) 3 (1%) 8 (1%)
    Urinary tract infections 12 (6%) 4 (5%) 14 (5%) 30 (5%)
Abbreviations: BMI: body-mass index; BRCA: breast cancer, early onset gene; LUTS: lower urinary tract symptoms.
In the initial screening round, PSA was elevated in 75 participants (table 2). Six of these men also had 
abnormalities on DRE. Of the participants with an elevated PSA, 69 underwent prostate biopsies 
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including all six men with an abnormal DRE. In fourteen of these men PC was diagnosed (PPV 14/69 
= 20%), none of whom had abnormalities on DRE. Seven men with a normal PSA had abnormalities on 
DRE, four of whom underwent prostate biopsies. Also, four men with a normal PSA and a normal DRE 
underwent prostate biopsies. No PCs were found among these men. The detection rate in BRCA2-
mutation carriers was 4.0% versus 1.6% in BRCA1-carriers and 2.6% in non-carriers.
In the repeat screening round among 52 men with an elevated PSA and negative biopsies, five PCs 
were diagnosed. In the two-year screening round, 50 men had an elevated PSA, including four with an 
abnormal DRE. Twenty-five men underwent prostate biopsies. Four PCs were detected in 435 
screened men (78% of the 556 men at risk). One of these four men also had abnormalities on DRE in 
this round and three had a PSA <3.0 ng/ml in the initial screening round. PSA in the initial screening 
round was elevated for all thirteen intermediate- and high-risk PCs detected in this study (table 3), 
eleven of which were detected in the first biopsy session. PSA performed best among BRCA2-mutation 
carriers, i.e., in this group all PCs were detected in the initial screening round. Using the gold standard 
of PC detected in the first two years, the diagnostic performance of PSA among BRCA2 carriers was: 
PPV 25%, sensitivity 100%, negative predictive value (NPV) 100%, specificity 85%. DRE performed very 
poorly, with abnormalities in only two (one low-risk and one intermediate-risk PC) of the 23 PCs.
Table 2. Breakdown of serum PSA values and screening strategies at different time points, stratified by BRCA-mutation 
status
BRCA1 carriers BRCA2 carriers Non-carriers Total
Initial screening
Participants with valid serum PSA (n) 191 75 308 574
    Serum PSA ≥ 3.0 ng/ml 19 (10%) 12 (16%) 44 (14%) 75 (13%)
    Abnormal DRE 5 (3%) 3 (4%) 5 (2%) 13 (2%)
    Prostate biopsies 18 (9%) 12 (16%) 47 (15%) 77 (13%)
    Prostate cancer 3 (1.6%) 3 (4.0%) 8 (2.6%) 14 (2.4%)
1-year repeat screening (only for men with a known elevated PSA)
Participants with valid serum PSA (n) 17 7 28 52*
    Serum PSA ≥ 3.0 ng/ml 14 (82%) 2 (29%) 19 (68%) 35 (67%)
    Abnormal DRE 1 (6%) 0 1 (4%) 3 (6%)
    Prostate biopsies 7 (41%) 0 15 (54%) 22 (42%)
    Prostate cancer 2 (12%) 0 3 (11%) 5 (10%)
2-year screening
Participants with valid serum PSA (n) 148 (out of 186) 62 (out of 72) 225 (out of 298) 435* (out of 556)
    Serum PSA ≥ 3.0 ng/ml 18 (12%) 3 (5%) 29 (13%) 50 (12%)
    Abnormal DRE 2 (1%) 0 6 (3%) 8  (2%)
    Prostate biopsies 9 (6%) 2 (3%) 17 (8%) 28 (6%)
    Prostate cancer 1 (0.7%) 0 3 (1.3%) 4 (0.9%)
*Reported reasons for non-participation in the subsequent screening rounds were mainly: personal reasons (n = 19), 
health insurance issues (n = 28), other illness (n = 11), second-year screening still to be performed (n = 17), second-year 
screening results still to be received (n = 20).
Abbreviations: BRCA: breast cancer, early onset gene; DRE: digital rectal examination; PSA: prostate-specific antigen; 
PCA3: prostate cancer gene 3; PC: prostate cancer.
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Patient Detection Mutation status Age, yr Disease risk  
classification*
PSA
ng/ml†
Abnormal 
DRE†
PCA3 
score†
Gleason score† pTNM/cTNM Primary treatment
1 Initial screening Non-carrier 61 High 4,80 N >69 3+3=6 pT2cNxMxR0 RALP
2 Initial screening Non-carrier 62 High 4,80 N 21 3+3=6 pT2cN0R0 RRP
3 Initial screening Non-carrier 53 High 3,40 N 25 3+3=6 pT2cNxMxR0 RALP
4 Initial screening Non-carrier 62 High 3,28 N 23 3+3=6 pT2c RALP
5 Initial screening Non-carrier 65 High 4,70 N 30 3+3=6 pT2cN0M0 RALP
6 Initial screening BRCA1 mutation 64 Low 6,20 N 13 3+3=6 cT1c active surveillance
7 Initial screening BRCA1 mutation 57 High 3,70 N 27 3+3=6 pT2cNxMxR0 RRP
8 Initial screening BRCA2 mutation 61 Low 3,60 N 38 3+3=6 cT1c brachytherapy
9 Initial screening Non-carrier 62 High 9,90 N - 3+3=6 pT2cN0MxR0 RALP
10 Initial screening Non-carrier 60 Low 5,50 N 27 3+3=6 cT1c active surveillance
11 Initial screening BRCA2 mutation 55 High 4,50 N 14 4+3=7 pT3b RRP 
12 Initial screening Non-carrier 57 High 4,50 N 17 3+4=7 pT2c RALP
13 Initial screening BRCA2 mutation 61 High 6,30 N 61 8 pT2b RRP
14 Initial screening BRCA1 mutation 61 Intermediate 9,70 N 22 4+3=7 pT2aR0 RRP
15 Repeat screening Non-carrier 67 Low 4,40/2,50 N / N 40 NM / 3+3=6 cT2NxM0 active surveillance
16 Repeat screening Non-carrier 62 Intermediate 3,70/ - N / N 144 NM / 3+4=7 pT2aN0M0 RALP
17 Repeat screening BRCA1 mutation 67 Low 6,49/5,30 N / Y 56 NM / 3+3=6 - -
18 Repeat screening BRCA1 mutation 59 Low 9,00/4,40 N / N 103 NM / 3+3=6 cT1cNxMx active surveillance
19 Repeat screening Non-carrier 62 Low 4,20/11,0 N / N 16 NM / 3+3=6 cT1a -
20 Two-year screening BRCA1 mutation 57 Low 2,60/4,40 N / N 35 / >41 3+3=6 cT1c active surveillance
21 Two-year screening Non-carrier 60 Low 2,50/3,10 N / N 44 / 32 3+3=6 cT1cNxMx active surveillance
22 Two-year screening Non-carrier 53 Low 2,30/3,20 N / N <16 / 8 3+3=6 cT1c active surveillance
23 Two-year screening Non-carrier 59 Intermediate 9,2/11,0/14,9 N / N / Y 47 / - NM / NM / 3+3=6 cT1a -
x1 before IMPACT Non-carrier 50 Low 5,10 - - 5 pT2aNxMx RRP
x2 before IMPACT Non-carrier 59 High 5,40 - - 8 pT2cNxM0 laparoscopic / RALP
x3 before IMPACT Unknown 65 High - - - 6 pT3aNxM0 RRP
x4 before IMPACT BRCA1 mutation 61 High 7,90 - - 7 cT2cNxM0 TURP + thermo-ablation
x5 before IMPACT BRCA2 mutation 56 High 6,00 - - 7 pT2cNxMx RRP
x6 before IMPACT Non-carrier 56 High - - - 7 pT2cNxMx RRP
x7 before IMPACT BRCA1 mutation 58 High 6,20 - - 6 pT2cNxM0 RRP
x8 before IMPACT BRCA1 mutation 65 High 4,40 - - 7 pT2cNx laparoscopic / RALP
x9 before IMPACT BRCA2 mutation 61 High 12,3 - - 9 cT1cN0M0 EBRT
x10 before IMPACT BRCA1 mutation 59 Low - - - 6 pT2NxMx RRP
x11 before IMPACT BRCA2 mutation 52 High 130 - - 9 cT2NxM1B HT (surgical)
x12 before IMPACT BRCA2 mutation 63 Low 2,10 - - 6 pT2aNx laparoscopic / RALP
x13 before IMPACT Unknown 47 High - - - 9 cT3N1M1 HT (medicinal)
x14 before IMPACT Non-carrier 65 High - - - 6 pT2cNxMx RRP
x15 before IMPACT Non-carrier 59 High 7,70 - - - pT3aN0M0 RRP
x16 before IMPACT BRCA2 mutation 64 High 40,0 - - 7 cT1cN1M0 HT (medicinal)
x17 before IMPACT Unknown 65 High - - - 9 cT2cN1M0 HT (medicinal)
x18 before IMPACT BRCA1 mutation 59 Intermediate 16,3 - - - cT2bN0M0 EBRT + HT (medicinal)
x19 before IMPACT BRCA1 mutation 59 Low 6,3 - - 6 pT2aNxM0 laparoscopic / RALP
x20 before IMPACT BRCA2 mutation 59 High 25,6 - - 6 cT3aN0M1 HT (medicinal)
x21 before IMPACT BRCA2 mutation 50 High - - - 6 pT2cNxMx RRP
x22 before IMPACT BRCA1 mutation 59 Low 8,30 - - 6 cT1cNxM0 active surveillance
x23 before IMPACT Non-carrier 54 Low 3,70 - - - pT2aNxMx RRP
x24 before IMPACT Unknown 63 Low - - - - cT1cN0Mx active surveillance
x25 before IMPACT BRCA2 mutation 62 High 96,0 - - 7 cT3aN1M0 EBRT + HT (medicinal)
x26 before IMPACT Non-carrier 60 High 18,1 - - 6 cT2cN0M0 EBRT
x27 before IMPACT BRCA2 mutation 57 High 20,1 - - 7 pT2cN0M0 RRP
x28 before IMPACT Unknown 62 High 8,60 - - 7 pT2cNxM0 laparoscopic / RALP
x29 before IMPACT BRCA2 mutation 68 Intermediate 4,43 - - 7 cT1cNxM0 active surveillance
x30 before IMPACT BRCA2 mutation 51 High 29,5 - - 6 cT3aN0M0 EBRT + HT (medicinal)
x31 before IMPACT BRCA2 mutation 63 High 7,20 - - 8 cT3aN1M0 HT (medicinal)
x32 before IMPACT BRCA1 mutation 61 High 37,80 - - 7 cT3aN1M0 HT (medicinal)
x33 before IMPACT BRCA2 mutation 64 Intermediate 4,40 - - 6 pT2bNxMx RRP
x34 before IMPACT Non-carrier 60 Low 7,30 - - 6 cT1cNxM0 brachytherapy
x35 before IMPACT BRCA1 mutation 66 High 8,40 - - 6 pT2cN0M0 RRP
x36 before IMPACT BRCA2 mutation 62 High 15,3 - - 6 pT3aNxM0 RRP
x37 before IMPACT Non-carrier 58 Low - - - - cT2aNxM0 EBRT
x38 before IMPACT Non-carrier 57 High 6,40 - - 6 pT2cN0M0 laparoscopic / RALP
x39 before IMPACT BRCA2 mutation 63 Low 6,00 - - 6 pT2NxMx RRP
x40 before IMPACT BRCA2 mutation 68 Low - - - 6 cT1cNxM0 active surveillance
x41 before IMPACT BRCA1 mutation 63 Low - - - 5 cT1aNxMx TURP
x42 before IMPACT Non-carrier 54 High 134 - - 7 pT3bN0M0 EBRT + HT (medicinal)
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Table 3. (left page) Clinical and diagnostic characteristics of the Dutch prostate cancer patients detected in different 
screening rounds, including family members diagnosed with PC before IMPACT
* Risk stratification was performed according to the 2014 NICE guidelines: high-risk PC: any PC with pT ≥ T2c, pN+, 
pM+, PSA > 20 ng/ml or Gleason score ≥ 8; intermediate risk: any PC pT2b, PSA 10-20 ng/ml or Gleason score = 7; low-risk: 
all PCs with pT1-pT2a, PSA <10 ng/ml and Gleason score 6. If pathological TNM staging and Gleason score were not 
available, clinical stage and biopsy Gleason score were used.
† For men with PC detected after the initial screening round, outcomes of the tests, as well as the outcomes of previous 
prostate biopsy sessions are denoted in consecutive order.
Abbreviations: BRCA: breast cancer, early onset gene; DRE: digital rectal examination; EBRT: external beam radiation 
therapy; HT: hormonal therapy; NM: no malignancy (on prostate biopsy); PC: prostate cancer; PCA3: prostate cancer 
gene 3; PSA: prostate-specific antigen; RALP: robot-assisted laparoscopic prostatectomy; RRP: radical retro-pubic 
prostatectomy; pTNM/cTNM: tumor-node-metastasis staging system (post-surgical pathological vs. clinical stage); 
TURP: trans-urethral resection of the prostate.
The PCA3-score was successfully determined in 552 men (96%). Correlation between PSA and PCA3 
was 0.19 (figure 3). Use of PCA3 ≥25 as a supplementary marker would result in 157 additional 
biopsies, more than double the number of biopsies indicated by PSA alone (table 4). Among these 
157 men (28%), two men were diagnosed with PC during the two-year screening round, based upon 
an increased PSA. A PCA3-score ≥35 would indicate prostate biopsies for 109 (20%) additional men, 
including the same two men with PC diagnosed after two years. The results for PCA3 ≥35 were best 
for the BRCA2-mutation carriers (PPV 13% (in the absence of biopsies indicated by high PCA3), NPV 
98%), although the absolute numbers were small. 
Figure 3. Correlation (Spearman rho = 0.19) between serum PSA and urinary PCA3 in 552 participants with a valid PCA3-
score, stratified by BRCA-mutation status
Abbreviations: BRCA1/2: breast-cancer, early-onset gene 1/2; PCA3: prostate cancer gene 3; PSA: prostate-specific 
antigen
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Table 4. Concordance between PSA and PCA3 at the initial screening and cancer detection, stratified by BRCA-mutation 
status.
BRCA1 carriers BRCA2 carriers Non-carriers Total
PSA in the initial screening round 
Participants with valid PCA3 
score (n)
181 73 298 552†
PCA3 ≥25 PCA3 <25 PCA3 ≥25 PCA3 <25 PCA3 ≥25 PCA3 <25 PCA3 ≥25 PCA3 <25
  PSA ≥3.0 ng/ml 7    (3 PC) 10    (2 PC) 6    (2 PC) 5    (1 PC) 18  (7 PC) 22    (4 PC) 31    (12 PC) 37    (7 PC)
  PSA <3.0 ng/ml* 60  (1 PC) 104  (0 PC) 14  (0 PC) 48  (0 PC) 83  (1 PC) 175  (1 PC) 157  (2 PC) 327  (1 PC)
PCA3 ≥35 PCA3 <35 PCA3 ≥35 PCA3 <35 PCA3 ≥35 PCA3 <35 PCA3 ≥35 PCA3 <35
  PSA ≥3.0 ng/ml 5    (2 PC) 12    (3 PC) 6    (2 PC) 5    (1 PC) 14  (4 PC) 26    (7 PC) 25    (8 PC) 43    (11 PC)
  PSA <3.0 ng/ml 41  (1 PC) 123  (0 PC) 9    (0 PC) 53  (0 PC) 59  (1 PC) 199  (1 PC) 109  (2 PC) 375  (1 PC)
† Note that one of the men with PC (table 2, patient 9) did not have a valid PCA3-score.
* Only men with a PSA ≥3.0 ng/ml underwent prostate biopsies. The 3 PCs in men with an initial PSA <3.0 ng/ml were 
detected during the 2-year screening round; these participants underwent prostate biopsies because of a PSA that had 
increased to ≥3.0 ng/ml in the time between the initial and the 2-year screening round. Six of the PCs detected in men 
with a PSA ≥3.0 ng/ml were detected in the repeat and second screening rounds after negative biopsies in the previous 
screening round.
Abbreviations: BRCA: breast cancer, early onset gene; PSA: prostate-specific antigen; PCA3: prostate cancer gene 3; PC: 
prostate cancer.
Use of PCA3 to withhold biopsies in men with an elevated PSA would have reduced the number of 
biopsies in the initial screening round by more than half from 68 to 31 (table 4). A PCA3 cut-off of ≥35 
would have decreased this further to 25 biopsy sessions. This would come at the cost of missing, 
respectively, 7 and 11 PCs of the 22 PCs in this sub-study. Among these, multiple intermediate- and 
high-risk PCs would have been present.
DISCUSSION
This study did not find a clear role for PCA3 in addition to PSA screening among BRCA-mutation 
carriers. Use of PCA3 as a supplementary indicator of prostate biopsies seemed to result in a rela-
tively large number of additional prostate biopsies to identify only a few PCs. However, in the absence 
of end-of-study biopsies, it is impossible to estimate the real PPV of PCA3 at this point. We can conclude 
that a restrictive use of PCA3, i.e., to diminish the number of biopsies among men with an elevated 
PSA, is not a good strategy in this study population. Too many intermediate- and high-risk PCs 
would be missed, if prostate biopsies were to be withheld based on the PCA3-score. 
PSA in the initial screening round performed rather well, appearing to miss only three PCs that were 
detected in the two-year follow-up, although not all PCs were found in the first biopsy session. All PCs 
that were detected during the two-year screening round, were low-risk PCs that revealed themselves 
by an increased PSA during the two-year screening round. These results might be an overestimation, 
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as no end-of-study biopsies were performed. One may argue that end-of study biopsies would give 
a more reliable estimate of the negative predictive value of PSA than our somewhat arbitrary gold 
standard of PC detected in the first two years in this study. The counter argument is that end-of-
study biopsies lead to a considerable over-diagnosis of PC, as was shown, e.g., in the PCPT trial20. 
A better alternative for end-of-study biopsies is a much longer follow-up in order to see which men 
will be diagnosed with PC. Another comment to the current screening strategy could be that, even 
though it does not seem likely that many high-risk PCs were missed, the BRCA2-mutation carriers 
might require an even more stringent PSA cut-off, as discussed by Bancroft et al21. In the absence 
of end-of-study biopsies or longer follow-up we can only speculate about whether a different PSA 
cut-off should be used in BRCA2-mutation carriers. Unfortunately, a limitation of the study is that the 
financial resources prohibited more screening rounds. For example, for a good evaluation of the risk 
of interval cancers, complete follow-up until the third screening round is necessary. 
The results for PCA3 seem modest. For comparison purposes, the most important study is that by 
Roobol et al., which is to our knowledge the only study that used PCA3 (cut-off value PCA3 ≥10) as 
a supplementary indicator for prostate biopsies22. Their biopsy protocol (biopsy indicated for either 
PSA ≥3.0 ng/ml or PCA3 ≥10) resulted in 721 of the 965 men (75%) being biopsied. In these biopsy 
sessions, 122 PCs were diagnosed, only 19 of which were classified as ‘serious’ PCs (defined as 
stage ≥cT2a or any Gleason score >6, i.e., all non-serious PCs would be low-risk PCs according to 
the NICE definition)18. If they had used the higher cut-off as described in our sub-study to indicate 
prostate biopsies (PCA3 ≥35), this would still have resulted in biopsies in far too many men in their 
study (48% of their participants had a PCA3 ≥35 as compared to 24% in our study). The authors 
reported a higher PPV for PCA3 ≥35 (24%) when looking at all PC. However, only 16% of the detected 
PCs were intermediate- or high-risk PCs. The Roobol-study was different from ours in several ways: 
the participants were on average older and had all undergone multiple previous screening sessions. 
The most important difference is that PCA3 was used to indicate prostate biopsies. When compar-
ing the PPV in our study with yet other studies, the results in our study are still rather modest15,23,24. 
As discussed before, however, we cannot give a definitive statement about the PPV of PCA3 as follow-
up is still too short. With respect to the NPV of PCA3, the performance was also modest compared 
to the other studies. A relatively large number of intermediate- and high-risk PCs would have been 
missed at PCA3 cut-off values that have performed significantly better in previous studies. A possible 
explanation for this could be that PC in BRCA-families might have a different etiological pathway not 
involving (early) increased PCA3 expression. However, as no study investigated this hypothesis, we 
can only guess as to the correct explanation for the relatively modest performance.
In our sub-study, the BRCA2-mutation carriers had an increased prevalence of PC in the first screening 
round. This difference diminished, as PCs in the consecutive screening rounds were only detected 
among BRCA1 mutation carriers and non-carriers. The suggested association between BRCA-muta-
tions, particularly BRCA2-mutations, and PC risk is more supported by the number of PCs detected 
prior to the study (table 3). This may be the reflection of the genetically increased risk of PC that 
men with a BRCA-mutation have been reported to have. An alternative explanation is ascertainment 
bias. It is imaginable that particularly men with a known BRCA-mutation were more intensively screened 
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for PC before IMPACT than non-carriers, as a relationship between BRCA mutations and PC has 
been reported for quite some time. Either way, assuming that a causal relationship exists between 
a germline BRCA-mutation and PC, the exclusion of these family members from this study cannot 
affect the results among screening-naïve participants25. 
The fact that the highest PPV for PSA was found for BRCA2-mutation carriers, suggests that this might 
be the most interesting group for further research. PCA3 also performed best among BRCA2-mutation 
carriers. However, the absolute numbers (three PCs were detected among 75 BRCA2-mutation carriers) 
are small, warranting caution when drawing any conclusions. 
CONCLUSIONS
PCA3 should not be used as a restrictive marker next to PSA for PC screening in BRCA-mutation carriers. 
PCA3 did not show sufficient additive value to be implemented as a supplementary indicator of 
prostate biopsies next to PSA, although in the absence of prostate biopsies based on PCA3, its true 
diagnostic performance cannot be calculated. Longer follow-up is needed to show whether PCA3 
will be a valuable addition to any PC screening protocol.
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ABSTRACT
Background More than 70 single nucleotide polymorphisms (SNPs) have been reported to be asso-
ciated with prostate cancer (PC) risk; these were mainly identified in the general population with 
predominantly sporadic PC (SPC). Previous studies have suggested similar associations between a 
selection of these SNPs and hereditary PC (HPC). Our aim was to evaluate the effect of all known 
PC risk-SNPs and their discriminative value for SPC and HPC.
Methods Seventy-four PC susceptibility SNPs (reported in literature up to June 2014) were genotyped 
in a population-based series of 620 SPC patients, 312 HPC patients from the national Dutch registry 
and 1,819 population-based referents. Association analyses were performed using logistic regression, 
focusing on directional consistency of the odds ratios (ORs) with those in the original reports, i.e., 
whether the OR was in the same direction as in the original report. Discriminative performance was 
evaluated by a genetic risk score, used in logistic regression and receiver operating characteristic 
(ROC) curve analyses. 
Results Directional consistency was seen for 62 SNPs in SPC and 64 SNPs in HPC, 56 of which 
overlapped. ORs were mostly higher for HPC with 22 ORs >1.25 vs. 5 for SPC. Discriminative perfor-
mance was better for HPC with an area under the ROC curve of 0.73 vs. 0.64 for SPC. 
Conclusions A large overlap was found for the associations between low-penetrance susceptibility 
SNPs and SPC and HPC, suggesting a similarity in genetic etiology. This warrants a reconsideration 
of ‘HPC’ and a restrictive policy towards PSA testing in men with a positive family history. Genetic 
risk scores might be used for PC risk stratification on the population level.
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INTRODUCTION
Globally, 307,000 men died from prostate cancer (PC) in 20121. This high number fuels the continuous 
search of the global research community for better biomarkers to identify men at high risk of PC, to 
improve (early) detection, and to identify new therapeutic targets. In addition to urinary biomarkers 
such as PCA3 and TMPRSS2-ERG, 74 germline single nucleotide polymorphisms (SNPs, reported in 
literature up to June 2014) have been discovered that are associated with PC risk (Table 1). Most of 
these SNPs were identified and replicated in genome-wide association studies (GWAS) conducted in 
the general population, i.e., predominantly sporadic PC (SPC)2-5. SPC is considered to be multifactorial, 
resulting from a combination of environmental factors and rare to common genetic variants with 
small to modest risk-increasing effects. By contrast, the cause for ‘hereditary’ PC (HPC, defined as 
PC in three or more first-degree relatives, two or more first-degree relatives diagnosed under 55 years 
of age, or PC in three consecutive generations) is sought in high-penetrance mutations6. Linkage 
analysis studies in HPC families have indeed identified causal mutations, e.g., in RNASEL (HPC1), 
HPC2/ELAC and MSR17. However, these variants are rare and the results about their relevance in 
HPC are inconsistent among studies, making them inefficient as tests in genetic counseling. 
It has been suggested that a considerable part of HPC families may not have an increased PC risk 
caused by a high-penetrance mutation8. In these families, more likely an accumulation of SPCs has 
occurred, because of increased PC awareness and testing7-9. With the most recent discovery of PC 
susceptibility SNPs, it was estimated that the low-penetrance variants may explain as much as 30% 
of familial PC (FPC) risk10. In addition, the International Consortium for Prostate Cancer Genetics 
(ICPCG) found that 20 out of 25 SPC-associated SNPs were similarly associated with familial PC11. 
It is interesting to know whether these low-penetrance genetic risk factors for SPC play a similar 
role in HPC. A large overlap might indicate that HPC nowadays is predominantly an accumulation of 
SPCs. That would mean that the globally used HPC definition, based on the number of diagnoses in 
a family, might fail to identify men with an inherited risk of PC. It would imply that, for the greater 
part, the men in the HPC families are more likely part of the general population and merely at the end 
of a normal distribution of common low-risk risk variants. This could also mean that there is no 
good reason to pursue PSA screening in all HPC families if such screening is not advocated in the 
general population. Here, we aim to extend the findings of the ICPCG by performing association 
analyses for all 74 known PC risk-SNPs (as reported in the literature up to June 2014) in Dutch SPC 
and HPC patients and to compare their discriminative value for SPC and HPC.
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MATERIAL AND 
METHODS
PATIENTS AND REFERENTS
The SPC patients were recruited for a population-based study into the genetic susceptibility of PC 
and breast cancer (the EU 6th Framework Programme funded project ‘Polygene’), which has been 
described in detail elsewhere12. This study invited all newly diagnosed PC patients registered between 
2003-2006 by the Comprehensive Cancer Centre the Netherlands (IKNL), location Nijmegen, who 
were 75 years or younger at diagnosis, living in the IKNL catchment area, and alive at the date of 
invitation (between September 2006 and June 2007). After exclusion of all nonwhite, non-Western 
patients, 795 participants who completed a postal questionnaire and donated a blood sample were 
available for analysis. Of these participants, 175 (22%) were excluded because of a positive family 
history of PC. The HPC patients were recruited through the Netherlands Foundation for the Detection 
of Hereditary Tumours (NFDHT). The NFDHT registry holds 191 Dutch HPC families comprising 836 
HPC patients, including 663 with a PC diagnosis verified by medical file review13. All families were 
informed both by telephone and in writing about the current investigation in 2009, at which point 
378 of the 663 verified HPC patients were still alive. Eighteen families denied consent and 26 were 
non-informative, as all HPC patients were deceased. In total, 312 (81%) verified HPC patients, all of 
Caucasian descent, from 147 families provided sufficient material for germline DNA isolation, which was 
either saliva (Oragene® OG-500 DNA Tube) or blood (two vials). Clinical information was success-
fully collected for 613 SPC and 309 HPC patients by cancer registry personnel of the IKNL via medical 
file review and used to stratify patients for PC aggression. Aggressive PC was defined according to 
the d’Amico criteria, i.e., pT ≥ T2c, and/or pN+, and/or pM+, and/or PSA > 20 and/or Gleason score 
≥ 8. If a patient had missing data on one or more clinical characteristics, the remaining data were 
used to determine aggression using the same criteria. Aggressive PC was present in 387 SPC and 
204 HPC patients14.
The referents were selected from the Nijmegen Biomedical Study (NBS; a population-based investi-
gation initiated in 2001 by the Radboud university medical center (Radboudumc) in Nijmegen)15. 
In short, 6,468 age- and sex-stratified randomly selected inhabitants of Nijmegen completed a postal 
questionnaire including questions about lifestyle, health status and medical history and donated a 
blood sample for DNA isolation and biochemical studies. 1,980 of these participants, frequency-matched 
for age and gender to patients with PC and female patients with breast cancer were chip-genotyped 
(Illumina HumanHapCNV370-Duo BeadChip) to serve as referents in GWAS (financial limitations 
prohibited the chipping of all participants)16. A total of 1,819 referent samples passed quality control 
(sample yield ≥96% [after exclusion of intensity-only markers (n=23,573)], Caucasian ancestry ≥90% 
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[based on Structure analysis], SNP yield ≥96%). All participants provided written informed consent 
and approval to conduct these studies was obtained from the Institutional Review Board of the 
Radboudumc.
GENOTYPING
Germline DNA was isolated at the Radboudumc (HPC patients and referents) or at the deCODE 
Genetics facilities in Reykjavik, Iceland (SPC patients). Single-SNP genotyping for SPC and HPC was 
carried out by deCODE Genetics, applying the Centaurus (Nanogen) platform17. The quality of each 
Centaurus SNP assay was evaluated by genotyping each assay in the CEU and/or YRI HapMap sam-
ples and comparing the results with the HapMap publicly released data. Assays with >1.5% mismatch 
rate were not used. Correlated SNPs were used for rs11135910 (rs6984769; r2 = 1) and for rs2405942 
(rs35330386; r2 = 0.987), because we did not succeed in developing a working genotyping assay for the 
originally reported SNPs. For the referents, 10 SNPs had already been genotyped using the previously 
mentioned chip. For the other SNPs, single-SNP genotyping was performed as described above. 
Missing genotypes for the referents (due to quality control issues) were filled using imputed data 
from the genome-wide chip, which was available for 70 of the 74 SNPs (three X-chromosomal SNPs 
and rs3096702 were not imputed). Regarding imputation of the genome-wide chip data: 323,414 
SNPs passed quality control [minor allele frequency (MAF) ≥1%, and Hardy-Weinberg equilibrium 
(HWE) p-value >10-6] and were used for imputation using 1000genomes phase1 integrated version 
3 as a reference sample using IMPUTE v2 software. (http://mathgen.stats.ox.ac.uk/impute/impute_
v2.html)18. Genotype probabilities were extracted for the SNPs present in the imputed data and 
transformed to hard calls using the software GTOOL (http://www.well.ox.ac.uk/~cfreeman/software/
gwas/gtool.html) and a genotype probability threshold of 0.9. Correlations of genotypes measured 
with single-SNP assays and imputed genotypes were r2>0.9 for all SNPs except for rs2242652 
(r2=0.55), rs2736098 (r2=0.74), rs16901979 (r2=0.86), rs16902094 (r2=0.87), rs4054823 (r2=0.86), 
rs11649743 (r2=0.80), rs4430796 (r2=0.84) and rs5759167 (r2=0.83). Individuals with a SNP call rate 
<90% were excluded, leaving 609 SPC and 282 HPC patients and 1803 referents available for analysis. 
Very recently, a meta-analysis reported 23 additional SNPs for prostate cancer19. These new markers 
could not be included anymore in the present analysis because of logistical reasons.
STATISTICAL ANALYSES
Association analyses were performed using Plink v1.07 (http://pngu.mgh.harvard.edu/purcell/
plink/), Stata v9.1 (Statacorp, College Station, Texas, USA) and SPSS for Windows, release 20 (IBM 
Corporation, Armonk, NY, USA)20. Logistic regression models were used, assuming an additive relation-
ship between the risk variants and PC. ORs and 95% confidence intervals (95%CI) were calculated 
for SPC and HPC separately, relative to the referents. As the referents were age-matched, the logistic 
regression models only included the individual SNPs as a variable. The X-chromosomal SNPs were 
analyzed using male referents only. The ‘risk allele’ for each SNP, defined as the PC risk-increasing 
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allele, was extracted from www.genome.gov or from the original article (Table 1). Our prime interest 
was directional consistency of the ORs in the SPC and HPC groups as compared with the literature, i.e., 
an OR >1.00 for the risk-increasing allele in the patient groups. Statistical significance was considered 
to be of less relevance, because the difference in group size (the SPC group was twice as large as 
the HPC group) makes that SPC would need a smaller effect size to reach the same significance level. 
Additionally, analyses were stratified by tumour aggressiveness. The analyses for HPC were repeated 
using a generalized estimating equation (GEE) regression analysis, which takes familial correlations 
into account.
To compare the discriminative value of the 74 SNPs for SPC and HPC patients, genetic risk scores 
were constructed by summing the number of risk alleles carried by each individual. Because all 
SNPs were replicated previously and our main purpose was to compare SPC vs. HPC, all SNPs were 
included in the models, irrespective of statistical significance. The analyses were based only on 
patients and male referents with complete SNP data (169 SPC patients, 151 HPC patients and 587 
referents, respectively). The genetic risk score distribution among the referents with complete geno-
type data was used to generate 10 risk strata based on 10%-percentiles. Logistic regression was 
used to calculate the OR per stratum for SPC and HPC separately, as compared to the two middle 
strata (41st-60th percentile). The risk score was also evaluated as a continuous variable in a logistic 
regression analysis. The area under the receiver-operating characteristic curves (AUC) of the genetic 
risk score was also calculated. This was done for: (1) the subset of participants with complete geno-
type data; (2) all participants after imputation of missing genotypes with the mean risk allele dosage 
for each SNP in the subgroup that the participant belonged to.
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Table 2 lists the demographic and clinical characteristics of the groups. Tumor characteristics were 
comparable for the PC groups.
Table 2. Baseline and clinical characteristics of the SPC patients, HPC patients and referents
SPC patients
(N = 620)
HPC patients
(N = 312)
Referents
(N = 1,819)
Age at diagnosis (patients) or selection 
(referents) – mean / range
65 / 43-75 62 / 40-85 61 / 27-78
N % N % - -
T-stage
    T1 116 18.7 40 12.8 - -
    T2 285 46.0 148 47.4 - -
    T3 192 31.0 86 27.6 - -
    T4 15 2.4 7 2.2 - -
    unknown 12 1.9 31 9.9
N-stage
    N0/Nx 581 93.7 303 91.7 - -
    N1 39 6.3 9 2.9 - -
M-stage
    M0/Mx 594 95.8 306 98.1 - -
    M1 26 4.2 6 1.9 - -
Gleason score
    2-6 355 57.2 161 51.6 - -
    7 150 24.2 49 15.7 - -
    8-10 61 9.8 22 7.1 - -
    unknown 54 8.7 80 25.6 - -
PSA at diagnosis (ng/ml)
    <4 66 10.6 21 6.7 - -
    4-10 271 43.7 144 46.2 - -
    10-20 135 21.8 66 21.2 - -
    >20 137 22.1 65 20.8 - -
    unknown 11 1.8 16 5.1 - -
Aggressive PC*
    yes 387 62.4 204 65.4 - -
    no 226 36.5 105 33.7 - -
    unknown 7 0.9 3 1.0 - -
* Aggressive PC was defined as PC with any or more of the following characteristics: pT ≥ T2c, and/or pN+, and/or 
pM+, and/or PSA > 20 and/or Gleason score ≥ 8. If post-surgical pathological TNM staging and Gleason score were not 
available, clinical stage and biopsy Gleason score were used.
Abbreviations. PC: prostate cancer; HPC: hereditary prostate cancer; PSA: prostate-specific antigen
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SINGLE SNP ASSOCIATIONS FOR
SPC AND HPC
For SPC, 62 of the 74 SNPs showed directional consistency as compared to the literature (OR >1.00) 
(Table 1). ORs were mostly between 1.05 and 1.25, in accordance with the original reports. For HPC, 
64 SNPs showed directional consistency. Fifty-six of these overlapped with the SNPs with directional 
consistency for SPC. The ORs were higher in HPC, with 22 ORs exceeding 1.25, as compared to only 
five for SPC. The SNPs with the highest ORs overlapped for SPC and HPC, i.e., rs16901979 (SRRM1P1 - 
POU5F1B) and rs1447295 (intergenic variant near LOC727677).
In the stratified analysis, 64 ORs >1.00 were seen for non-aggressive SPC vs. 59 for aggressive SPC 
(data not shown). ORs >1.00 were seen for 62 SNPs in non-aggressive HPC vs. 60 in aggressive 
HPC. The ORs in the stratified analyses were similar to the overall analysis. The GEE-analyses for 
HPC [312 patients from 147 different families with a mean of two patients per family (range 1-7)], 
showed similar ORs with slightly wider 95% CIs (data not shown).
DISCRIMINATIVE VALUE OF 
SNPS FOR SPC AND HPC
With 74 SNPs (71 in autosomes and 3 on the X-chromosome), each person can carry between 0 and 
145 risk alleles. SPC and HPC patients carried more risk alleles than the referents (median [P5-P95] 
SPC: 67 [58-76]; HPC: 69 [60-78]; referents: 64 [55-73]) (Figure 1). The discriminative value of the 
SNPs was better for HPC and the genetic risk scores showed a clear dose-response pattern with in-
creasing ORs for men carrying more risk variants (table 3A/3B). In both groups, the top-20% of the 
risk-distribution had ORs of >1.8 as compared to the reference 41st-60th percentile group. The HPC 
patients had a higher per-allele OR than the SPC patients (1.14 vs. 1.09) and a higher AUC (0.73 
[95%CI 0.69-0.76] vs. 0.64 [0.62-0.67]).
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Figure 1. Distribution of the number of risk-alleles for SPC patients, HPC patients and male referents
Median number of risk alleles carried (P5-P95): SPC patients (n = 609) 67 (58-76); HPC patients (n = 282) 69 (60-78); 
referents (n = 894) 64 (55-73)
Table 3A. Genetic risk score analysis for SPC (n = 169) and HPC (n = 151) patients vs. all male referents with complete 
genotype data (n = 587)
Percentiles Risk alleles Referents SPC HPC
N N OR (95%CI) N OR (95% CI)
1-10% ≤ 57 59 11 0.73 (0.35-1.55) 2 0.17 (0.04-0.74)
11-20% 58-59 63 5 0.31 (0.12-0.84) 6 0.48 (0.19-1.22)
21-30% 60-61 67 9 0.53 (0.24-1.17) 4 0.30 (0.10-0.89)
31-40% 62 33 6 0.72 (0.28-1.85) 8 1.21 (0.50-2.92)
41-60% 63-65 130 33 reference 26 reference
61-70% 66 40 16 1.58 (0.79-3.16) 13 1.62 (0.76-3.45)
71-80% 67-69 84 34 1.60 (0.92-2.77) 27 1.61 (0.88-2.94)
81-90% 70-71 50 23 1.81 (0.97-3.38) 22 2.20 (1.14-4.23)
91-100% ≥ 72 61 32 2.07 (1.17-3.67) 43 3.52 (1.99-6.26)
Percentile categories were based on the risk allele distribution in the referents with complete genotype data. The ORs 
and 95%CIs were calculated in logistic regression analyses, as compared to the reference population median (i.e., the 
41-60% percentile), which was 63-65 carried risk alleles.
 
A separate logistic regression analysis using the genetic risk score as a continuous variable resulted in a per-allele OR 
of 1.09 (95%CI 1.05-1.12) for SPC and 1.14 (95%CI 1.10-1.18) for HPC.
 
Abbreviations: SPC: sporadic prostate cancer; HPC: hereditary prostate cancer; OR: odds ratio; CI: confidence interval
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Table 3B. Discriminative value of genetic risk models for SPC and HPC vs. male referents, calculated as the area under 
the receiver operating characteristic curve
Referents SPC HPC
N N AUC (95% CI) N AUC (95% CI)
Model 1: risk score (complete genotype data) 587 169 0.63 (0.59-0.68) 151 0.70 (0.66-0.75)
Model 2: risk score (missings imputed) 890 609 0.64 (0.62-0.67) 282 0.73 (0.69-0.76)
Abbreviations: SPC: sporadic prostate cancer; HPC: hereditary prostate cancer; AUC: area under the receiver operating 
characteristic curve; CI: confidence interval
DISCUSSION
This study evaluated the effects of all 74 known susceptibility SNPs for PC in both SPC and HPC 
groups. The differences between SPC and HPC were relatively small, while both patient groups clearly 
differed from the referents. The highest ORs for individual SNPs as well as for the risk scores were 
found for HPC. Stratified analyses indicated similar SNP effects for aggressive and non-aggressive 
PC. Recently published results from the ICPCG study in which 25 risk SNPs were evaluated, showed 
ORs similar to those of our study11. The ICPCG genotyped 9,516 patients who were classified as 
familial PC. They concluded that the majority of the known PC risk SNPs also contributed to the risk 
of familial PC, as well as to aggressive familial PC in a subgroup analysis. Our results very much resem-
ble the ICPCGs results, even though methodological differences between our studies are present. 
For instance, we used a less stringent definition of aggressive PC, genotyped an SPC group for direct 
comparison and included all known SNPs in the genetic risk score21. 
The similarity in SNP associations for SPC and HPC suggests an overlap in genetic etiology. Had PC 
in HPC families been caused by rare high-penetrance mutations (as has been assumed in all previous 
linkage analyses), then the low-penetrance SNP distribution of the HPC patients was expected to be 
similar to that of the referents. By contrast, our results show that the SNPs may even be somewhat 
stronger associated with HPC. This suggests that most likely (known or unknown) high-penetrance 
mutations play only a minor role in HPC etiology. The results raise the question whether, nowadays, 
the larger part of HPC is different from SPC at all. Since the HPC definition was introduced in 1993, 
an increasing number of men have undergone opportunistic testing for PC, particularly men with an 
affected relative. A previous study concluded that the increased diagnostic activity among men with 
a family history of PC in itself contributed to their PC ‘risk’9. Within some families this may have led to 
the detection of multiple (relatively low-stage) PCs and, subsequently, ‘HPC’. As a result, a (probably 
growing) part of HPC might simply be an accumulation of SPCs22,23. This is supported by a screening 
study among non-affected first-degree relatives of HPC patients, in which no elevated PC risk was 
found8. Also, population studies have not consistently shown differences between SPC and HPC 
with regard to clinical characteristics and prognosis, except for a lower age at diagnosis for HPC22,24. 
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The results of this study and the previous investigations may therefore warrant a revision of the 
HPC definition. In its current form it will continue to lose validity as a criterion for selection of men 
to undergo targeted PC screening and/or genetic (sequencing) studies to identify novel, rare mutations. 
A new definition should attempt to incorporate an adjustment for the number of male relatives and the 
clinical characteristics of the diagnosed PCs, including the fact whether the PCs were screen-detected 
or symptomatic. Obviously, in families with a known high-risk mutation or families in which aggressive 
PCs are detected at young age, individual targeted screening remains important to prevent PC-related 
mortality25. One of the mutations that may become important in the near future, is a relatively new 
G84E-variant in the HOXB13-gene, that was first described in the 4 American HPC-families25. The 
HOXB13-variant is not a SNP, as its population frequency in the Netherlands is <1%, so it was not 
included in this analysis. Still, also in our populations, the variant was more frequently present in both 
SPC (17/620 = 2.7%) and HPC (9/312 = 2.9%; this included one family with three affected carriers of 
the HOXB13-variant and one family with two affected carriers of the HOXB13-variant) than in the 
referents (7/1819 = 0.4%). In the (near) future, as also attempted in this study, genetic risk scores 
will hopefully be able to replace or complete family history in trying to better estimate an individual’s 
genetic susceptibility to PC. A comprehensive genetic test in the future might combine the SNPs 
with the known high-risk variants, such as mutations in, e.g., MSR1, BRCA2 and HOXB13 into one 
genetic risk score7,25,26. Although the currently known SNPs have limited discriminative power, 
Eeles et al. already demonstrated that risk-alleles might be used for risk stratification at the group 
level10. Our results support this idea, with ORs of >1.8 for the top-20% of the risk allele distribution, 
as compared to the population median. This indicates that these SNPs might already be useful in 
risk calculators that incorporate factors with similar ORs, such as family history, age and urinary 
complaints.
CONCLUSIONS
The results of this study suggest a large overlap between SPC and HPC with respect to low-penetrance 
susceptibility SNPs, indicating a similarity in genetic etiology. For a considerable part, nowadays, 
HPC most probably is merely an accumulation of SPCs. This warrants a discussion about the 
current value of the definition of ‘HPC’, as our results suggest that there might not be a strong 
reason to pursue PSA screening in all HPC families, as such screening is not advocated in the 
general population. Genetic risk scores could play a role in better risk stratification, if they are incor-
porated into risk calculators.
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ABSTRACT
Background 
- The definition of hereditary prostate cancer (HPC) is based on family history and age at onset only.
- There is limited data on the clinical phenotype of HPC.
Objective 
- To determine the prognosis of HPC in comparison with the sporadic form of prostate cancer (SPC). 
Design, Setting, and Participants
- HPC patients were identified through a national registry of HPC families in the Netherlands, 
 selecting patients diagnosed from the year 2000 onwards (n = 324). 
- SPC patients were identified from the Netherlands Cancer Registry (NCR) between 2003-2006 for 
a population-based study into the genetic susceptibility of PC (n = 1,664). 
- Detailed clinical data were collected by NCR-registrars, using a standardized registration form. 
Follow-up extended up to the end of 2013.
Outcome measurement and Statistical Analysis
- Differences between the groups were evaluated by cross-tabulations. Kaplan-Meier analyses 
were used to evaluate differences in progression-free and relative survival, the latter being a proxy 
for PC-specific survival. 
Results and Limitations
- HPC patients were on average three years younger at diagnosis, had lower PSA values, lower 
Gleason scores and more often locally confined disease. 
- Of the HPC patients, 35% had high-risk disease (NICE-criteria) versus 51% of the SPC patients.
- HPC patients were less often treated with active surveillance. 
- Progression-free survival after radical prostatectomy was comparable for HPC and SPC. The five-
year relative survival was 98% (95%CI 94-100%) for HPC vs. 90% (95%CI 88-92%) for SPC (p<0.01).
- The major limitation is the absence of a genetics-based definition of HPC which leads to over- 
diagnosis of PC in men with a family history of prostate cancer.
Conclusions
- HPC has a favorable clinical phenotype. 
- HPC patients more often underwent radical treatment. 
- The HPC definition should be re-evaluated, aiming at a reduction of over-diagnosis and overtreatment 
among men with multiple relatives diagnosed with PC.
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INTRODUCTION
Prostate cancer (PC) poses a major burden to society. It is the most frequently diagnosed cancer 
among Western males1. If detected at an early stage, PC can be treated curatively. Prostate-specific 
antigen (PSA), available since 1987, is the only commonly used test for early detection of PC2. PSA 
testing is advised in men in families with hereditary PC (HPC), as opposed to the general population 
(predominantly sporadic PC – SPC), in which the amount of overtreatment caused by PSA screening 
still outweighs the potential mortality benefit after 13 years of follow-up3,4. Because no genetic tests 
for high-penetrance genetic predisposition of PC are available, the definition of HPC is based on 
family history and age at onset only5. HPC is defined as PC detected in at least I. three first-degree 
relatives, II. two first- or second-degree relatives diagnosed before the age of 55 or III. three consecutive 
generations. Since the introduction of this definition in 1993, an increase has occurred in opportunistic 
PSA testing, particularly among family members of PC patients6. This may have led to an increase 
in the detection of relatively ‘low-risk’ PCs within families. As a consequence, an increasing part of the 
HPC families might represent clusters of PC due to increased PSA testing instead of high-penetrance 
genetic predisposition. This is supported by the findings of two recent studies that showed that the 
same low-penetrance genetic risk variants are found in SPC and HPC7,8. It could also mean that 
HPC patients have a relatively favorable prognosis, while intuitively HPC is the more ‘serious phenotype’ 
of PC. Only a few studies comprising series from the pre-PSA era have specifically reported on the 
clinical and prognostic characteristics of HPC, not finding any differences in staging, grading or 
prognosis9,10. If the clinical phenotype of PC in HPC-families is similar or, since the PSA era, even favor-
able as compared to SPC, the current management of HPC families needs revision. In this study, we 
aimed to evaluate whether clinical phenotype differences exist between HPC and SPC in the PSA era.
PATIENTS AND 
METHODS
HPC PATIENTS
The Netherlands Foundation for the Detection of Hereditary Tumours (NFDHT) holds a nation-wide 
registry of Dutch HPC-families. The NFDHT-registry is clinician-driven, i.e., all probands of families 
have been referred by a urologist who suspects HPC based on family history taking. After referral, a 
genetic registrar contacts the family and collects pedigree and medical data for all PC patients. All 
affected men are asked to provide written informed consent for access to their medical files to confirm 
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the diagnoses. For men who are already deceased before registration, their next of kin are requested 
to provide informed consent. 
For this study (conducted as part of the European Union 7th Framework Programme ‘ProMark: genetic 
PC variants as markers of disease progression’), all HPC-families registered until June 2011 were 
contacted (196 families, reporting 869 HPC patients, 676 of whom were confirmed by medical file 
review). The NFDHT data were expanded by extracting standard diagnostic data from the Netherlands 
Cancer Registry (NCR) and by medical file review. The medical file review was performed by the regis-
trars of the NCR held by the Comprehensive Cancer Centre the Netherlands (IKNL) using a standard-
ized registration form.
SPC PATIENTS
From 2003-2006, all men up to 75 years of age who were newly diagnosed with PC in the catchment 
area of the Netherlands Cancer Registry (NCR), location Nijmegen, were selected from the NCR to 
participate in the European Union 6th Framework Programme-funded Polygene study, which has 
been described in more detail before11. In short, for this study into the genetic susceptibility of PC, 
detailed clinical information was collected from medical files from a population-based series of PC 
patients (n = 1,664). In 2013, additional data were gathered for all these men by the registrars of the 
NCR, using an identical form as in the aforementioned data collection for HPC patients.
The completed data set for both groups comprised PC diagnostics, clinical and postsurgical TNM-
stage and Gleason grade (or WHO grade if Gleason score was not reported), primary and salvage 
therapies, disease progression and vital status. The patients were stratified by PC aggressiveness, 
according to the 2014 NICE-classification, which is similar to the d’Amico classification: high-risk = 
all PC with lymph node or distant metastasis and PC with the following characteristics: ≥cT2c, PSA 
> 20 or biopsy Gleason score ≥ 8; intermediate risk = PC without high-risk features and with cT2b, 
PSA 10-20 ng/ml or biopsy Gleason score = 7; low-risk = PC without high-risk or intermediate-risk 
features12,13. For patients with an unknown Gleason score, WHO-grade ≥ 3 was considered as a 
criterion for high-risk, WHO-grade 2 for intermediate-risk and WHO-grade 1 for low-risk PC. The study 
protocols were approved by the Institutional Review Board of the Radboud university medical center.
STATISTICAL ANALYSIS
To improve the comparability of the HPC and SPC patients, only the HPC patients who were diagnosed 
in the year 2000 or later (i.e., the PSA era) and who were 75 years of age or younger at diagnosis were 
selected. A total of 324 out of the 676 confirmed HPC patients met these criteria. For three patients, no 
clinical data could be retrieved (two because they were diagnosed abroad, one because the medical 
file was already destroyed), leaving 321 HPC patients available for analysis. All 1,664 SPC patients 
were included in the analysis. Differences between the two groups were evaluated by cross-tabu-
lations. Chi-square testing and the independent sample T-test were used to test for differences in 
categorical and continuous variables, respectively. Progression after radical prostatectomy (RP) 
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was defined as two separate serum PSA measurements ≥ 0.2 ng/ml, histologically confirmed recur-
rence, initiation of salvage treatment (started in the absence of ‘formal’ recurrence) or metastasis. 
Kaplan-Meier analyses and log-rank tests were used to evaluate differences in progression-free and 
relative survival as an alternative for PC-specific survival. Relative survival was calculated as the ratio 
of the survival per patient group to the survival in the age- and gender-matched Dutch population. 
For comparison purposes, the relative survival was also stratified by age (age at diagnosis <55, 55-65 
and 65-75 years of age). Where appropriate, 95% confidence intervals (95%CI) were calculated. Data 
analyses were performed using SPSS for Windows (release 20.0, IBM Corporation, Armonk, NY, 
USA) and SAS software (SAS system 9.3, SAS Institute, Cary, NC). 
RESULTS
The mean age of the HPC patients was 62.4 years versus 65.6 years for SPC (mean difference 3.1 
years, 95%CI 2.4-3.9 years) (table 1). HPC patients had lower pre-diagnostic serum PSA values, e.g., 
18% of the HPC patients had a serum PSA >20 ng/ml versus 29% of SPC (p<0.01). The HPC patients 
less often had locally extended disease (cT-stage ≥T3: 12.8% versus 23.1% of the SPC patients, 
p<0.01) and less often presented with lymph node (5.0% versus 8.3%, p=0.04) or distant metastases 
(6.2% versus 9.1%, p=0.09). Gleason scores were more often unknown for HPC patients (21% versus 
8%). When recoding the WHO-grades into Gleason scores, HPC patients more often had low-risk 
disease according to the NICE-classification: 34% versus 21%. Also, HPC patients less often had 
high-risk disease: 38% versus 51% (p<0.01).
Despite the favorable stage and grade distribution, HPC patients were less often treated with active 
surveillance: 7% versus 14% (table 2). Most often, they underwent localized radical treatment: 41% 
underwent a RP and 21% received RT versus 36 and 11% of the SPC patients. HPC patients less often 
received hormonal therapy (HT) as monotherapy.
The median follow-up was 66 months for HPC patients and 94 months for SPC patients. Biochemical 
recurrence rates after RP were comparable (table 2), with a five-year progression-free survival of 
78% for HPC versus 74% for SPC (p=0.16). The five-year overall survival was 90% (95%CI 86-93%) 
for HPC and 80% (95%CI 78-82%) for SPC. The five-year relative survival was 98% (95%CI 94-100%) 
for HPC and 90% (95%CI 88-92%) for SPC (p<0.01). When stratifying by age, this advantage for HPC 
was present only in men diagnosed under 65 years of age (figure 1).
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Table 1. Clinical characteristics of the HPC patients and SPC patients.
  HPC patients   SPC patients Difference
     (N = 321)     (N = 1664)
Age at diagnosis* N % N % p < 0.01†
    40-45 1 0.3 3 0.2
    45-50 9 3.1 15 0.9
    50-55 30 9.3 70 4.2
    55-60 69 21.5 245 14.7
    60-65 88 27.4 336 20.2
    65-70 66 20.6 471 28.3
    70-75 58 18.1 524 31.5
Period of diagnosis -
    2000-2002 86 26.8 - -
    2003-2005 132 41.1 1524 91.6
    2006-2008 79 24.6 140 8.4
    2009-2011 24 7.5 - -
Mean age at diagnosis* 62.4 65.6 Mean difference 3.1 years 
median (p5-p95) 63 (50-73) 67 (54-74) (95%CI 2.4 – 3.9 years)‡
Method of diagnosis p < 0.01†
    needle biopsy 297 92.5 1503 90.4
    TURP 8 2.5 111 6.7
    (cysto)prostatectomy 1 0.3 23 1.4
    unknown/other 15 4.7 27 1.6
Serum PSA at diagnosis (ng/ml) p < 0.01†
    <4 48 14.9 170 10.2
    4-10 134 41.7 653 39.2
    10-20 62 19.3 342 20.6
    >20 59 18.4 475 28.5
    unknown 18 5.6 24 1.4
cTNM-stage
    cT1 120 37.4 622 37.4 p < 0.01†
    cT2 138 43.0 601 36.1
    cT3 34 10.6 333 20.0
    cT4 7 2.2 52 3.1
    cT0/Tx 22 6.9 56 3.4
    cN0/Nx 305 95.0 1526 91.7 p = 0.04†
    cN+ 16 5.0 138 8.3
    cM0/Mx 301 93.8 1513 90.9 p = 0.09†
    cM1 20 6.2 151 9.1
Gleason score biopsy p < 0.01†
    2-6 187 58.3 979 58.8
    7 42 13.1 325 19.5
    8-10 24 7.5 222 13.3
    Gleason score unknown: 68 21.2 138 8.3
        (WHO grade 1)     22     6.9     51     3.1
        (WHO grade 2)     16     5.0     21     1.3
        (WHO grade 3/4)     4     1.2     5     0.3
        (WHO grade unknown)     26     8.1     61     3.7
NICE-risk stratification** p < 0.01†
    low-risk PC 109 34.0 349 21.0
    intermediate risk PC 90 28.0 462 27.8
    high-risk PC 122 38.0 853 51.3
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†. Chi-square test used to test for differences between categorical variables
‡. Student-T test used to test for differences between normally distributed continuous variables
* The maximum age for inclusion in this study was set at 75 years of age, according to the Polygene study
** PC risk stratification based on the 2014 NICE-guidelines. High-risk PC = all PC with lymph node or distant metastasis 
and localized PC with any or more of the following characteristics: cT ≥ T2c, PSA > 20 or biopsy Gleason score ≥ 8; 
intermediate risk PC = localized PC without any of the high-risk features and with cT = T2b, PSA 10-20 ng/ml or biopsy 
Gleason score = 7; low-risk PC = localized PC without any high-risk or intermediate-risk features, i.e., cT1-T2a, PSA< 10 
ng/ml and biopsy Gleason score ≤ 6. If the Gleason score of the biopsy was not reported/unknown, a WHO grade ≥ 3 
was considered as a criterion for high-risk PC, WHO grade 2 was considered a criterion for intermediate-risk PC and 
WHO grade 1 as considered a criterion for low-risk PC, if available.
 
Abbreviations. 95%CI: 95% confidence interval; HPC: hereditary prostate cancer; PC: prostate cancer; PSA: prostate-specific 
antigen; SPC: sporadic prostate cancer; TURP: trans-urethral resection of the prostate
Table 2. Treatment characteristics and prognosis of the HPC and SPC patients.
 HPC patients   SPC patients
    (N = 321)     (N = 1664)
Primary treatment
    active surveillance 22 6.9 227 13.7
    localized therapy
    RP 130 40.5 600 36.1
    cryotherapy - 3 0.2
    radiation therapy 66 20.6 183 11.0
        EBRT     34     10.6     123 7.4
        brachytherapy     32     10.0     60 3.6
    RP + RT 2 0.6 5 0.3
    systemic therapy
    RP + HT 5 1.6 16 1.0
    EBRT + HT 50 15.6 288 17.3
    HT monotherapy 37 11.5 323 19.4
    chemotherapy - - 1 0.1
    other therapy - - 3 0.2
    unknown 8 2.5 15 0.9
Progression after RP*
5-year progression-free survival 78% (95%CI 70-86%) 74% (95%CI 72-76%)
Survival
5-year overall survival 90% (95%CI 86-93%) 80% (95%CI 78-82%)
5-year relative survival 98% (95%CI 94-100%) 90% (95%CI 88-92%)
† Kaplan-Meier analyses (and log-rank testing) were used to test for differences in survival.
* Progression after RP was defined as the occurrence of any of the following events: biochemical recurrence, i.e., two 
serum PSA measurements ≥ 0.2 ng/ml; histological evidence of local recurrence; initiation of salvage treatment (e.g., 
radiation therapy) without documented evidence of biochemical recurrence; detection of metastatic disease. 
 
Abbreviations: EBRT: external-beam radiation therapy; HT: hormonal therapy; RP: radical prostatectomy; RT: radiation 
therapy
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Figure 1. Relative survival per patient group, stratified by age at diagnosis. A. Age at diagnosis < 55 years of age. 
B. Age at diagnosis 55-64 years of age. C. Age at diagnosis ≥ 65 years of age.
DISCUSSION
We found that, in the Dutch population, HPC patients were diagnosed at a younger age. This is logical 
considering the age-criterion of HPC and consistent with previous reports9,10. As men in HPC families 
are expected to be at risk for early-onset, aggressive PC, men in ‘HPC families’ are advised to undergo 
annual PSA screening between 50-75 years of age in the Netherlands3. This means that the screening 
advice itself can lower the average age at PC diagnosis. A similar phenomenon could occur if the 
first PC patient is one of the older brothers. His younger siblings might be more aware of PC, which 
could lead to lower ages at diagnosis. It may also lead to the detection of more non-aggressive PCs and 
eventually even a HPC ‘diagnosis’14. The younger age at diagnosis was accompanied by a beneficial 
clinical phenotype of HPC, as can be illustrated by the lower percentage of high-risk disease (38% 
versus 51%). One should bear in mind that, if the Gleason score was not available, the WHO-grade 
was used for NICE-risk stratification. This may have led to small differences, as a higher percentage 
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of the HPC patients had an unknown Gleason score (21% versus 8%). This was probably due to the fact 
that part of the HPC patients was diagnosed before 2003, when WHO-grading was still the standard. 
Because a central pathology revision was not performed, we preferred to use the WHO-grade as a 
surrogate for the Gleason score, instead of leaving Gleason score ‘missing’.
HPC patients were less often treated with active surveillance. This is remarkable, as more HPC patients 
were eligible for this option according to the risk classification (34% low-risk disease versus 21% for 
SPC). One explanation for this could be that active surveillance was not yet commonly advised as a 
therapy option in the beginning of the 21st century (2000-2002). Another explanation could be that 
men in HPC families were more inclined to undergo radical treatment: they might have been more 
afraid of dying from PC or they have close relatives with good experiences of a specific treatment. 
The role of the urologist could also be of importance, although we are not aware of any specific data 
on this topic. Interestingly, brachytherapy was chosen more often by HPC patients (10% versus 4%). 
It could be that this relatively low-impact treatment (as compared to RP) was chosen as an alternative 
for active surveillance for low-risk HPC patients. 
No differences were seen in progression-free survival after RP. Unfortunately, the absolute numbers 
are too small to evaluate progression after other local therapies (including RT). Remarkably, for 
HPC, the relative survival in patients diagnosed under 65 years of age was superior to SPC. This 
might be the result of extensive and early PSA testing, which is known to happen particularly within 
families6. This phenomenon may even have led to the registration of families as ´HPC´ without the 
presence of a high-penetrance genetic predisposition for prostate cancer. 
Unfortunately, we were not able to stratify the SPC cohort into men with and without a family history 
of PC, i.e., ‘familial PC’ (FPC) and ‘true’ SPC, as the questionnaire covering this item was only completed 
by 956 of the 1664 Polygene-participants at a later stage of the study in 2008. In an attempt to deal 
with this, family history was included as an item in the clinical data collection, but it was not reported 
in the medical files in a remarkably high 75% of the cases. An exploratory analysis of the 956 SPC 
patients who completed the questionnaire identified a beneficial stage distribution for the 210 men 
with FPC, which would be in line with results in this article (FPC versus SPC: cT ≥ T2c 28% versus 
37% (p=0.06); cN+ 4% versus 8% (p=0.06); cM+ 3% versus 5% (p=0.22)). The differences were not 
statistically significant, though, and the Gleason score distribution was similar (data not shown). 
Recent studies showed that SPC and HPC were largely similar with respect to the prevalence and 
associated risks for known low-penetrance genetic variants7,8,15. Most of these studies focused on 
the potential of these single nucleotide polymorphisms (SNPs) to aid in the identification of men at 
increased risk of PC, concluding that the SNPs also explain part of the PC risk in familial PC (FPC) 
or HPC. Much fewer studies have reported in detail on the clinical phenotype of HPC. A literature 
search (December 2014) in PubMed identified only two original (non-review) articles on prognosis 
of FPC and HPC (see supplementary data)9,10. Grönberg et al. evaluated the prognosis for 241 familial 
PC cases as compared to 304 non-familial cases, while Bratt et al. evaluated 201 HPC patients and 
402 age-matched controls with non-hereditary PC. Both found no differences with respect to tumor 
grade, initial therapy or overall and prostate-cancer specific survival. To our knowledge, the current 
analysis is the largest and only PSA era study into the clinical characteristics of HPC. Given our results 
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and the results of the literature search, we conclude that there is no convincing evidence that HPC 
is more aggressive than SPC. 
In our opinion, a discussion should be initiated about the recommended strategies for men with 
multiple affected relatives (HPC). Obviously, in certain families, PC is highly prevalent and aggressive. 
In these families, it is important to provide timely PC counselling and screening. In families in which 
mainly asymptomatic low-risk PCs were diagnosed, it is doubtful whether family members benefit 
from increased PC awareness, diagnostics and treatment. Therefore, in the absence of a genetic 
test for HPC, we suggest that HPC is redefined. The focus should move from the number of affected 
relatives to the phenotype of the PCs within a family. We suggest to ignore all patients with low-risk 
PC (i.e., <cT2b stage and Gleason score ≤ 6 and PSA < 10) as well as all patients with localized prostate 
cancer diagnosed above 75 years of age in the count of the number of patients within the family. In 
the future, this phenotypic definition of HPC may be replaced by a genetic definition, if a comprehensive 
genetic PC-test including all known high-risk variants as well as the PC susceptibility SNPs becomes 
available16,17. Such a test might be used to select men for PC screening in a population-wide setting. 
CONCLUSIONS
HPC in the PSA era has a beneficial clinical phenotype as compared to SPC. HPC patients more often 
underwent radical treatment, emphasizing the need for an incorporation of the clinical phenotype 
into the HPC definition. This might reduce over-diagnosis and overtreatment among men with multiple 
relatives diagnosed with PC
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ABSTRACT
A family history of prostate cancer (PCa) is an established risk factor for PCa. In case of a positive 
family history, the balance between positive and adverse effects of prostate-specific antigen (PSA) 
testing might be different from the general population, for which the European Randomized Study 
of Screening for Prostate Cancer (ERSPC) showed a beneficial effect on mortality. This, however, 
went at the cost of considerable overtreatment. This study assessed Dutch physicians’ knowledge 
of heredity and PCa and their ‘post-ERSPC’ attitude towards PCa testing, including consideration of 
family history. In January 2010, all Dutch urologists and clinical geneticists (CGs) and 300 general 
practitioners (GPs) were invited by email to complete an anonymous online survey, which contained 
questions about hereditary PCa and their attitudes towards PCa case-finding and screening. 109 
urologists (31%), 69 GPs (23%) and 46 CGs (31%) completed the survey. CGs had the most accurate 
knowledge of hereditary PCa. All but 1 CG mentioned at least one inherited trait with PCa, compared 
to only 25% of urologists and 9% of GPs. CGs hardly ever counseled men about PCa testing. Most 
urologists and GPs discuss possible risks and benefits before testing for PCa with PSA. Remarkably, 
35 to 40% of them do not take family history into consideration. Knowledge of urologists and GPs 
about heredity and PCa is suboptimal. Hence, PCa counseling might not be optimal for men with a 
positive family history. Multidisciplinary guidelines on this topic should be developed to optimize 
personalized counseling. 
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INTRODUCTION
A positive family history of prostate cancer (PCa) is an established risk factor for PCa. First-degree 
relatives of affected men have a 2-3 fold increased risk of PCa1. When 3 or more first-degree relatives 
are affected (or at least 2 first-degree relatives before the age of 55 years), the family is considered a 
‘Hereditary Prostate Cancer’ (HPC) family according to the so-called Johns Hopkins or Carter criteria2. 
An estimated 5-10% of PCa has a genetic cause. Yet, only a few very rare high-penetrance gene muta-
tions have been identified to cause HPC3. In recent years, genome-wide association studies have 
added approximately 40 low-penetrance genetic polymorphisms that are associated with an increased 
risk of PCa4,5. Several polymorphisms have also been identified that are associated with serum 
prostate-specific antigen (PSA), the most commonly used marker for early detection of PCa6,7. 
An ongoing matter of debate is whether prostate-specific antigen (PSA) testing should be used 
for population-wide screening8. In a population-based setting, the European Randomized Study of 
Screening for Prostate Cancer (ERSPC) showed a decrease in PCa mortality of 31% in the screening 
arm after correction for non-attendance and contamination. However, this mortality reduction coin-
cided with considerable overtreatment9,10. By contrast, the Prostate, Lung, Colorectal and Ovarian 
Cancer Screening Trial (PLCO), found no effect of PSA screening on mortality11, but suffered from 
methodological problems which severely hamper interpretation of the results12. 
Previous studies into the effectiveness of PSA screening in men with an increased risk due to family 
history have yielded largely inconsistent results. These range from a marked benefit for men in 
high-risk PCa families (particularly for families with early onset PCas) to a decreased risk of PCa for 
non-affected men in HPC families13,14. The increasing use of PSA testing in the general population 
has also had an important influence on men with a family history of PCa. Men with a positive family 
history are relatively more active in pursuing PSA testing than men in the general population. This 
has led to an increased detection of mainly of small localized tumors15.
To guide the public and physicians in translating the results of the ERSPC and PLCO into clinical 
practice, the Dutch Association of Urology (NVU) and the Dutch College of General Practitioners 
(NHG) concurrently released a policy statement in March 2009. This statement referred men to a 
website (http://www.prostaatwijzer.nl/) with information about PCa and PSA testing and advised 
them to consult their GP for further counseling16. It did, however, not discuss dealing with a family 
history of PCa or HPC. To date, in absence of official internationally accepted guidelines, the advice 
is to attempt to distinguish genetic predisposition-based families with multiple PCa cases from 
ascertainment-based multiple-case families and offer PCa screening only to the former13.
This study assessed the knowledge of Dutch urologists, GPs and clinical geneticists (CGs) about 
HPC and PCa as a phenotype in hereditary syndromes. Furthermore, their attitude towards PCa 
testing and the role of family history in clinical decision-making about PCa testing were assessed. 
To our knowledge, this is the first study to investigate this in different professions that counsel men 
about PCa testing.
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MATERIALS AND 
METHODS
After publication of the results of the ERSPC and PLCO and the statements of the NVU and NHG, an 
online survey was developed17. This survey, targeted at Dutch urologists, GPs and CGs, contained 
questions about HPC and assessed the participants’ general attitude towards PCa testing. In addition 
to this, it inquired into the role that family history played in the physician’s daily clinical practice 
regarding PCa testing. The survey also included case descriptions of a man requesting to be tested 
for PCa. This fictitious man presented at different ages, in absence of family history and physical 
complaints. The survey could be completed anonymously.
In January 2010, all Dutch urologists (n=351), clinical oncogeneticists (n=32), clinical geneticists in 
training (n=50) and genetic counselors (n=68) were invited by e-mail from their respective profes-
sional associations. GPs in the region of the Comprehensive Cancer Centre East (CCCE) who were 
enlisted to receive the CCCE’s e-newsletter (n=300) were invited by e-mail. 
For statistical analysis, descriptive analyses were performed, stratified by profession. Because of small 
numbers, clinical oncogeneticists, CGs in training and genetic counselors were pooled into one stratum 
(CGs). Chi-square testing was used to test for differences between professions. Participants who 
never counseled men about PCa testing were excluded from the analysis.
RESULTS
In total, 225 surveys were completed (overall response rate 28%). These were submitted by 109 
urologists (31%), 69 GPs (23%) and 46 CGs (31%). One pediatric urologist and two CGs were excluded 
from analyses because they never counseled men for PCa testing. Occasionally, participants did 
not complete all questions, causing small differences in the subtotals for different questions. Of the 
urologists, 66% (71/107) counseled men about PCa testing at least once a week and 93% (100/107) 
did this at least once a month. In comparison, 85% of the GPs (59/69) did this at least once a month, 
as opposed to only 2% (1/44) of the CGs.
By contrast, the CGs had the most accurate knowledge of the HPC criteria: 72% (31/43) correctly 
selected the minimum of three affected first-degree relatives for the criterion that is most frequently 
fulfilled (Table 1). In comparison, only 36% (38/105) of the urologists and 18% (12/66) of the GPs 
correctly selected this criterion (p<0,001). A majority of the GPs (59%) indicated not to know this 
definition. CGs were also best informed about the number of affected first-degree relatives with a 
PCa diagnosis before 55 years of age to meet the definition of HPC, although the differences between 
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the groups were smaller. The third definition of HPC, i.e., three consecutive generations with PCa, 
was known to only a few participants.
Almost all CGs (41/42, 98%) listed at least one inherited trait with PCa as part of the phenotype, 
compared to only 24% (25/103) of the urologists and 9% (6/66) of the GPs. The most frequently 
mentioned traits were the BRCA2 gene mutation (n=60), the BRCA1 gene mutation (n=40) and Lynch 
syndrome (n=10). The rare HPC1, HPCX, MSR1, RNASEL and HPC2/ELAC2 mutations were sporadically 
mentioned.
Table 1. Responses to the question “What is the minimum number of relatives with prostate cancer to meet the Carter 
criteria1 for hereditary prostate cancer (HPC)?”
Urologists GPs CGs
Number of affected first-degree relatives (all ages)†
Two 35 (33%) 9 (14%) 1 (2%)
Three 38 (36%) 12 (18%) 31 (72%)
Four 1 (1%) 2 (3%) 2 (5%)
> Four 3 (3%) 0 (0%) 1 (2%)
Don’t know 15 (14%) 39 (59%) 7 (16%)
Not a criterion 13 (12%) 4 (6%) 1 (2%)
Total 105 66 43
Number of affected first-degree relatives (diagnosis < 55 years of age)†
Two 72 (68%) 33 (48%) 34 (76%)
Three 6 (6%) 0 (0%) 3 (7%)
Four 1 (1%) 1 (1%) 0 (0%)
> Four 5 (5%) 2 (3%) 0 (0%)
Don’t know 12 (11%) 32 (46%) 7 (16%)
Not a criterion 10 (9%) 1 (1%) 1 (2%)
Total 106 69 45
Number of consecutive generations with prostate cancer†
Two 10 (10%) 10 (15%) 9 (21%)
Three 15 (15%) 6 (9%) 5 (11%)
Four 3 (3%) 1 (2%) 1 (2%)
> Four 2 (2%) 1 (2%) 0 (0%)
Don’t know 25 (25%) 39 (58%) 10 (23%)
Not a criterion 44 (44%) 10 (15%) 19 (43%)
Total 99 67 44
    yes 387 62.4 204
    no 226 36.5 105
    unknown 7 0.9 3
† p<=0,001 for differences between the physician groups
1 correct answers are underscored
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Urologists had the least reservations towards PCa testing in a man with no physical complaints and 
no family history of PCa: 46% (32/69) of the GPs and 49% (22/45) of the CGs preferred to refrain 
from testing unless there were strong reasons to test (Table 2), as compared to 31% (33/108) of the 
urologists. For a man presenting at 55 and 75 years of age, urologists and GPs gave similar answers. 
Between 70% and 80% of them would first inform him about the possible benefits and risks of PCa 
testing. CGs were more inclined not to test for PCa. At 45 years of age, more physicians in all groups 
would not test for PCa. 
Table 2. Responses to the question “Would you test this man for PCa?” regarding a man with no physical complaints/
no family history of PCa, requesting to be tested for PCa
 
Age at presentation Test for prostate cancer Urologists GPs CGs
General attitudea Will test, unless… 35 (32%) 13 (19%) 3 (7%)
Will not test, unless… 33 (31%) 32 (46%) 22 (49%)
Leave choice to patient 37 (34%) 22 (32%) 9 (20%)
Other* 3 (3%) 2 (3%) 11 (25%)
45 years of age Yes 20 (19%) 5 (7%) 1 (2%)
No 12 (11%) 18 (26%) 28 (64%)
First discuss pros and cons of prostate cancer testing 75 (70%) 46 (67%) 15 (34%)
55 years of ageb Yes 29 (27%) 16 (23%) 1 (2%)
No 0 (0%) 1 (1%) 16 (36%)
First discuss pros and cons of prostate cancer testing 79 (73%) 52 (75%) 27 (61%)
75 years of agec Yes 21 (19%) 10 (15%) 9 (21%)
No 8 (7%) 3 (4%) 14 (33%)
First discuss pros and cons of prostate cancer testing 79 (73%) 56 (81%) 20 (47%)
*Answers under “Other”: most often (8/11) CGs indicated not to perform this kind of testing themselves, but would refer the 
man to their GP 
a. p<0,001 for differences between the physician groups
b. No significant difference between urologists and GPs; p=0,40
c. No significant difference between urologists and GPs; p=0,45
 
Age played a role when considering PCa testing. Of the urologists, 70% reported to use age limits, 
with 45 years as the mean and median lower age limit. This lower age limit was higher for GPs (60% 
reported age limits) and CGs (30% reported age limits), with 50 years of age being the median lower 
age limit. The median maximum age limit was 80 years (mean 77) for urologists and GPs, compared 
to 75 years (mean 74) for CGs. CGs always took family history into consideration when deciding 
whether or not to test for PCa. By contrast, 35 to 40% of urologists and GPs answered that family 
history would not influence the decision whether or not to test for PCa (table 3). This did not vary 
between physicians with different general attitudes towards PSA testing (p = 0.47 for the urologists 
and p = 0.78 for the GPs), as was assessed in a previous question.
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Table 3. Responses to the question (A) “Does family history play a role in the decision whether or not to test a man for 
PCa?” and the follow-up question (B) “How extensively do you inquire about the family history?”
A.
Does family history play a role? Urologists GPs CGs
Yes 67 (62%) 44 (65%) 40 (98%)
No 41 (38%) 24 (35%) 1 (2%)
Total 108 68 41
B.
Extent of inquiring about the family history?
Only PCa 29 (43%) 16 (37%) 0 (0%)
PCa and other malignancies 38 (57%) 27 (63%) 40 (100%)
Total 67 43 40
 
A majority of the urologists (76%) knew the ERSPC and PLCO results, compared to only 14% and 8% 
of CGs and GPs, respectively. Ninety-two percent (75/82) of the urologists who knew the studies 
found the ERSPC results more valuable. The statements of NVU and NHG, advising men to visit the 
website and consult the GP if further counseling was needed, were better known than the results of 
the trials: 85% (92/108) of the urologists and 59% (41/69) of the GPs was familiar with the statements. 
Of them, 12% (11/91) of the urologists and 24% (10/41) of the GPs did not agree with the statements. 
Only 2 of the 43 CGs (5%) were familiar with the statements.
DISCUSSION
A positive family history of PCa is an important risk factor for PCa and the balance between pros 
and cons of PSA testing may be different in men with affected relatives. It is therefore remarkable 
that urologists and GPs are poorly informed about HPC. Only one in three urologists and one in five 
GPs is familiar with the criteria for HPC. Almost 60% of the GPs indicated not to know the definition. 
CGs were better informed, but they hardly ever counsel men about PCa testing.
The BRCA1 gene mutation was frequently selected as an inherited trait with PCa as part of the 
phenotype. The evidence for an increased risk of PCa due to a BRCA1 gene mutation is quite weak, 
though. By contrast, for BRCA2 gene mutations (selected by 14 urologists and all 42 CGs) there is 
fairly solid evidence of familial clustering of aggressive PCa18,19. Lynch syndrome was also selected 
10 times, 7 times of which by urologists. Recently, an elevated risk of PCa for carriers of a mismatch-
repair gene mutation was indeed found20. This has, however, not been confirmed in other studies, 
so it remains unclear whether the physicians who selected Lynch syndrome are correct. It should be 
noted that urologists and GPs hardly ever counsel patients with an elevated PCa risk based on these 
inherited traits.
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In general, urologists reported the least reservations towards PCa testing and would test at a younger 
age than GPs and CGs. However, the majority of urologists and GPs stated to first discuss the risks 
and benefits of PSA testing and only test if a man would still want to be tested. So, even though 41% 
of GPs was not familiar with the statements regarding PCa testing and 92% of them did not know the 
ERSPC and PLCO results, they adhered just as well to the guidelines as the urologists. Participants 
who disagreed with the NVU/NHG statements, mostly indicated that the statements lacked attention 
for patients’ preferences.
In contrast with the urologists and GPs, CGs would more often not test for PCa. This might be 
explained by the fact that the CGs mainly have an advisory role and refer their patients to a GP or 
urologist for PCa testing. CGs hardly ever counsel men about PCa testing, as there is no frequently 
occurring genetic defect known to cause PCa. This may change, however, when more data become 
available about the risk of PCa among BRCA2 carriers. An international study is currently examining 
this risk (www.impact-study.co.uk).
One of the most striking observations might be that more than one in three urologists and GPs 
would not take family history into account when deciding whether or not to test a man for PCa. 
Intuitively, one would think that men with a positive family history, and thus a higher a-priori risk of 
PCa, would benefit more from PSA screening. Arguing against this is that HPC cases do not seem 
to differ from sporadic cases with respect to Gleason scores and PCa-specific survival21,22. Even 
more so, screening programs amongst non-affected men in HPC families have shown that the 
chance of finding PCa in non-affected men in HPC families is low13. 
Although we did not address this in our study, when a man requesting PCa testing does have, e.g., 
an affected brother, he will very likely be tested, not in the least for reasons of anxiety management. 
However, whether this is beneficial, is doubtful. To better guide physicians in this matter, an addendum 
to PCa guidelines should be developed in a multidisciplinary collaborative effort, describing how to 
deal with PCa testing in case of a positive family history and HPC. The conclusion from a previous 
study to assess the extent and nature of the family history (predisposition-based vs. ascertainment-
based) might well serve as a starting point for such a guideline13. In addition to this, the use of decision 
aids, e.g., the SWOP-PRI should be promoted23, as they already include the effect of family history 
in the risk estimates.
The results of this study should be interpreted with some caution. Although the responder groups 
were reasonably large in absolute numbers, the response rate was only 31% at best (for urologists and 
CGs). Hence, it is difficult to extrapolate the results to all Dutch physicians providing PCa counseling. 
Even more so, if physicians with more interest in this topic completed the survey more often, the 
results regarding knowledge about HPC and adherence to guidelines might be overoptimistic. On 
the other hand, intuitively physicians who take care of most of the counseling are most eager to 
complete the survey. It is also important to bear in mind that the results may not easily be extrapolated 
to other countries as they may be influenced by the health care system. In the Netherlands, e.g., men 
cannot visit a urologist without a referral from their GP.
In conclusion, the majority of urologists and GPs adhered to PCa testing guidelines. However, these 
guidelines do not include family history and many physicians indicated not to consider family history. 
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Hence, PCa counseling might not be optimal for men with a positive family history. We propose that 
additional guidelines on this topic are developed in a multidisciplinary effort to optimize counseling.
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ABSTRACT
Objective Some studies have suggested an inverse association between acne vulgaris and the acne-
related bacterium Propionibacterium acnes and prostate cancer (PCa). Self-reported acne might be 
an easily obtainable marker to identify men at relatively low risk of PCa and might be incorporated 
into PCa risk calculators. This study aimed to evaluate the association between self-reported acne 
and PCa in a large case-referent study.
Methods and materials The case group comprised 942 PCa patients recruited from a population-
based cancer registry in 2003 to 2006, 647 of whom met the criteria for aggressive PCa. The referents 
(N=2,062) were a random sample of the male general population. All subjects completed a question-
naire on risk factors for cancer, including questions about acne. Odds ratios (ORs) and 95% confidence 
intervals (95%CI) were calculated using multivariable logistic regression for PCa and aggressive 
PCa as separate endpoints, while adjusting for age and family history of PCa.
Results A history of acne was reported by 320 cases (33.9%) and 739 referents (35.8%). Self-reported 
acne was not significantly associated with PCa (adjusted OR=0.95; 95%CI 0.80-1.12) nor with 
aggressive PCa: adjusted OR=0.97 (95%CI 0.80-1.18). 
Conclusion Self-reported acne is not suitable as a marker to identify men at low risk of aggressive PCa.
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INTRODUCTION
Early detection of prostate cancer (PCa) is possible by testing serum prostate-specific antigen (PSA)1. 
Population-based PSA screening is not adopted, though, as this would coincide with considerable 
overtreatment2. Therefore, the global research community is evaluating new (bio)markers that may 
identify men at increased risk of (aggressive or ‘clinically significant’) PCa, in whom the benefits of 
screening might outweigh the adverse effects. Established PCa risk factors are African descent, older 
age and a positive family history of PCa, but none of these has sufficient discriminative power to be 
used in a public health setting.
Androgens play an important role in PCa growth and development and have been a target for PCa 
treatment since the 1950s. Although the exact relationship between androgens and the risk of PCa 
is still to be unraveled, androgen status is an obvious target to serve as a marker for PCa3. Several 
proxies for androgen status, e.g., acne vulgaris and male-pattern baldness, have been investigated 
as possible markers for PCa4-9. The associations between either acne or male-pattern baldness and 
PCa were most often of inverse nature, but were also often not statistically significant.
Recently, besides this suggested link with acne as a proxy for androgen status, another possible 
mechanism to underlie an association between acne vulgaris and PCa was studied. Propionibacterium 
acnes (P. acnes), a skin bacterium associated with acne, is known to be prevalent in prostate tissue 
and has been suggested to be associated with prostatic inflammation and PCa carcinogenesis10,11. 
In a large case-referent study, an association was found between higher concentrations of circulating 
P. acnes antibodies and a decreased risk of PCa, particularly locally advanced and metastatic PCa12. 
The authors hypothesized that the higher antibody titers may reflect an increased immune response 
against P. acnes, providing cross-immunity against its possible carcinogenic effects.
In theory, the identification of men at relatively low risk of PCa by simple phenotypes such as a history 
of acne could result in screening policies with a better balance between intended and unintended 
effects. This might be achieved by incorporating information about acne history into PCa risk calcu-
lators and decision aids. In this paper, we describe a large case-referent study on the association 
between self-reported acne and PCa. 
METHODS AND  
MATERIALS
The study population and study design have been described in detail before13,14. In brief, the case group 
was recruited for an ongoing study on genetic susceptibility of (prostate) cancer (Polygene study; 
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www.polygene.eu). All patients diagnosed with PCa in the period 2003-2006 and registered by the 
regional cancer registry held by the Comprehensive Cancer Centre the Netherlands (IKNL) Location 
Nijmegen were included. Eligibility criteria were age at diagnosis of 75 years or younger, alive at the 
date of invitation to the study and living in the catchment area of the IKNL. Overall, 1330 patients 
met these criteria and were invited for the study between September 2006 and June 2007. In total, 
1020 patients stated to be willing to participate (77%). Participation consisted of donation of a blood 
sample and completion of a risk factor questionnaire. Finally, 956 patients (72%) actually completed 
the questionnaire. The registration staff of the IKNL had already collected clinical and pathology data 
of all patients in the cancer registry. These standard data were supplemented with more detailed 
information obtained from the medical files in the 7 hospitals where the patients were treated.
The referents were recruited for the Nijmegen Biomedical Study (NBS; www.nijmegenbiomedische-
studie.nl), a population-based survey conducted in 2002 by the Department of Epidemiology and 
Biostatistics and the Department of Clinical Chemistry of the Radboud University Nijmegen Medical 
Centre (RUNMC). 21,756 (49% of whom were males) age and sex-stratified randomly selected in-
habitants of Nijmegen, the Netherlands, were invited to fill out a questionnaire and donate two tubes 
of blood for a study on gene-environment interactions in multifactorial diseases such as cancer. 
9,350 people returned a completed questionnaire (response 43%), 46% of whom were males. The NBS 
participants who had completed the NBS questionnaire, had given consent for further research, 
were still alive and had known addresses (N=7,950 of whom 3,625 were males) were contacted 
again in 2008 and invited to fill out an additional questionnaire containing, among others, questions 
about acne. 5,613 individuals (2,552 males) completed the questionnaires (response 71%). Participants 
with a history of PCa at the time of recruitment in 2002 were excluded from the analyses.
The questions about acne inquired whether the subject ever had acne, at what age the acne had 
started and ended, and the location of the acne (face, shoulders/neck, back, and chest). All non-
Western, non-white subjects were excluded from the analyses, as it is known that acne patterns differ 
between different races and because non-Western, non-white subjects comprise only a small 
minority in this part of The Netherlands15. Referents under 43 years of age (the youngest age of 
diagnosis among the PCa cases) were excluded to improve the comparability of the age distributions 
of cases and referents.
All participants in the POLYGENE and NBS studies were fully informed about the goals and procedures 
of the study and gave written informed consent. The study protocols were approved by the Institutional 
Review Board of the RUNMC.
STATISTICAL ANALYSIS
The association between acne and PCa was evaluated by cross-tabulation. For participants who re-
ported a history of acne, the location of the acne was specified, including the proportion of participants 
reporting that location within the participant group.
Odds Ratios (ORs) and corresponding 95% confidence intervals (CI) were calculated in order to 
quantify the strength of the association between acne (all locations) and PCa. Multivariable logistic 
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regression modeling was used to calculate the association between acne and PCa adjusted for positive 
family history (dichotomized, i.e. ≥ 1 first-degree relative with PCa, included in the model as a nominal 
variable) and age at the time of completing the questionnaire (continuous linear variable). Acne was 
included in the models as a dichotomous (nominal) variable, using no acne as reference category.
Additional analyses were performed using aggressive and non-aggressive PCa as separate endpoints. 
Aggressive PCa was based on d’Amico’s criteria for PCa progression and defined as PCa with any of 
the following characteristics: pathological T-stage≥T2c or positive lymph nodes or distant metastasis 
or a Gleason score of 8 or higher or a pre-diagnostic serum PSA higher than 20 ng/ml16. The clinical 
TNM stage was used for disease stage if pathological TNM was not available. Likewise, the Gleason 
score of the biopsy specimen was used if there was no Gleason score available from a radical pros-
tatectomy. A second analysis for aggressive PCa was performed, replacing the criterion pT≥T2c by 
pT≥T3, to compare our results to the analysis performed by Severi et al.12. SPSS version 16.0.01 
was used for statistical analysis.
RESULTS
The total number of men with PCa in this study was 956. Fourteen non-Caucasian cases were ex-
cluded from the analyses. Of the 2,552 male referents who completed the questionnaire, 2,484 were 
Caucasian. Of these men, 422 were younger than 43 years at time of completion of the questionnaire 
and were excluded from the analyses. Table 1 lists the characteristics of the 942 cases and 2,062 
remaining referents in the analysis, as well as the PCa-related characteristics of the cases. Of the 
cases, 22% had a positive family history of PCa, compared to 6% of the referents.
In the overall analysis, there were no apparent differences between cases and referents for self- 
reported acne (table 2). Of the cases with non-aggressive PCa, 31.9% reported acne, as compared 
to 34.9% of the cases with aggressive PCa. For the cases who did report acne, the distribution of acne 
over the body did not differ between aggressive and non-aggressive cases. Among the participants 
who had reported acne, isolated facial acne was reported less often among referents than among 
cases.
In the multivariable logistic regression analysis (table 3), adjusted for family history and age at com-
pletion of the questionnaire, no association was found between self-reported acne and PCa: OR 0.95 
(95%CI 0.80-1.12). The same was true for the subgroup analyses, which showed that there was no 
association between acne and either aggressive PCa (OR 0.97; 95%CI 0.80-1.18) or non-aggressive 
PCa (OR 0.90; 95%CI 0.67-1.19). Also when using a different cut point for aggressive PCa, replacing 
the criterion pT≥T2c by pT≥T3, acne showed no significant association with aggressive PCa: OR 
0.96 (95%CI 0.76-1.22), nor with non-aggressive PCa: OR 0.94 (95%CI 0.75-1.16).
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Table 1. Characteristics of cases and referents and PCa-related characteristics of cases 
Cases Referents
All cases
(N = 942)
Aggressive PCaa 
(N = 647)
Non-aggressive 
PCaa (N=295)
All referents
(N = 2062)
N % N % N % N %
Age at completion of the  
questionnaire in years
<55 34 3.6 25 3.9 9 3.1 458 22.2
55-59 93 9.9 66 10.2 27 9.2 222 10.8
60-64 193 20.5 141 21.8 52 17.6 263 12.8
65-69 230 24.4 168 26.0 62 21.0 241 11.7
70> 392 41.6 247 38.2 145 49.2 878 42.3
Mean age in years (SD) 67.2 (6.4) 66.8 (6.3) 68.1 (6.7) 66.3 (12.4)
Median age in years 68.0 67.0 69.0 66.9
Family history of PCa
No first-degree relative affected 732 77.7 499 77.1 233 79.0 1945 94.3
≥1 first degree-relative affected 210 22.3 148 22.9 62 21.0 117 5.7
Clinical T-stage
cT1 382 40.6 185 28.6 197 66.8 - -
cT2 363 38.5 273 42.2 90 30.5 - -
cT3 171 18.2 171 26.4 - - - -
cT4 16 1.7 16 2.5 - - - -
cT0/x 10 1.1 2 0.3 8 2.7 - -
Clinical N-stage
cN0 375 39.8 297 45.9 78 26.4 - -
cN1 65 6.9 64 9.9 1 0.3 - -
cNx 502 53.3 286 44.2 216 73.2 - -
Clinical M-stage
cM0 588 62.4 445 68.8 143 48.5 - -
cM1 41 4.4 41 6.3 - - - -
 cMx 313 33.2 161 24.9 152 51.5 - -
Gleason score
2-6 570 60.5 339 52.4 231 78.3 - -
7 238 25.3 199 30.8 39 13.2 - -
8-10 100 10.6 100 15.5 - - -
unknown 34 3.6 9 1.4 25 8.5 - -
PSA in ng/ml
< 4 93 9.9 38 5.9 55 18.6 - -
4-10 417 44.3 253 39.1 164 55.6 - -
10-20 204 21.7 135 20.9 69 23.4 - -
 > 20 219 23.2 219 33.8 - - - -
unknown 9 1.0 2 0.3 7 2.4 - -
a PCa with any of the following characteristics: T-stage ≥ T2c or N+ or M+ or Gleason score 8–10 or PSA > 20 ng/ml; 
non-aggressive PCa: PCa with none of the aggressive characteristics 
Abbreviations: PSA: prostate-specific antigen; PCa: prostate cancer
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Table 2. Self-reported acne and acne location for the different participant groups 
Cases Referents
All cases
(N = 942)
Aggressive PCaa 
(N = 647)
Non-aggressive 
PCaa (N=295)
All referents
(N = 2062)
N % N % N % N %
Self-reported acne
      ever had acneb 320 33.9 226 34.9 94 31.9 739 35.8
        isolated facial acne 214 66.9 151 66.8 63 67.0 441 59.7
        isolated corporal acne 12 3.8 9 4.0 3 3.2 33 4.5
          generalized acne 94 29.4 66 29.2 28 29.8 248 33.6
          not specified - - - - - 17 2.3
       never had acne 621 65.9 421 65.1 200 67.8 1281 62.1
      missing 1 0.1 0 - 1 0.3 42 2.0
a PCa with any of the following characteristics: T-stage ≥ T2c or N+ or M+ or Gleason score 8–10 or PSA > 20 ng/ml; 
non-aggressive PCa: PCa with none of the aggressive characteristics
b Participants who initially answered “no” to the question whether they aver had acne, but did indicate a location where 
acne was located, were recoded to “yes” for the question whether they ever had acne.
Abbreviations: PSA: prostate-specific antigen; PCa: prostate cancer
Table 3. Association between acne and prostate cancer
All subjects Aggressiveb PCa Non-aggressiveb PCa
Referents 
N = 2020
Cases
N = 941
ORa 95%CI Cases
N = 647
OR 95%CI Cases
N = 294
OR 95%CI
Self-reported acne
    Ever had acnec 739 320 0.95 (0.80-1.12) 226 0.97 (0.80-1.18) 94 0.90 (0.67-1.19)
    Never acne 1281 621 1.00 421 1.00 200 1.00
a ORs were adjusted for age at the time of completion of the questionnaire and family history
b PCa with any of the following characteristics: T-stage ≥ T2c or N+ or M+ or Gleason score 8–10 or PSA > 20 ng/ml; 
non-aggressive PCa: PCa with none of the aggressive characteristics
c Participants who answered “no” to the question whether they aver had acne, but did indicate where on the body the 
acne was located, were recoded to “yes” for the question whether they ever had acne.
Abbreviations: OR: odds ratio; CI: confidence interval; PSA: prostate-specific antigen; PCa: prostate cancer
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DISCUSSION
In this large case-referent study, in which we evaluated self-reported acne for almost 1,000 PCa cases 
and more than 2,000 referents, we found no significant association between self-reported acne and 
PCa. We also did not find any association between acne and either aggressive or non-aggressive 
PCa. This went for both analyses when using pT≥T2c as a cut point for aggressive PCa, as suggested 
by d’Amico et al., as well as when replacing this criterion by pT≥T3 as used by Severi et al.12,16. These 
results are in contradiction with the results of the study on P. acnes antibody titer and PCa, which 
found an association between titers at or above the median and PCa with an OR of 0.73, and an OR 
of even 0.59 for advanced PCa12. 
Other studies that previously investigated the association between acne and PCa have yielded varying 
results. These results range from a negative association for facial acne scarring and PCa in a large 
Australian case-referent study (over 1,497 cases and 1,434 referents) to no significant differences 
for self-reported acne and PCa to a (non-significant) positive association between adulthood acne 
and prostate cancer mortality5,6,8. In our opinion, given the additional results from this investigation 
in a large population, a history of acne cannot be used as a marker for PCa risk. 
Potential biases in a case-referent design include recall bias. However, we have no reason to believe 
that men who have been diagnosed with PCa have a different recollection of acne occurrence as 
compared to healthy individuals. Differential misclassification is therefore not likely, but non-differ-
ential misclassification may have led to some underestimation of the real strength of the association. 
Because of the nature of this study, selection bias is also unlikely to have played a role. The patients 
and referents were selected for this study regardless of past or current acne status and the questions 
on acne were part of a broader investigation into risk factors for PCa where an extensive risk factor 
questionnaire was taken along with blood samples for DNA. Confounding is by definition impossible 
because, naturally, we were not investigating any direct causal relationship between acne and PC. 
We were merely interested in the correlation between the two, as to evaluate whether acne might be 
a useful phenotype for screening purposes, independent of age and family history.
This study shows that the association between self-reported acne and (aggressive) PCa, if present 
at all, is too weak to be useful in clinical practice. Therefore, we conclude that acne is not suitable 
as a marker to identify men at low risk of aggressive PCa.
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ABSTRACT
Background Androgens are assumed to play a central role in the pathophysiology of both prostate 
cancer (PC) and androgenic alopecia (AA). A correlation between the two phenotypes may be relevant 
for identification of men at high risk of PC. We evaluated the association between AA at different 
ages and PC in a large case-control study.
Methods The case group comprised 938 PC patients recruited from a population-based cancer registry. 
The controls (N=2160) were a random sample of the male general population. All subjects completed 
a questionnaire on risk factors for cancer, including questions on hair pattern at different ages using 
an adapted version of the Hamilton-Norwood scale, race and family history of PC. Odds ratios (ORs) 
and 95% confidence intervals were calculated using multivariable logistic regression.
Results Baldness at early age appeared to be associated with a lower risk of PC (baldness at age 20: 
OR=0.86;95%CI 0.69-1.07 and baldness at age 40: OR=0.81;95%CI 0.70-0.96). Baldness at completion 
of the questionnaire was not associated with PC: OR=1.10;95%CI 0.89-1.34. 
An isolated “frontal baldness” or “vertex baldness” pattern was not significantly associated with PC 
at any age. Presence of a combined “frontal and vertex” baldness pattern at age 40 was associated with 
a decreased risk of PC (OR=0.62;95%CI 0.45-0.86). There were no significant associations between 
AA and aggressive PC.
Conclusions We did not find consistent positive associations between AA at different ages and PC. 
Surprisingly, if anything, baldness at early age is inversely related to PC in this study. Androgenic 
alopecia is not useful as an indicator of men at high risk of PC. 
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INTRODUCTION
Prostate cancer (PC) and androgenic alopecia (AA), also known as male pattern baldness, are two 
common conditions in aging males. AA produces patterned hair loss beginning with bi-temporal 
recession of the frontal hair line, followed by diffuse thinning over the vertex. Over time there is 
complete hair loss centrally on the vertex, producing a bald patch. The patch enlarges and joins the 
receding frontal hair line, leaving behind an island of hair on the frontal scalp. In some men the loss 
over the vertex occurs more rapidly than the frontal loss; in others the entire frontal hairline marches 
back before a bald patch on the vertex develops. Androgens are assumed to play a central role in 
the pathophysiology of both AA and PC. The link between androgens and AA is well-established, 
with reports of lack of balding in eunuchs and androgen-insensitive or 5α-reductase deficient indi-
viduals, while high levels of the androgen receptor (AR) and low levels of aromatase, which converts 
testosterone to estrogen, have been associated with male-pattern balding1-3.
PC growth is stimulated by androgens via expression and up-regulation of AR activity, ligand-indepen-
dent activation of the AR and mutations in the AR gene4. In the Prostate Cancer Prevention Trial, the 
use of finasteride, a 5-alpha-reductase inhibitor (5ARI) which is FDA approved in the USA to treat 
male pattern hair loss (marketed as Propecia®), has shown to reduce prostate cancer prevalence by 
25% in men who participate in an annual PSA screening protocol with prostate biopsies at the end of 
the study5. Also, in the REduction by DUtasteride of prostate Cancer Events trial (REDUCE), dutasteride, 
another 5ARI, decreased the risk of prostate cancer over 4 years by 23% among men at increased 
risk of prostate cancer, i.e. men who have a PSA of 2.5-10 ng/ml with negative prostate biopsies6. 
In the last three years several genome-wide association studies (GWAS) have identified more than 
30 susceptibility loci for prostate cancer7. These loci do not overlap with the two susceptibility loci 
that have been found in a GWAS of AA, located in the AR region at Xq11-12 and in the region between 
PAX1 and FOXA2 on chromosome 20p11.22, but a linkage study in hereditary prostate cancer did find 
evidence for a potential role of the AR gene for prostate cancer8-11. Other attempts to find evidence 
for a common pathophysiology between AA and PC have yielded inconsistent and inconclusive 
results12-14.
A proven underlying common cause of PC and AA may be very important for the development of 
decision aids whether or not to screen for prostate cancer. Recently, the European Randomized 
Study of Screening for Prostate Cancer reported a reduction in prostate cancer mortality as a conse-
quence of programmed screening with prostate specific antigen (PSA), but at the cost of significant 
over-diagnosis15. Identification of men who are at increased risk of PC on the basis of simple 
phenotypes such as AA might lead to screening policies with a better balance between intended 
and unintended effects. In this paper, we describe a large case-control study on the association 
between AA and prostate cancer.
Proefschrift Ruben Cremers Binnenwerk.indd   111 08-03-15   18:39
112
Chapter 8 Androgenic alopecia not associated with PC
METHODS
The study population and study design have been described in detail before16,17. In brief, the case 
group was recruited for the so-called POLYGENE study and consists of all patients diagnosed with 
prostate cancer in the period 2003-2006 and registered by the regional cancer registry held by the 
Comprehensive Cancer Centre East (CCCE) in Nijmegen, the Netherlands. Eligibility criteria included: 
age at diagnosis of 75 years or younger, alive at the date of invitation to the study, living in the catch-
ment area of the CCCE. Eligible patients were contacted between September 2006 and June 2007. 
Overall, 1330 patients fulfilled the inclusion criteria and were invited for the study. In total 1020 patients 
were willing to participate (77%). Participation included the donation of a blood sample and the 
completion of a questionnaire. Finally, 956 patients (72%) actually filled out the questionnaire. The 
registration staff of the CCCE had already collected clinical and pathology data of all patients in the 
cancer registry. These standard cancer registry data was supplemented with more detailed data by 
extraction from the medical files in the hospitals where the patients were treated. 
The control individuals were recruited for the Nijmegen Biomedical Study (NBS), a population-based 
survey conducted in 2002 by the Department of Epidemiology and Biostatistics and the Department 
of Clinical Chemistry of the RUNMC. Twenty-two thousand four hundred and fifty-one (49% of whom 
were males) age- and sex-stratified randomly selected inhabitants of Nijmegen, the Netherlands, 
were invited to participate in a study on gene-environment interactions in multifactorial diseases 
such as cancer. Between August 2002 and December 2003, all subjects who were still alive and 
whose addresses were known (n=21,756) were invited to fill out the same questionnaire as was sent 
in the pilot phase (NBS1) and to donate two tubes of blood. Forty-three percent (9350) of the invited 
persons returned a completed questionnaire, 46% of whom were males. The NBS participants who 
filled out the NBS questionnaire, had given consent for further research, were still alive and had 
known addresses were again contacted in 2008 and invited to fill out an additional questionnaire 
containing, among others, questions on hair pattern. In total, 8109 people were approached (3691 
males) of whom 7950 received the questionnaire (n=3625 males) (n=159 were deceased or had 
moved). In total, 5613 completed questionnaires (response 71%) were returned, 2552 of which were 
returned by males. Participants who had a history of prostate cancer at the time of recruitment were 
excluded from analysis.
All the cases and controls in the POLYGENE and NBS studies were fully informed about the goals 
and procedures of the study. The study protocols were approved by the Institutional Review Board of 
Radboud University Nijmegen Medical Centre and all study subjects gave written informed consent.
The questionnaires that were completed by cases and controls included questions on their balding 
pattern at the ages of 20 years, 40 years and at the time of completion of the questionnaire. For 
evaluation of the subject’s baldness pattern, a set of four pictures was used, adapted from the 
Hamilton-Norwood scale (Figure 1)12,18. Non-Caucasian subjects were excluded from the analysis, 
as the balding patterns and the risk of PC differ between different races. We also excluded controls 
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younger than 40 (none of the cases was younger than 40) in order to prevent missing values on the 
balding questions and to improve comparability of age distributions between cases and controls.
Figure 1. Adjusted Hamilton-Norwood scale of baldness. a. No baldness; b. Frontal baldness; c. Vertex baldness; d. Frontal 
and vertex baldness.
STATISTICAL ANALYSIS
The associations between PC and AA at ages 20, 40 and at the time of completion of the questionnaire 
were evaluated by cross-tabulation. No baldness (Figure 1a) was used as reference for the other 
baldness patterns (Figure 1b to 1d). Odds ratios (ORs) and corresponding 95% confidence intervals 
(CI) were calculated for specific baldness patterns as well as for the presence of any type of baldness 
in order to quantify the strength of any association. Multivariable logistic regression modeling was 
used to calculate the independent association between balding and PC, in addition to positive family 
history (i.e. ≥ 1 first-degree relative with PC, included in the model as a nominal variable) and age at 
the time of completing the questionnaire (continuous linear variable). Baldness pattern was included 
in the model as a categorical variable with 4 strata, with “no baldness” as the reference category, except 
for the overall comparison of “any baldness” vs. “no baldness”, for which a dichotomous variable 
was created for the presence of any form of baldness (nominal variable).
Subgroup analyses were performed by PC aggressiveness, based on TNM-stage of disease, Gleason 
grade and serum PSA. Aggressive PC was defined as either growth within both prostate lobes or 
extending the capsule (pT-stage ≥ T2c and/or N+ and/or M+), a Gleason score of 8 or higher, or a 
pre-diagnostic serum PSA higher than 20 ng/ml19. cTNM was used for stage of disease if pTNM 
was not available, i.e. if surgery was not performed. Likewise, Gleason grade of biopsies was used 
if Gleason grade of a prostatectomy specimen was not available. SPSS version 16.0.01 was used 
for statistical analysis.
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RESULTS
STUDY POPULATION
The total number of men with PC in this study was 956. Fourteen men were non-Caucasian and 
were therefore excluded from analyses. Four additional patients were excluded because their age at 
the time of completion of the questionnaire was unknown. 
Of the 2552 male controls who completed the additional questionnaire, 2492 were of Caucasian 
origin. Of these Caucasian controls, 332 were under 40 years of age at the time of completion of the 
questionnaire and were excluded from the analyses. Demographic characteristics of the remaining 
938 cases and 2160 controls with respect to age and family history of PC as well as the patient and 
tumour characteristics of the cases are listed in table 1. The mean age at diagnosis of the cases was 
5 years higher than the mean age at recruitment of the controls. The difference in mean age between 
the groups at completion of the questionnaire was 2 years.
Association between androgenic alopecia and prostate cancer
The presence of any baldness at the time of completion of the questionnaire showed a non-significant 
association with PC with an OR of 1.11 (95%CI 0.90-1.35) (table 2). The separate baldness patterns 
at the time of completion of the questionnaire all showed a trend towards a higher risk of PC, but the 
ORs were not statistically significant. Vertex baldness showed the strongest association with PC 
with an OR of 1.19 (95%CI 0.94-1.52).
Baldness at age 40 was significantly associated with a lower risk of PC with an OR of 0.83 (95%CI 
0.71-0.98). Only the combination “frontal and vertex” baldness at this age was significantly associated 
with a lower risk of PC with an OR of 0.61 (95%CI 0.44-0.86). The other baldness patterns at this age 
showed a trend towards a lower risk of PC, but the ORs were not statistically significant. Androgenic 
alopecia at age 20 was not significantly associated with PC, but the numbers of men with “vertex” 
or with “frontal and vertex” balding at this early age were very small.
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Table 1. Characteristics of prostate cancer patients and controls 
Patients Controls
All patients
(N = 938)
Aggressivea  
cancer (N = 609)
Non-aggressivea 
cancer (N = 329)
All controls 
(N = 2160)
N % N % N % N %
Age at completion of the  
questionnaire in years
<55 27 2.9 19 3.1 8 2.4 542 25.1
55-59 99 10.6 68 11.2 31 9.4 231 10.7
60-64 191 20.4 128 20.9 64 19.5 264 12.2
65-69 229 24.4 159 26.1 70 21.3 242 11.2
70> 392 41.8 236 38.8 156 47.4 881 40.8
Age at diagnosis in years
<55 49 5.2 36 5.9 13 4.0
55-59 157 16.7 98 16.1 59 17.9
60-64 217 23.1 149 24.5 68 20.7
65-69 263 28.0 185 30.4 78 23.7
70> 252 26.9 141 23.2 111 33.7
Family history of prostate cancer
No first-degree relative affected 729 77.7 473 77.7 256 77.8 1808 83.7
Any first degree-relative affected 209 22.3 136 22.3 73 22.2 120 5.6
Missing 0 0 0 232 10.7
Clinical T-stage
cT1 381 40.6
cT2 361 38.5
cT3 170 18.1
cT4 16 1.7
cT0/x 10 1.1
Clinical N-stage
cN0 374 39.9
cN1 65 6.9
cNx 499 53.2
Clinical M-stage
cM0 586 62.5
cM1 41 4.3
cMx 311 33.2
Gleason score
2-6 567 60.4
7 237 25.3
8-10 100 10.7
unknown 34 3.6
PSA in ng/ml
< 4 93 9.9
4-10 413 44.0
10-20 204 21.7
> 20 219 23.3
unknown 9 1.0
aAggressive cancer: T-stage ≥ T2c and/or N+ and/or M+ and/or Gleason score 8-10 and/or PSA > 20 ng/ml; non- 
aggressive cancer: prostate cancer with none of the aggressive characteristics
Abbreviations: PSA: prostate-specific antigen
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Table 2. Association between androgenic alopecia at different ages and prostate cancer
All subjects Aggressive cancerb Non-aggressive cancerb
Controls 
N = 2160
Cases
N = 938
ORa 95%CI Cases
N = 609
OR* 95%CI Cases
N = 329
OR* 95%CI
Alopecia at  
completion of 
questionnaire
    No balding 421 183 1.00 112 1.00 71 1.00
    Frontal balding 563 270 1.08 (0.86-1.37) 168 1.09 (0.83-1.45) 102 1.03 (0.73-1.44)
    Vertex balding 454 252 1.19 (0.94-1.52) 165 1.31 (0.98-1.74) 87 1.02 (0.72-1.45)
    Frontal and  
vertex balding
473 233 1.05 (0.82-1.34) 164 1.23 (0.92-1.64) 69 0.75 (0.52-1.09)
Any balding vs.  
no balding at  
completion of  
questionnaire
1.11 (0.90-1.35) 1.19 (0.94-1.53) 0.94 (0.70-1.26)
Alopecia at age 40
    No balding 829 453 1.00 276 1.00 176 1.00
    Frontal balding 632 293 0.86 (0.71-1.03) 189 0.91 (0.73-1.13) 104 0.78 (0.59-1.02)
    Vertex balding 285 137 0.89 (0.70-1.13) 102 1.09 (0.83-1.44) 36 0.58 (0.39-0.86)
    Frontal and  
vertex balding
163 55 0.61 (0.44-0.86) 42 0.77 (0.53-1.12) 13 0.38 (0.21-0.70)
Any balding vs. no 
balding at age 40
0.83 (0.71-0.98) 0.94 (0.78-1.13) 0.67 (0.53-0.85)
Alopecia at age 20
    No balding 1593 796 1.00 508 1.00 288 1.00
    Frontal balding 262 123 0.96 (0.75-1.22) 88 1.08 (0.83-1.42) 35 0.79 (0.54-1.15)
    Vertex balding 45 17 0.81 (0.45-1.43) 12 0.89 (0.46-1.71) 5 0.65 (0.25-1.66)
    Frontal and  
vertex balding
12 2 0.31 (0.07-1.46) 1 0.24 (0.03-1.90) 1 0.42 (0.05-3.36)
Any balding vs. no 
balding  at age 20
0.91 (0.73-1.14) 1.02 (0.79-1.32) 0.75 (0.53-1.07)
a. All ORs were adjusted for age at the time of completion of the questionnaire and family history
b. Aggressive cancer: T-stage ≥ T2c and/or N+ and/or M+ and/or Gleason score 8-10 and/or PSA > 20 ng/ml; non- 
aggressive cancer: prostate cancer with none of the aggressive characteristics
Abbreviations: OR: odds ratio; CI: confidence interval; PSA: prostate-specific antigen
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ASSOCIATION BETWEEN  
BALDNESS PATTERN AND  
PROSTATE CANCER  
AGGRESSIVENESS
Of the 938 patients in the study, 609 met the criteria for aggressive PC while 329 patients had PC 
without any aggressive features. The presence of baldness at the time of completion of the ques-
tionnaire was non-significantly associated with aggressive PC with an OR of 1.19 (95%CI 0.94-1.53). 
Evaluation of specific baldness patterns at the time of completion of the questionnaire identified 
“vertex” baldness as the pattern with the strongest, again non-significant, association with aggressive 
PC with an OR of 1.31 (95%CI 0.98-1.74). Also, none of the baldness patterns at ages 40 and 20 were 
significantly associated with aggressive PC.
For non-aggressive PC, the presence of any baldness at 40 years of age was significantly associated 
with a lower risk of non-aggressive PC, with an OR of 0.67 (95%CI 0.53-0.85). Evaluation of specific 
baldness patterns at this age showed “vertex” and “frontal and vertex” baldness to be significantly 
associated with non-aggressive PC with ORs of 0.58 (95%CI 0.39-0.86) and 0.38 (95%CI 0.21-0.70), 
respectively. At age 20, no significant association between baldness (pattern) and non-aggressive 
PC was found.
DISCUSSION
We found that baldness at age 40 showed some indication of an inverse association with PC, mainly 
non-aggressive PC, whereas baldness at the time of completing the questionnaire seemed to occur 
more frequently among men with PC, especially men with aggressive PC. Most of the associations 
were, however, not statistically significant and the associations between AA at the time of completion 
of the questionnaire and PC were fairly weak. The strongest associations for PC in general were 
found for “frontal and vertex” baldness at ages 20 and 40 with ORs of 0.31 and 0.61, respectively. On 
the other hand, as “frontal and vertex” baldness has a very low prevalence at the ages of 20 and 40 
years, the 95% confidence intervals were wide. The ORs for aggressive PC, which included 609 cases, 
were even weaker than this. The strongest (non-significant) association was found for any baldness 
at the time of completion of the questionnaire with an OR of 1.19 (strongest association of between 
“vertex” baldness and aggressive PC with an OR of 1.31).
Potential biases in our study include recall bias, particularly for AA at age 20. On the other hand, 
we do not have any reason to believe that men who have been diagnosed with PC have a different 
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recollection of their baldness pattern at young age as compared to healthy individuals. Differential 
misclassification is therefore not likely, but non-differential misclassification may have led to some 
underestimation of the real strength of the association. Because of the nature of this study, selection 
bias is also unlikely to have played a role. The patients and controls were selected for this study 
regardless of their observed hair pattern and the questions on baldness pattern were only part of a 
broader investigation into risk factors for PC where an extensive risk factor questionnaire was taken 
along with blood samples for DNA. Therefore, we consider it very unlikely that a person’s hair pattern 
has had any influence on whether to participate in this study. 
In the mid-1990s, a large population-based case-control study was performed in Australia to investi-
gate the relationship between AA and PC with emphasis on early age at diagnosis and higher grade 
PC12. In this study 1446 cases and 1390 controls were interviewed. A significant association between 
vertex baldness at the time of the interview and PC was reported with an OR of 1.54 (95%CI 1.19-2.00). 
No associations were found between PC and frontal baldness or with frontal baldness concurrent 
with vertex baldness. The highest ORs were found for patients aged 60-69 with high-grade disease 
(Gleason score 8-10): 1.80 (95%CI 1.02-3.16) for frontal baldness and 1.95 (95%CI 1.10-3.45) for 
frontal and vertex baldness. Another smaller case-control study, investigating a possible relation 
between early-onset vertex baldness at ages 30 and 40 and PC, produced consistent but statistically 
non-significant associations between vertex baldness at ages 30 or 40 and PC: OR=2.20 (95%CI 
0.89-5.43) for vertex baldness at age 30 and OR=1.67 (95%CI 0.75-3.72) for vertex baldness at age 
4020. However, early frontal baldness was associated with a decreased risk of PC with ORs of 0.66 
(95%CI 0.19-2.35) for frontal baldness at age 30 and 0.88 (0.40-1.94). Possibly the small number of 
subjects with baldness in this study caused the reversed association for vertex baldness as compared 
to our results.
To our knowledge, we are the first to assess AA patterns for subjects at both younger age and after 
diagnosis of PC. We showed that AA at the time of completion of the questionnaire was associated 
with a higher risk of (aggressive) PC, but that baldness at earlier age would be indicating men at lower 
risk rather than men at higher risk of (non-aggressive) PC. These results may suggest a different effect 
of androgens on AA and PC at different ages. However, the associations were relatively weak and, 
even in this large study, mostly non-significant. Therefore, combined with the results from earlier 
studies, we conclude that the association between AA and PC, especially with respect to early-onset 
baldness, is too inconsistent and weak to have any predictive value for prostate cancer. Male pattern 
baldness should not influence the decision whether or not to test a man for PC.
CONCLUSION
Although a common cause for androgenic alopecia and prostate cancer is intuitive, androgenic alo-
pecia is not useful as an indicator of men at high risk for prostate cancer.
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In this thesis, we aimed to evaluate reported markers for an increased risk of prostate cancer. We 
focused especially on hereditary prostate cancer (HPC), evaluating the discriminative performance 
of single nucleotide polymorphisms (SNPs) and studying the clinical phenotype in men with HPC, 
and on markers for aggressive prostate cancer. We showed that the SNPs performed at least as 
well in discriminating HPC patients from referents as in discriminating sporadic prostate cancer 
(SPC) patients from referents. The clinical phenotype of HPC was less aggressive compared to SPC. 
We could not replicate the effect of the previously reported (bio)markers PCA3, male-pattern baldness 
and acne for the identification of men with an increased risk of (aggressive) prostate cancer. In this 
chapter, I will discuss the implications of the results presented in the previous chapters as well as 
the most important general controversies in prostate cancer research and clinical practice. 
PSA TESTING HAS A SIGNIFICANT 
IMPACT ON PROSTATE CANCER 
HEALTH CARE IN THE  
NETHERLANDS
PSA, first described in 1987, is a protein that is produced by prostate cells, although other tissues 
such as breast cancer tissue and salivary glands have also been described to express PSA1,2. As 
prostate cancer tissue is associated with higher serum levels of PSA than non-malignant prostate 
tissue, PSA can be used to discriminate men with and without prostate cancer. After its introduction, 
the use of PSA as a test to determine whether a man should be referred for prostate biopsies increased 
very quickly in the USA, causing a sharp peak in prostate cancer incidence in the early 1990s3. This 
peak mainly consisted of locally confined, low-risk prostate cancers. In the Netherlands, the PSA 
test was introduced with a considerable delay and general practitioners (GPs) and urologists were 
less enthusiastic about the liberal use of the PSA test. Nevertheless, because of increasing prostate 
cancer awareness in the 1990s (which might have been a side-effect of the availability of PSA) and 
tardier spreading of PSA testing, prostate cancer incidence in the Netherlands increased to 11,000 
new cases annually4,5. This increase went more gradually without the peaking incidence observed 
in the USA, which indicated the detection of many prevalent, low-risk prostate cancers. Nowadays, 
approximately one in four Dutch men over 40 years of age have had their PSA tested in the previous 
5 years; this number increases to 48% for men between 65 and 75 years of age6.
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THE PCA3 URINE TEST CANNOT 
BE USED TO LOWER THE  
NUMBER OF PROSTATE BIOPSIES 
IN PSA SCREENING AMONG  
BRCA2-MUTATION CARRIERS
Men with a BRCA-mutation form a distinct risk group when it comes to prostate cancer. Preliminary 
results so far indicate that PSA-screening might be feasible in BRCA2-mutation carriers7. The PCA3 
urine test, which might be used to lower the number of prostate biopsies among men with an elevated 
PSA, did not perform well in our study among BRCA-mutation carriers. Many of the prostate cancers 
were found in patients with a normal PCA3 score. In theory, the different underlying genetic etiology 
in BRCA-related prostate cancers may result in a lower expression of PCA3 in BRCA-related prostate 
cancer cells. If this would indeed be the case, known diagnostic methods such as a PCA3 test, but 
potentially also the PSA test, may not be reliable markers for detection of prostate cancer in this specific 
(genetic) subgroup. It would be worthwhile to investigate this in the near future. If the diagnostic 
performance of the commonly used tests would indeed be inferior in men with an underlying BRCA-
mutation, this might also apply to (hereditary) prostate cancers that are caused by other rare and 
highly penetrant mutations. An alternative explanation could be that the discriminative power of 
PCA3 is simply too low for use as a first-line test. PCA3 has often been suggested to perform non-
inferior compared to PSA, but this was almost always in men with an indication for biopsy because 
of an elevated PSA. Only Roobol et al. evaluated PCA3 as an independent indicator of prostate biopsies. 
They showed that use of a PCA3 cut-off value of 10 for prostate biopsies led to an extremely high 
number of prostate biopsies; 96% of the men in the study population, who had already all undergone 
(several) previous prostate biopsy sessions, had a PCA3 higher than 108-10. If a PCA3 cut-off value 
of 35 had been used, still 48% of the men would have been biopsied, whereas mostly low-risk prostate 
cancers were detected. Continued follow-up in our IMPACT-NL cohort should reveal whether the rela-
tively poor performance of PCA3 as found by Roobol et al. will be seen as well in this, potentially, 
high-risk group. 
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THE MAJORITY OF THE 
DUTCH HPC FAMILIES MAY  
BE CAUSED BY CLUSTERS OF  
MULTIFACTORIAL PROSTATE 
CANCERS
In 2014, the International Consortium of Prostate Cancer Genetics (ICPCG) reported that a selection of 
25 SNPs detected in population-based (predominantly sporadic prostate cancer – SPC) genome-wide 
association studies was also associated with familial prostate cancer (FPC)11. If one would assume 
that the underlying etiology of FPC is no different from SPC, then one would indeed expect the SNPs 
to show a similar association to FPC. In chapter 4, we took this one step further and showed that 
the vast majority of the - at that time - 74 known SPC susceptibility SNPs showed similar, though 
slightly stronger, association to HPC. These and the ICPCG data indicate that FPC and HPC families 
are actually a collection of families in which many low-risk prostate cancers were identified by 
opportunistic screening, rather than families with a genetic predisposition for (aggressive) prostate 
cancers due to a high-penetrance mutation. This fits with the known increase in the detection of low-
risk prostate cancers through PSA testing in the past decades, especially present among family 
members of affected probands12. Another indication that opportunistic screening plays an increasingly 
important role in the detection of prostate cancer in families is that the decrease of the age at which 
prostate cancers are detected, is more pronounced among relatives too4,13. Obviously, exceptions 
to this are present; families with multiple aggressive prostate cancers diagnosed at young age 
should be closely monitored and advised about early prostate cancer testing. 
THE CLINICAL PHENOTYPE OF 
HEREDITARY PROSTATE CANCER 
IS LARGELY SIMILAR TO THAT OF 
SPORADIC PROSTATE CANCER
Our analysis of the HPC and SPC phenotypes suggested that HPC is less aggressive. HPC patients 
were diagnosed at younger ages with lower PSA, lower Gleason scores and a better stage distribution. 
HPC patients much less often chose for active surveillance than SPC patients, even though a much 
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larger percentage had low-risk disease (34% vs. 21%). This might imply that men in HPC families 
were more inclined to undergo radical treatment. As no study has ever showed that HPC has a 
worse prognosis than SPC, this puts HPC patients at an increased risk of overtreatment14,15. This is 
actually a double risk burden, as we already highlighted that men with affected relatives are more 
likely to undergo opportunistic PSA testing12. We have to consider two opposing phenomena which 
can influence this analysis. For one, in the current prevalent HPC-registry, part of the patients will be 
screen-detected due to the prior identification of the family as an HPC family. This can lead to screen-
ing bias in which more low-risk prostate cancers are identified at a young age, potentially resulting 
in a more favourable phenotype for HPC as a whole. This can be avoided if only the probands are 
considered. On the other hand, that could lead to an underestimation of the aggressiveness of the 
HPC phenotype due to the potential omission of family members with aggressive HPCs in families 
with a true high-risk genetic predisposition. Secondly, urologists will most likely report families with 
either a very large number of affected relatives or families with very aggressive phenotypes. This 
can lead to the registration of mainly relatively aggressive HPCs. Without the means to ascertain 
HPC families in an unbiased way, some bias will remain. 
THE KNOWLEDGE OF GPS  
AND UROLOGISTS ABOUT  
HEREDITARY PROSTATE  
CANCER IS SUBOPTIMAL FOR 
COUNSELING MEN ABOUT THE 
INFLUENCE OF HEREDITY ON 
PROSTATE CANCER SCREENING
In this thesis, we showed that urologists and general practitioners (GPs), the health care professionals 
that most often counsel men about prostate cancer testing, have suboptimal knowledge regarding 
heredity and prostate cancer16. Considering the complexity of interpreting ‘HPC’, family history and 
the increasing role of PSA testing, it must be very difficult for individual professionals to provide 
their patients with personalized counseling that can be substantiated with relevant data. A clear advice 
about how to deal with family history of prostate cancer should complete the current national and 
international guidelines on prostate cancer health care17. This advice should be agreed upon with 
the GPs and included in GP guidelines as they are, in the Netherlands, the true gatekeepers against 
over-diagnosis of prostate cancer. It is an interesting thought that the dependence on family history 
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might become redundant if a validated population-wide genetic test would be developed to aid GPs 
and urologists in prostate cancer counseling. The effects of such a test on risk estimates might be 
made insightful in a similar way as the ERSPC risk calculator (www.prostaatwijzer.nl), which provides 
a visual representation of prostate cancer risk factors and the calculated risk by means of rotating 
wheels (see figure 1).
Figure 1. Images from www.prostaatwijzer.nl, showing a graphical depiction of prostate cancer risk and the influence 
of risk factors by means of rotating wheels; the images depict the risk of prostate cancer in case of a negative family 
history (left) vs. a positive family history (right) for a 60 year-old male without urinary complaints
THE ‘HEREDITARY PROSTATE 
CANCER’ DEFINITION SHOULD 
BE REVISED
The current HPC definition and registration is based on the frequency of prostate cancer within a 
family18. Early-onset HPC (defined as two first- or second-degree relatives with prostate cancer 
diagnosed before 55 years of age) is considered worse than later-onset HPC (defined as three first-
degree relatives with prostate cancer). The provided screening advices, however, do not differ very 
much between early-onset and late-onset HPC families; PSA screening commences either 5 years 
before the age at diagnosis of the youngest HPC patient or at 50 years of age. These advices do not 
incorporate specific modifications for the clinical phenotypes or the methods of detection of the 
HPCs. The research presented in this thesis has shown that HPC very much resembles SPC with 
regard to underlying genetics and clinical phenotype, indicating no reasons for differences in 
screening advice for HPC families and SPC. Therefore, in the absence of a comprehensive test for 
genetically predisposed high risk HPC, I argue that we should redefine HPC. We should include only 
clinically relevant prostate cancers in the family frequency calculation as suggested in the discussion 
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for chapter 5. Ideally, the definition should also incorporate the number of men at risk in the family. 
This would value the occurrence of aggressive prostate cancers in relatively small families and prevent 
over-diagnosis and over-treatment of low-risk prostate cancers in families with relatively many male 
siblings. One could for instance imagine devising a scoring system, based on age (at diagnosis), 
means of diagnosis, clinical stage, metastases and prostate cancer-related death, incorporating the 
number of men in the age-period at risk. Such a system, which would have to be newly developed, 
would also enable a family that was once deemed a HPC family to be removed from the registration 
if more men have been tested but do not have prostate cancer. This would do more justice to the 
current clinical situation, in which PSA testing plays a much more prominent role than in 1993 when 
the HPC definition was introduced.
A COMPREHENSIVE GENETIC 
‘SCREENING’ TEST COULD  
IMPROVE PROSTATE CANCER 
COUNSELING FOR ALL MEN
When a man has multiple relatives with prostate cancer and is registered at the Netherlands 
Foundation for the Detection of Hereditary Tumours (NFDHT), a screening advice is likely provided 
for. But in the absence of a genetic test for HPC, we actually do not know whether he carries a high-
penetrance genetic prostate cancer variant. In chapter 4, we showed that a common solution for all 
men might be feasible. The known susceptibility SNPs were at least as good in discriminating HPC 
patients from the referents as in SPC. The SNPs also allowed stratification of men for HPC/SPC risk, 
indicating that the top 20% of the SNP risk score distribution carried a twofold increased risk of 
prostate cancer. This is something that has also been reported by other groups based on a smaller 
number of SNPs11,19,20. This approach of a population-wide SNP test would however not be acceptable 
for men with a hereditary risk of aggressive prostate cancer due to a high-penetrance mutation, as 
testing the susceptibility SNPs would not identify them as having an increased risk. Therefore, I 
would like to make a plea for developing a comprehensive genetic screening test for all men, which 
is to be taken at, e.g., 40 years of age. The first stage of the test should include all known high-risk 
variants for aggressive prostate cancer, such as the recently described HOXB13-variant and the 
RNASE-L and ELAC2 variants21,22. This would identify the men who carry a high-penetrance mutation 
who require timely prostate cancer testing. Family members could also be tested for the specific 
mutation. This approach would have the benefit that it would also detect a high-risk genetic predis-
position in small families with only one or a few siblings. The second step would be to genotype (the 
minimal required set of) the available susceptibility SNPs that would allow stratification of all other 
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men for their prostate cancer risk, followed by a counseling session. After our paper (chapter 4 of 
this thesis) was accepted, a new meta-analysis identified another 23 additional susceptibility SNPs 
for prostate cancer risk23. These might also be incorporated in this test, which might further improve 
the discriminative performance. Further analyses in an independent patient group can be performed 
to identify a subset of SNPs that provides an optimal balance between the number of SNPs needed 
to test and the discriminative performance. This test would enable us to incorporate the germline 
genetic risk of prostate cancer into risk estimates without having to rely on family history as a proxy. 
The main caveat of the first step of the test is the fact that unknown high-risk variants will not be 
identified. The identification of new variants will have to remain dependent on, e.g., targeted research 
in very high-risk families. The problem with the second step would be the men with an ‘intermediate-
risk’ based on the genetic variants. Nevertheless, the addition of this test will provide them with a 
better risk estimate and better means for counseling about prostate cancer testing than the current 
situation in which we are only informed about the potential presence of high-risk genetic mutations 
based on family history.
ACNE AND EARLY BALDNESS, 
REPORTED AS MARKERS FOR 
AGGRESSIVE PROSTATE CANCER, 
ARE NOT USEFUL IN CLINICAL 
PRACTICE
In medical literature, an enormous number of markers for prostate cancer has been reported. The 
MeSH-search terms ‘prostate cancer’ and ‘(bio)marker’ generated more than 20,000 hits in PubMed, 
including almost 600 papers published in 2014 (search performed November 19th, 2014). The 
majority of the markers focuses on the detection of prostate cancer, but most often they cannot 
be replicated in following reports. Due to difficulties in publishing ’null’ results, caused in part by 
publishing policies biased towards reporting ‘significant’ results, an overrepresentation in medical 
literature exists of published biomarkers with false-positive results. This was already brought to the 
attention of medical professionals by Ioannidis in 2005, who argued that 95% of the published results 
in medical literature were false24. In chapters 7 and 8, we report two large case-control studies 
investigating the association between an easily obtainable marker and aggressive prostate cancer. 
These markers, both related to ’androgens’, were previously reported to be associated with aggres-
sive prostate cancer25,26. In our ‘replication studies’, both markers were not associated with prostate 
cancer at all. In hindsight, this should be no surprise. For example, Severi et al., reported an association 
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between antibody titers of Propionibacterium acnes and prostate cancer25. In their paper they performed 
many statistical tests in many subgroups, but focused only on the results that were statistically sig-
nificant. They, and the readers, did not take the increased chances of obtaining a false positive result 
due to multiple testing into account. In the years following the publication of our null result for male-
pattern baldness and prostate cancer, several studies replicated the study but found inconsistent 
results for vertex, frontal or general balding27,28. Muller et al. found that the risk estimates changed 
with the age at diagnosis: the proportional hazards assumption in the Cox regression models was 
actually not met. After correcting for this, vertex balding at age 40 was associated with a higher chance 
of early-onset prostate cancers and with a lower chance of late-onset prostate cancer29. In my opinion, 
however, Muller et al. still focused too much on borderline statistically significant results obtained 
after the performance of multiple tests, without performing any form of internal or external validation 
and without mentioning the possibility of reporting a false-positive result. In our analyses, we did 
include age at diagnosis (patients) or selection (referents) in our analyses, but we did not look at 
specific subgroups for age. I would propose to be clearer about the definition of prostate cancer 
before the analyses; which prostate cancers do we want to find, and up to what age? Given the large 
number of contradicting reports that have been published, I remain to believe that the effects of 
these androgen-related phenotypes are too small and inconsistent to be of use in clinical practice. 
BIOMARKER REPORTS SHOULD 
INCLUDE EXTERNAL VALIDATION 
WHEREVER POSSIBLE
Adjustment for multiple testing does reduce the absolute number of false positive findings, but it 
does not allow the distinction of true from false positive findings. Biomarker discovery studies 
should therefore ideally include at least one independent replication study. In genetic epidemiology, 
this has already been the standard for quite some time, combining the strength of doing multiple 
tests at once (efficient, high sensitivity) with scientific scrutiny as to prevent over-reporting of false-
positive results30. The implementation of this, would help in diminishing the number of publications 
of false-positive results as well as lower the number of poorly formulated reports in the media, which 
are generally more inclined towards reporting ‘significant’ results. For example, we were surprised 
by an online news message (http://www.nu.nl/gezondheid/2450314/kale-man-heeft-meer-kans-
prostaatkanker.html), quoting a study by Yassa et al. on the association between early-onset baldness 
and prostate cancer. This message was published several months after our study that reported the 
null-effect27. Similar to the aforementioned Severi paper on acne, this paper and the news report 
focused on the single borderline statistically significant (p = 0.03) result: men with any balding at 
age 20 would be at an increased risk of prostate cancer (OR 2.01 [95%CI 1.07-3.97])25,27. Yassa et 
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al. concluded that this was an interesting result and that more work should be done on unraveling 
the relationship between androgens and prostate cancer27. Whereas I agree with their conclusion 
that improving our knowledge about the role of androgens would be valuable, I disagree with their 
interpretation of the one p-value that was below the unadjusted 0.05 threshold. I think that (although 
probably unintended) un-reproduced positive reports on biomarkers can be seriously harmful if 
interpreted incorrectly. The scientific community has already undertaken several steps to improve 
the quality of reporting of observational research, especially with the STROBE-statement which was 
published simultaneously in many high-end scientific journals in 200731. Whereas this already was 
a big improvement, the addition of a highlighted item regarding ‘Reproducibility’ to this checklist 
could guide reviewers and editors further in judging these observational studies and prevent the 
publication and uptake of false-positive results.
FUTURE PERSPECTIVES
There are still many questions to be answered about prostate cancer. In this section, I will reflect on 
some of the most important issues that are influencing prostate cancer health care in the Western 
world. Firstly, most people know by now that prostate cancer is a disease that is not necessarily lethal: 
in the general opinion, most often men at high age get prostate cancer and even then they will more 
likely die ‘with’ prostate cancer than ‘from’ prostate cancer. Nevertheless, ‘cancer’ is a terrifying term 
and it brings up fears of death, suffering and loss of loved ones in many if not all of us. So, we should 
ask ourselves as physicians: which prostate ‘cancers’ do we ‘want’ to find? As part of the solution, I 
think that we have to redefine not only the HPC definition, but also the prostate cancer definition as a 
whole. We should start by determining which cancers are ‘severe’, ‘aggressive’, ‘high-risk’, ‘metastasiz-
ing’ or ‘potentially lethal’. Simultaneously, we should try to reach a consensus on which term to use 
for determining this clinical phenotype of prostate cancers, instead of the many terms used before. 
This would ultimately imply that the other prostate cancers that we see as ‘insignificant’ or ‘non- 
aggressive’ might no longer be called ‘cancer’. In my opinion, this could be perfectly defendable if 
these low-risk tumors do not (or almost never) metastasize. An adapted follow-up regimen for men 
with these types of neoplasms, a type of ‘active surveillance’, might be sufficient to find a worsening 
of disease in a timely fashion. 
A parallel can be imagined with, e.g., basal cell carcinoma, a type of skin cancer that shows invasive 
growth on a histological level, but almost never metastasizes. I believe that removing the ‘C-word’ 
would make it easier for men to accept the current therapy advice for low-risk prostate cancers, 
which is an active surveillance strategy17. The assumption underlying the suggestion to remove the 
‘cancer’ stigma from some types of invasively growing atypical prostate cells is that these prostate 
cells do not (quickly) evolve from the relatively harmless type to the lethal type, do not metastasize 
and do not cause local problems. Active surveillance series on how many ‘low-risk’ cancers actually 
show progression have reported that 10-30% these men are eventually advised to undergo radical 
treatment, with a very low risk of dying from prostate cancer (< 3% after 10 years)32. The chance of 
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dying from a non-prostate cancer related causes was calculated to be 18 times higher (hazard ratio) 
than the chance of dying from prostate cancer. One of the most important issues still to address is 
how to diminish the proportion of false-negative results. So far, the active surveillance studies have 
relied heavily on PSA kinetics and random prostate biopsies to determine whether to offer radical 
treatment. Therefore, the introduction of a new term for prostate cancer with, e.g., ‘low-malignant or 
unknown malignant potential’ would have to be accompanied by an unrelenting search for better 
biomarkers for aggressive prostate cancer and better imaging techniques (in the current research 
climate: most probably multi-parametric MRI). Several of these studies are already underway, one 
of which is coordinated by the Radboudumc: “4M” or “Met (prostaat) MRI meer mans”. This project 
simultaneously investigates the diagnostic value of the ‘Prostaatwijzer’ (www.prostaatwijzer.nl), 
MRI and biomarkers including the PCA3 urine test among men with an elevated PSA9,33,34. 
All new developments aside, we should not forget that we already know that PSA screening can 
accomplish a mortality benefit of 30% after 13-years of follow-up, with numbers needed to screen 
and treat of 781 and 2735. The amount and severity of the side-effects of the treatment is the real 
explanation for the consensus not to screen the entire population and to discourage PSA testing in 
absence of symptoms in the general practitioners’ guidelines35,36. Therefore, another way of dealing 
with this would be to further refine (radical) therapies into modalities that can kill all the malignant 
cells (e.g., focused treatment of prostate cancer within the prostate region, targeted antibodies which 
specific target prostate cancer cells) without the current side-effects, which include incontinence 
and impotence.
In the (near) future, developments in (genetic) biomarkers, sampling techniques and refinements in 
radical treatment will guide us in dealing with the issues mentioned. We will hopefully be able to 
timely identify which men are at most risk to suffer and die from prostate cancer. Those men and 
those men only should be tested for prostate cancer and, if necessary, treated with a superior radical 
treatment with minimal side-effects. 
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Chapter 10 Summary
Chapter 1 starts by defining prostate cancer and sets the tone for the manuscript, reporting differences 
in prostate cancer incidence and mortality in the world. The most important risk factors for prostate 
cancer are discussed, focusing on the risk factors that play a prominent role in this manuscript, i.e., 
family history, genetic factors and androgen-related phenotypes. After explaining why population-
wide screening by prostate-specific antigen (PSA) is not advised while prostate cancer mortality 
can be reduced by PSA testing, the focus shifts to identifying high-risk groups for prostate cancer.
In chapter 2 the recent trends in prostate cancer incidence and mortality in the Netherlands are 
described. This was done using data from the Netherlands Cancer Registry from 1989-2006; in this 
period 120,965 men were newly diagnosed with prostate cancer in the Netherlands. Prostate cancer 
incidence (corrected for changes in age-distribution in the population) showed two distinct periods 
of increases. A detailed evaluation showed that the first increase in the mid-1990s was mainly 
caused by clinically palpable (cT2) prostate cancers, whereas the second increase since 2000 was 
mainly caused by non-palpable (cT1) prostate cancers, i.e., prostate cancers detected by opportunistic 
PSA testing. Prostate cancer mortality showed a slow but constant decrease, accompanied by an 
increase of prostate-specific survival (estimated by calculating relative survival) throughout all stages 
and ages, except for men over 85 years of age.
In chapter 3 the additional value of the PCA3 urine test among BRCA-mutation carriers was evaluated 
in a nation-wide screening trial. This trial was performed as a sub-study in a large international inter-
vention study, IMPACT, which already reported that mainly BRCA2-mutation carriers might benefit from 
PSA screening. Our study, which investigated 574 men of whom 75 were BRCA2-mutations carriers, 
showed that PCA3 cannot be used as an additional test to prevent unnecessary prostate biopsies in 
this population. Too many high-risk prostate cancers would have been missed. A definitive conclusion 
for the use of PCA3 as an additional indicator of biopsies could not be formulated, as PCA3 was not 
allowed to indicate prostate biopsies and no end-of-study biopsies were performed. Because end-of-
study biopsies would lead to over-diagnosis and over-treatment of low-risk prostate cancers, prolonged 
follow-up is needed to reveal the positive predictive value of PCA3 in addition to PSA in BRCA-mutation 
carriers.
We started exploring the differences between sporadic prostate cancer (SPC, i.e., prostate cancer 
occurring in the general population in men without a family history of prostate cancer) and hereditary 
prostate cancer, for which only a family-history based definition is available. In chapter 4, an associa-
tion analysis was performed, genotyping the 74 known risk SNPs for prostate cancer (detected in 
the general population) in 2 large groups with sporadic (n = 620) and hereditary prostate cancer (n 
= 312) and in a large referent group (n = 1,819). The analysis showed that the large majority of SNPs 
showed ORs > 1 for both SPC and HPC and that the effect sizes were mostly higher for HPC. The 
discriminative performance was also better for HPC. These results point to the possibility that HPC 
nowadays mainly comprises clusters of multifactorial prostate cancers, rather than families with a 
monogenetic hereditary cause of prostate cancer. An analysis of a (simple allele-count) genetic risk 
score indicated that such a score might be used to stratify all men for their prostate cancer risk 
(including men with what we now call ‘HPC’). Obviously, in families with many aggressive prostate 
cancer diagnosed at young ages, the possibility of Mendelian inheritance must always be kept in mind.
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In chapter 5 we further evaluated possible differences between SPC and HPC by comparing the clin-
ical characteristics and prognosis of SPC and HPC patients. We compared all Dutch HPC patients, 
registered at the Netherlands Foundation for the Detection of Hereditary Tumours, diagnosed from 
the year 2000 and later (n = 324) to SPC patients from a population-based study into the (genetic) 
susceptibility of prostate cancer, i.e., all men newly diagnosed with prostate cancer in the Nijmegen 
region from 2003-2006 (n = 1,664). HPC patients had a lower age at diagnosis and a more favourable 
phenotype than SPC, with lower PSA and Gleason scores and less locally advanced and metastasized 
disease. Although the percentage of patients with low-risk prostate cancer was much higher (34% 
of HPC patients vs. 21% of SPC patients), they less often chose for active surveillance (7% vs. 14%). 
The relative survival of HPC was also better than the relative survival of SPC. Both chapters 4 and 5 
suggest that the current definition of HPC no longer succeeds in identifying men with an inherited 
increased risk of aggressive prostate cancers. Therefore, we suggest a new definition for HPC, that 
also incorporates the phenotype.
We performed interviews through an online questionnaire among Dutch urologists, general practitio-
ners (GPs) and clinical geneticists (CGs) to evaluate whether they were up-to-date with their knowledge 
on HPC, to investigate their attitude towards PSA testing and to see whether they used family history 
in their clinical practice (chapter 6). Only 36% of urologists and 18% of the GPs knew the correct defini-
tion of HPC. Urologists were the most willing to do a PSA test, but in the absence of complaints 70-80% 
of them would first counsel a man who requests to be tested for prostate cancer (as would the GPs). 
Age played an important role in the consideration whether or not to perform a PSA test (after previous 
counseling) for urologists, whereas family history did not play a role in decision making in 35-40% 
of the urologists and GPs. CGs, by contrast, always took family history into consideration. 
Finally, in chapter 7 and chapter 8 two previously reported ‘markers’ (a self-reported history of acne 
in chapter 7 and the development of male-pattern baldness in chapter 8) for the risk of prostate 
cancer were evaluated. The aim of these studies was to replicate previously reported associations 
between these very easily obtainable markers and prostate cancer. The studies were designed identi-
cally and included approximately 1000 prostate cancer patients and 2000 randomly selected referents 
from the general population, who had all completed questionnaires which contained, among many 
other questions, items covering these two androgen-related phenotypes. Both markers showed no 
association with prostate cancer or with aggressive prostate cancer, bringing us to the conclusion 
that previous studies may have reported false-positive results. Unfortunately, the two phenotypes 
are of no use whatsoever in prostate cancer health care.
The manuscript is concluded in chapter 9 by a statement-wise overview of the most important findings 
of the previous chapters. Each conclusion is briefly reflected upon, before ending with a perspective 
on future possibilities for prostate cancer research, focusing on the most important hiatuses in our 
knowledge about prostate cancer. One of the most important questions at this time is how to identify 
‘aggressive’ prostate cancer, i.e., those prostate cancers requiring treatment. Reaching a clear 
(consensus) agreement on this, might pave the way towards an acceptance of not having to treat 
(preventing over-treatment) or, even better, not having to search for (preventing over-diagnosis) 
prostate cancers that men will not die from, but die with.
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In hoofdstuk 1 wordt begonnen met het vaststellen van de definitie van prostaatkanker en wordt er 
ingezoomd op verschillen in optreden en sterfte van prostaatkanker in de verschillende delen van de 
wereld. De belangrijkste risicofactoren voor prostaatkanker die later in het proefschrift aan bod komen 
worden uitgelicht: familieanamnese, genetische factoren en androgeen-gerelateerde fenotypes. Na 
een korte uitleg waarom screening door middel van prostaatspecifiek antigeen (PSA) bepaling niet 
wordt geadviseerd, hoewel de sterfte er wel mee verlaagd kan worden, gaat de focus naar het iden-
tificeren van hoogrisicogroepen voor prostaatkanker.
In hoofdstuk 2 worden de recente trends in prostaatkankerincidentie en -mortaliteit besproken. Deze 
analyse is gedaan met behulp van gegevens van de Nederlandse Kankerregistratie (NKR): tussen 
1989 en 2006 zijn 120,965 mannen gediagnosticeerd met prostaatkanker in Nederland. De prostaat-
kankerincidentie (gecorrigeerd voor veranderingen in leeftijdsopbouw in de populatie) liet twee aparte 
periodes met stijging zien. De eerste stijging (midden jaren ’90) werd veroorzaakt door voelbare 
prostaatkankers (bij rectaal toucher, cT2), terwijl de stijging vanaf 2000 werd veroorzaakt door PSA- 
gedetecteerde prostaatkankers. De prostaatkankermortaliteit toonde een langzame daling, vergezeld 
van een toenemende overleving voor alle stadia en leeftijden, behalve voor mannen boven de 85 jaar.
In hoofdstuk 3 beschrijven we de aanvullende waarde van de PCA3 urinetest naast PSA, uitgevoerd 
onder de Nederlandse deelnemers aan een internationale studie naar PSA screening bij BRCA-mutatie-
dragers. Deze studie, IMPACT, heeft al eerder gerapporteerd dat met name BRCA2-mutatiedragers 
baat zouden kunnen hebben bij PSA screening. Onze substudie, waaraan 574 mannen meededen 
(waarvan 75 mannen met een BRCA2-mutatie), liet zien dat PCA3 onder BRCA-mutatiedragers niet 
kan worden gebruikt om onnodige prostaatbiopsieën te vermijden. Te veel hoogrisico prostaatkankers, 
ontdekt op basis van een verhoogd PSA, hadden een lage PCA3 score. Een goede uitspraak over de 
waarde van PCA3 om aanvullende prostaatbiopsieën aan te wijzen kan niet worden gedaan, omdat 
PCA3 daarvoor, vanwege het juridisch kader rondom screening in Nederland, niet mocht worden 
gebruikt. Omdat het alternatief om dit toch te kunnen bestuderen (biopten voor alle deelnemers aan 
het einde van de studie) zou kunnen leiden tot een grote mate van overdiagnose en overbehandeling, 
is er langere follow-up nodig om een goede uitspraak te kunnen doen.
We verleggen hierna het focus naar de mogelijke verschillen tussen Erfelijk Prostaatkanker (HPC), 
waarvoor alleen een definitie op basis van familiegeschiedenis en leeftijd beschikbaar is, en prostaat-
kanker in de algemene bevolking (SPC). In hoofdstuk 4 wordt er een associatieanalyse uitgevoerd, 
waarbij de 74 bekende laagpenetrante genetische risicovarianten voor prostaatkanker worden 
gegenotypeerd in 2 grote groepen met HPC (n = 312) en SPC (n = 620) en in een grote controlegroep 
(n = 1819). Een grote meerderheid van deze SNPs (met name ontdekt in SPC) liet vergelijkbare 
resultaten zien voor HPC en SPC. Het onderscheidend vermogen leek zelfs groter te zijn voor HPC. 
Deze resultaten suggereren dat er in de loop van de tijd steeds meer families een ‘HPC-familie’ zijn 
geworden door uitgebreid zoeken naar prostaatkankers in de familie, in plaats van door Mendeliaanse 
overerving van hoogrisicovarianten. Een analyse van een (eenvoudige) genetische risicoscore liet 
zien dat een dergelijke score gebruikt kan worden om alle mannen (ook die in ‘HPC-families’) te 
stratificeren naar prostaatkankerrisico. Uiteraard moet Mendeliaanse overerving van hoogrisico-
varianten niet worden vergeten als mogelijke oorzaak van prostaatkanker. Soms kan dit reden zijn 
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voor screening in families waarin (op jonge leeftijd) veel agressieve prostaatkankers voorkomen.
In hoofdstuk 5 gaan we verder in op de mogelijke verschillen tussen HPC en SPC door de klinische 
karakteristieken en de prognose van deze twee groepen te vergelijken. We maken hierbij gebruik van 
gegevens van alle bekende HPC-prostaatkankers in Nederland (in samenwerking met de Stichting 
Opsporing Erfelijke Tumoren – StOET) gediagnosticeerd vanaf 2000 (n = 324). De SPC patiënten komen 
uit een epidemiologische studie naar de (genetische) aanleg voor prostaatkanker, met daarin alle 
mannen met prostaatkanker gediagnosticeerd van 2003 tot en met 2006 in de regio Nijmegen e.o. 
(in samenwerking met het Integraal Kankercentrum Nederland) (n = 1664).
HPC patiënten bleken gemiddeld genomen betere prostaatkankerkarakteristieken te hebben dan 
SPC (onder meer vaker laagrisico prostaatkanker), maar zij kozen vaker voor radicale therapie. De 
relatieve overleving van HPC was beter dan die van SPC. Samen met de resultaten van hoofdstuk 4 
suggereert dit dat de huidige definitie van HPC geen mannen met een erfelijk verhoogd risico op 
agressief prostaatkanker meer kan identificeren. Daarom stellen we in hoofdstuk 5 een nieuwe 
definitie voor, waar ook het fenotype in verwerkt is.
Om te bestuderen hoe artsen omgaan met het verrichten van (PSA-) onderzoek naar (erfelijk) prostaat-
kanker en welke factoren hierin een rol spelen, hebben we een online vragenlijst laten invullen door 
Nederlandse huisartsen, urologen en klinisch genetici. In hoofdstuk 6 beschrijven we de resultaten 
hiervan: slechts 36% van de urologen en 18% van de huisartsen herkenden de huidige definitie van 
HPC. Urologen waren het minst terughoudend met het verrichten van een PSA-test, hoewel alsnog 
70-80% van hen (net als de huisartsen) de voorkeur aangaf om een man eerst uitgebreid te counselen. 
Vooral leeftijd speelde daarbij een sturende rol, terwijl de familieanamnese (voor prostaatkanker) bij 
35-40% van de urologen en huisartsen geen rol speelde. Bij alle klinisch genetici speelde de familie-
anamnese echter wel een belangrijke rol in de overwegingen al dan niet een man te adviseren om 
zich te laten onderzoeken op prostaatkanker.
Tot slot beschrijven hoofdstuk 7 en 8 de resultaten van een tweetal case-referent studies naar de 
samenhang tussen twee mogelijke ‘markers’ (acne en kaalheid) en prostaatkanker. Het doel van 
deze studies was het reproduceren van eerder gepubliceerd onderzoek, waarin gesuggereerd werd 
dat deze relatief eenvoudig te identificeren ‘markers’ samenhangen met agressief prostaatkanker. 
Onze twee studies waren vrijwel identiek van opzet: een vergelijking tussen vragenlijsten ingevuld over 
de markers door 1000 (SPC) prostaatkankerpatiënten en 2000 referenten toonde in beide gevallen 
aan dat er geen verband was tussen deze markers en agressief dan wel niet-agressief prostaatkanker. 
Helaas zijn beide markers dus niet bruikbaar als marker voor prostaatkanker.
In hoofdstuk 9 nemen we de belangrijkste bevindingen van het proefschrift puntsgewijs door aan 
de hand van stellingen. Tot slot worden ook de belangrijkste hiaten in de prostaatkankerdiagnostiek 
in algemene zin behandeld. Een van de belangrijkste vragen op dit moment is hoe we ‘agressief’ 
prostaatkanker moeten definiëren en diagnosticeren. Oftewel: hoe vind je tijdig die prostaatkankers 
die je wil en moet behandelen? Het bereiken van een duidelijke overeenkomst hierover zou de weg 
kunnen vrijmaken naar een situatie waarin je met vertrouwen mannen kan adviseren dat zij niet 
behandeld hoeven te worden voor bepaalde soorten prostaatkanker of, wellicht nog beter, dat zij 
niet onderzocht hoeven te worden voor prostaatkanker waar zij niet aan, maar mee zullen overlijden.
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Prof. dr. Kiemeney, beste Bart. Wat een respect en waardering heb ik voor jou. Als wetenschapper 
met een ongekende hoeveelheid aan methodologische en biomedische kennis, als supervisor van 
mijn promotieonderzoek én als mens. Weinig mensen is het gegeven om zo ‘natuurlijk’ leiding te 
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zijn zeer op prijs gesteld.
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waarin we de methodologie wilden toepassen en je scherpe geest en kennis van de Engelse taal 
hebben enorm bijgedragen aan het slagen van mijn publicaties. Dank voor je kritische houding bij 
het sparren over mijn onderzoek, maar natuurlijk ook voor de gezelligheid tijdens de uitjes van de 
afdeling EBH/HEV.
Dr. van Oort, beste Inge. Als betrokken uroloog en coauteur in vrijwel al mijn publicaties was je, 
naast al mijn epidemiologische begeleiders, onmisbaar om goed op koers te blijven en juist die 
vragen te stellen die interessant zijn voor ons publiek: de uroloog. Dank voor je inspanningen en snel 
tot ziens in 2017, wanneer je me in het Radboudumc in de kliniek mag gaan superviseren. Hopelijk 
wordt dat net zo prettig en succesvol als je supervisie van mijn wetenschappelijke werk.
Dr. Aben, beste Katja. Jij bent eigenlijk wel beschouwd mijn vijfde (co)promotor. Dank voor al je werk, 
je geduld als ik weer met een vraag kwam, je hulp als ik er weer eens niet helemaal uitkwam met die 
lastige statistiekprogramma’s en je altijd snelle, kritische en waardevolle input voor onze stukken.
Prof. dr. Witjes, beste Fred. Dank voor jouw steun vanaf mijn eerste interesse in de Urologie. Ik ben 
via jou geïnteresseerd geraakt in het vak en dit onderzoekstraject ingegaan. Mijn geslaagde Agiko- 
aanvraag die dit proefschrift op deze manier mogelijk heeft gemaakt, was er zonder jouw steun niet 
geweest. Ik vond het mooi om afgelopen jaar in de Centrale Opleidingscommissie met je samen te 
mogen werken en zie er naar uit om nog heel veel van je te mogen leren vanaf 2017. 
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Geachte leden van de manuscriptcommissie, beste prof. dr. Geurts van Kessel, prof. dr. van Gool, 
dr. Somford, dank voor de goedkeuring van mijn manuscript. Ik zie uit naar een vruchtbare discus-
sie tijdens de verdediging.
Beste collega-promovendi van de afdeling Urologie, beste Boy, Bronte, Dick, Fawzy, Gisele, Hans, 
Harm, Jasmijn, Jos, Luc, Marije, Marlène, Martine, Max, Minja, Ola, Paul G., Paul de J., Peter, Rianne 
H., Rianne L., Rizal, Silvia, Tim, Tom en Vicky. Dank voor alle gezelligheid tijdens de koffiepauzes, de 
uitjes, de refereeravonden, het Aesculaven, de NVUs, de EAUs en alle leuke andere momenten. Jullie 
hebben mijn promotietijd tot een waar feest weten te maken. Ik hoop dat jullie allemaal slagen in jullie 
ambities, dat jullie vooral een erg prettige en gelukkige weg naar die ambities hebben en dat we elkaar 
nog maar lang mogen tegenkomen.
Beste collega’s van het Urologisch Research Laboratorium. Beste Dorien, Egbert, Elze, Gerald, Jack, 
Jeannette, Kees, Marion, Maureen, Mirjam, Nicoline, Onno, Renate en Tilly. Jullie hebben, onder de 
bezielende leiding van afdelings- en tafelhoofd Jack (dank voor alle ochtendkoffies, goede verhalen 
en de ondersteuning en initiatieven bij de onontbeerlijke plagerijtjes naar onze vrouwelijke collega’s), 
voor zo’n enorm fijne werkomgeving gezorgd! Te memoreren zijn zeker onder meer de pauzes met 
vooral Gerald en Mirjam aan de crypto’s, de pancake-uitjes (sneeuwballen!) en de hoge kwaliteit van 
ons eigen onderzoek. Een Laboratorium om trots op te zijn!
Beste collega urologen-in-opleiding, in het bijzonder de JUS d’Orange gangers. Wat kunnen wij goed 
plezier maken samen. Laten we dat nog vele jaren volhouden op alle congressen, cursussen en andere 
gelegenheden waar we elkaar hopelijk tegen zullen blijven komen. Ik vrees met grote vrezen voor 
alle foto’s die er nog gemaakt gaan worden.
Beste collega’s van de afdeling EBH / Health Evidence (te veel namen om op te noemen). Dank voor 
jullie immer vriendelijke ontvangst van deze vreemde-eend-in-de-bijt die overal altijd een beetje 
tussenin zweefde en die altijd wel iets te vragen had als hij over de vloer kwam. Jullie hebben mij laten 
zien dat de epidemiologie een prachtig vak is en ik ben trots dat ik mijn epidemiologische kennis via 
jullie heb mogen verkrijgen en vergroten. Jullie zijn het levende bewijs dat de geitenwollen sok NIET 
van toepassing is op dit vakgebied. Een speciale vermelding voor Tessel, die zo dapper was om mijn 
grootste onderzoek (hoofdstuk 4) feitelijk van mij over te nemen tijdens mijn afwezigheid voor de 
vooropleiding. Ik ben trots dat we het samen tot een hele mooie publicatie hebben weten te brengen.
Beste collega-promovendi van de NCEBP PhD Council 2010-2011, beste Gerdi, Karin en Paul. Dank 
voor jullie enthousiasme tijdens onze gezamenlijke inspanningen voor de promovendi van het 
NCEBP. Ik denk dat we in die jaren een mooie basis hebben weten te leggen voor wat het RIHS nu is 
geworden, met als noemenswaardigheden het ontwikkelen van de PhD Guide (ook samen met de 
andere Councils en Bob de Jonge) en zeker ook het organiseren van ‘onze’ eerste PhD Retreat!
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Beste collega-arts-assistenten van de AAVR, beste leden van de Centrale Opleidingscommissie. 
Dank voor de inspirerende sessies afgelopen jaar. Ik vind het fantastisch om te zien hoe veel mensen 
zich betrokken voelen bij het vormgeven en verzorgen van de opleiding van de medisch specialisten 
van de toekomst. Het Radboudumc en de OOR-ON regio hebben fantastisch mooie opleidingen, 
daar mogen we (hoe on-Nijmeegs dat ook is) trots op zijn, net als op onze open manier van commu-
niceren en de oprechte waardering voor de mening en input van de AIOS. Ik kom in 2017 met veel 
vertrouwen terug voor het laatste deel van mijn opleiding!
Beste collega’s van de afdeling Heelkunde uit het CWZ. Dank voor jullie gastvrijheid voor en geduld 
met deze relatief onervaren dokter. Jullie hebben van mij een stuk meer dokter weten te maken en 
me kennis laten te maken met het ‘echte’ snijden. Wat een mooi vak! Daarnaast zijn jullie ook bijzonder 
prettige collega’s geweest, de twee jaar vooropleiding zijn omgevlogen. Ik zal mijn best doen voor 
jullie een prettige consulterend collega te zijn en de ‘eeuwige’ uitnodiging voor het chirurgiefeest eer 
aan te doen.
Beste collega’s van de afdeling Urologie uit het CWZ. Dank voor de warme ontvangst op jullie afdeling. 
Ik heb alle vertrouwen dat ik de komende jaren nog veel van jullie mag leren en dat we een erg prettige 
samenwerking tegemoet mogen zien. 
Beste StOET-medewerkers, in het bijzonder Marjon, Janneke en Mary. Dank voor de gezelligheid en 
de altijd warme ontvangst in het Poortgebouw in Leiden. Het was iedere keer een leuk ‘uitje’ om naar 
jullie toe te mogen komen en fijn om gebruik te maken van jullie expertise, inzet en gastvrijheid.
Mijn dank gaat uit naar alle mannen die belangeloos geregistreerd staan bij de StOET, in het bijzonder 
naar hen die hebben meegewerkt aan ons onderzoek, als ook naar de deelnemers aan de studies waar 
ik gebruik van het mogen maken bij mijn onderzoek, waaronder de Polygene-studie en de Nijmegen 
Biomedische Studie. Ook dank ik het Integraal Kankercentrum Nederland en haar registratiemede-
werkers voor de prettige samenwerking en de ondersteuning van mijn projecten.
Ik dank de Europese Unie (Zevende Kaderprogramma), World Cancer Research (voorheen: Association 
for International Cancer Research) en ZonMW/NWO voor de financiële ondersteuning van onze projecten.
Mannen van Medisch Heerendispuut Ferus Ebrius, dank voor de mooie momenten waarop wij als 
steeds ouder wordende Roedelnaren met jullie samen toch nog zo nu en dan een stukje studenten-
leven mogen ervaren. Veel succes in jullie eigen carrières en levens, ik hoop dat ik jullie soms een 
beetje mag inspireren. Doe waar je plezier in hebt, deel dat plezier met je vrienden en geniet maximaal 
van het (studenten)leven!
Lieve vrienden, dank voor jullie interesse in en steun tijdens mijn onderzoekstijd. Het is een tijd met 
sporadische downs maar vooral heel veel ups geweest. Ik prijs me enorm gelukkig dat ik deze 
momenten met jullie heb mogen delen en hoop op nog heel veel ups samen!
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Stefan en Bram, mannen, het is een eer voor me dat jullie mij terzijde willen staan op dit unieke moment. 
Net als vroeger samen in zwart-wit kostuum met strikje, maar nu een schoon en een goed passend 
exemplaar! Onze vriendschap is al meer dan 10 jaar oud en wordt eigenlijk alleen maar mooier. Onze 
weekendjes weg, ook met de andere mannen samen, worden ieder jaar legendarischer, ik hoop dat 
we hier ook in de rest van onze levens, hoe hard ze ook veranderen, tijd voor kunnen blijven maken. 
Lieve zus, lieve Charlotte. Wat ben ik toch trots op jou. Het is als grote broer bijna ongelooflijk om te 
zien hoe sterk jij bent geworden. Mijn kleine zusje…ik vind het ontzettend knap dat je hebt durven 
kiezen om naar Zweden te gegaan om daar aan je carrière te werken. We zijn ondanks de fysieke 
afstand alleen maar dichter bij elkaar gekomen als broer en zus. Gelukkig is Sheffield een stukje 
dichter bij dan Stockholm, ik wens je daar alle geluk, liefde en gezondheid en wat dan ook nog meer 
samen met Lucas, het komt jullie toe. Ik ben heel trots dat ik jouw broer mag zijn!
Lieve ouders, lieve Rob en Marianne, aan jullie draag ik dit proefschrift op. Jullie zijn mijn inspiratie, 
jullie verdienen het. De onvoorwaardelijkheid van jullie steun aan mij, al meer dan dertig jaar, is de 
basis voor al mijn geluk in mijn leven, liefde en werk. De manier waarop jullie er altijd voor mij zijn 
geweest en nog steeds zijn, geeft zo ontzettend veel rust en vertrouwen, dat is met geen pen te 
beschrijven. Ik hoop dat we nog heel lang in gezamenlijke gezondheid samen mogen zijn en ik hoop 
jullie hier en daar wat terug te mogen geven van de liefde die ik altijd heb ontvangen.
Mijn liefste Maaike, mijn fantastische verloofde! Van een bruiloft komt een bruiloft, wat een epische 
woorden zijn het geworden! Ik ben zo gelukkig dat ik je op de bruiloft van Freek en Mara tegen ben 
gekomen! Dank je voor de heerlijke tijd die we al samen hebben gehad en de steun die ik van je krijg 
bij al mijn drukke hersenspinsels. Ik ben zo trots dat ik bij jou mag horen! Ik ben ook heel erg blij met 
hoe we het samen hebben, samen genieten en er voor elkaar zijn, bij alle mooie en bij alle moeilijke 
momenten. Het leven met jou is geweldig, met jou kan ik alles aan! Ik kan haast niet wachten tot 
september, dan horen we NOG meer bij elkaar! Ja, ik wil!
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Ruben Cremers was born in Baarlo (Limburg) in 1983. After graduating with honors from the 
Gymnasium at the Valuas College in Venlo, he studied Medicine from 2001-2008 at the UMC St 
Radboud in Nijmegen. Next to his Medicine studies, he was active as treasurer for the Medical 
Students’ Association Nijmegen (2003-2004), student representative for the Board of Directors 
at the Radboudumc (2005-2006) and president of M.H.D. Ferus Ebrius. In 2009, he started his PhD 
research under the supervision of prof. Bart Kiemeney, focusing on the identification of high-risk 
groups for prostate cancer and hereditary prostate cancer. Next to his PhD research, he was president 
of the Phd Council of the Radboud Institute for Health Sciences (formerly known as NCEBP). 
In 2010, the Netherlands Organisation for Health Research and Development approved his AGIKO-
application, supported by profs. Witjes and Kiemeney, for a combined track of both PhD training 
and clinical training to become a Urologist. After his General Surgery residencies in the Canisius-
Wilhelmina Hospital in 2012-2013, he returned to the Radboudumc in 2014 to finish his PhD thesis. 
Besides the scientific work in this year, he was president of the Residents’ Association and member 
of the Central Training Committee of the Radboudumc. Currently, Ruben is working as a Urology 
resident in the Canisius-Wilhelmina Hospital. His leisure time is mainly filled with sports (tennis and 
running), social events and preparations for his marriage to Maaike Bloemendal in September 2015.
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Name PhD student: RGHM Cremers PhD period: Jan 2009 – Dec 2011 and Jan – Dec 2014
Department: Health Evidence / Urology Promotor(s): Prof. dr. L.A.L.M. Kiemeney & 
Prof. dr. H.F.A. Vasen
Graduate School: Radboud Institute for Health Sciences Co-promotor(s): Dr. ir. S.H. Vermeulen & Dr. I.M. van Oort
Year(s) ECTS
TRAINING ACTIVITIES
a) Courses & Workshops
- Principles of Epidemiologic Data-analysis, NIHES, Rotterdam 2009 0.7
- Clinical Epidemiology, Biomedical Sciences, Radboud  
University Nijmegen (RUN), Nijmegen
2009 5.7
- Biometrics, PAO Heyendael, Nijmegen 2010 2.9
- Basiscursus Regelgeving en Organisatie voor Klinisch  
Onderzoekers (BROK), PAO Heyendael, Nijmegen
2010 1.4
- Introduction to Clinical and Public Health Genomics  
(Genetic Analysis in Clinical Research, NIHES, Rotterdam
2010 0.7
- Introduction into Clinical and Fundamental Oncology,  
Dutch - Association of Oncology, Ellecom
2010 1.4
- Genetic Epidemiology, Biomedical Sciences, RUN, Nijmegen 2010 6.0
- European School of Urology, multiple courses 2009-2014 NA
b) Seminars & lectures
- Journal Club / Work in Progress Urological Research Laboratory 
Medicine, Nijmegen (8x oral presentation of ± 30 minutes)
2011-2014 NA
- Uro-Oncology Congress, Antalya, Turkey 2011 NA
c) Symposia & congresses
- Joint meeting Dutch Association of Urology, Groningen  
(oral presentation)
2009 0.3
- Prostate Cancer Translational Research in Europe, Amsterdam 2009 0.6
- Symposium Experimental Research Surgical Specialisms 
(SEOHS), Nijmegen (oral and poster presentation)
2009 0.3
- Annual Congress European Association of Urology, Barcelona 
(poster)
2009 0.3
- Joint meeting Dutch Association of Urology, Nieuwegein (oral) 2010 0.3
- Werkgroep Epidemiologisch Onderzoek Nederland (WEON),  
Nijmegen (oral and poster)
2010 0.3
- Young Urological Professional Symposium (oral) 2010 0.6
- Werkgroep Epidemiologisch Onderzoek Nederland (WEON), 
IJmuiden (oral)
2011 0.3
- EAU review / AUA review 2011 0.4
- Radboud Institute for Health Sciences (RIHS) PhD Retreat,  
Wageningen (organization, chairing sessions)
2011 0.6
- Annual Congress European Association of Urology, Barcelona 
(poster presentation)
2014 0.3
- Werkgroep Epidemiologisch Onderzoek Nederland (WEON), 
Leiden (oral)
2014 0.3
- Radboud Research Round, Radboudumc, Nijmegen (oral) 2014 NA
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- RIHS PhD Retreat, Wageningen (oral) 2014 0.6
- Annual ProMark meetings (Barcelona, Amsterdam) 2009,2010 NA
- RIHS annual symposium 2009-2011, 2014 1.2
- Dutch Oncoforum 2009-2014 NA
d) Other
- Weekly epidemiology journal club at the Department for  
Health Evidence, Radboudumc, Nijmegen
2009-2014 3.6
- Seminars and colloquia at the Department for Health  
Evidence, Radboudumc, Nijmegen
2009-2014 3.6
- Member and President of the RIHS PhD council, RIHS,  
Nijmegen
2010-2011 NA
- Member of the Training and Supervision Committee, RIHS,  
Nijmegen
2010 NA
- Radboud Masterclasses 2010, PAO Heyendael, Nijmegen 2010 0.3
- President of the Radboudumc Residents’ Association 2014 NA
- Member of the General Education Committee, Radboudumc, 
Nijmegen
2014 NA
TEACHING ACTIVITIES
e) Lecturing
- Teacher in MSc course CKO9v: preparation research  
internship, Medicine, RUN, Nijmegen
2011, 2014 NA
f) Supervision of internships / other
- D. Heijnen, internship Biomedical Sciences, RUN, Nijmegen 2011 NA
TOTAL 32.7
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PROSTATE
CANCER
An evaluation of reported markers to identify men 
at increased risk
Prostate cancer is the most frequently diagnosed cancer among Western males. 
It is also a very heterogeneous disease: many men will die with prostate cancer 
instead of from prostate cancer. One of the most challenging issues is to 
identify those men at increased risk of aggressive prostate cancer. Many mark-
ers have been reported that claim to do this. In this thesis, a critical evaluation 
of these markers is performed, using different epidemiological designs.
Hereditary prostate cancer (HPC) is a speciﬁc sub-group 
of prostate cancer. There is no test for HPC: the diagno-
sis depends on the number of cases in a family and age 
of onset. Men in HPC families are advised to be tested 
for prostate cancer.
Intuitively, HPC comprises families in which aggressive 
prostate cancers occur. However, HPC might also 
increasingly be the result of extensive prostate cancer testing in families, 
ﬁnding mainly ‘non-aggressive’ cancers. Here, we explore whether differences 
exist between HPC and prostate cancer in the general population.
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